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Abstract 
 
It has been shown repeatedly that infectious diseases in humans have strong 
associations with the human leukocyte antigen system, but an understanding of the basis of 
these associations remains elusive. Adaptive immune responses involving CD4 and CD8 T 
lymphocytes are dependent on (1) the appropriate and effective processing of a peptide from 
a protein source, (2) the stable binding of the peptide to the HLA molecule and (3) the 
recognition of this complex by the T cell receptor. In this thesis, we present work helping to 
better define such host-virus dynamics, examining aspects relating to each of the described 
steps. We examined two large patient cohorts, the first infected with HIV-1 and the second 
with HCV. We identified viral escape mutations and thus potential immune epitopes. Also, 
we examined the possible effects of HLA genotypes on the development of drug resistance 
mutations (HIV-1) and the success of antiviral therapy (HCV). To better understand the 
stable binding of peptides to HLA molecules, we evaluated the performance of diverse HLA 
class I prediction methods on large datasets, showing that all leading methods are capable of 
good to excellent performance. Finally, we developed the first algorithms, based on the 
interactions found in actual experimental structures, which allow for the prediction of 
interactions between residues in the T cell receptor‟s CDR loops and residues in the HLA-
peptide antigen. The algorithms had good performance under cross-validation. 
  
 vi 
 
Kurzfassung 
 
Wiederholt wurden viele Zusammenhänge menschlicher Infektionskrankheiten mit 
dem Human-Leukozyten-Antigen-System aufgezeigt, doch ein vollständiges Verständnis 
dieser Zusammenhänge fehlt. Adaptive Immunantworten mit CD4- und CD8-T-
Lymphozyten sind abhängig von (1) einer angemessenen und effektiven Bearbeitung eines 
Peptids, (2) der stabilen Bindung des Peptids an das HLA-Molekül und (3) der Erkennung 
dieses HLA-Peptid-Komplexes durch den T-Zell-Rezeptor. In dieser Dissertation 
präsentieren wir Arbeiten, die helfen, diese Wirt-Virus-Dynamik besser zu definieren, indem 
wir Aspekte jedes dieser beschriebenen Schritte untersuchen. In zwei großen 
Patientengruppen (die erste mit HIV-1 und die zweite mit HCV infiziert) identifizierten wir 
virale Escape-Mutationen und damit potentielle Immun-Epitope. Wir untersuchten die 
möglichen Auswirkungen des HLA-Genotypes auf die Entwicklung von Resistenz-
Mutationen (HIV-1) und den Erfolg einer antiviralen Therapie (HCV). Um die stabile 
Bindung von Peptiden an HLA-Moleküle besser zu verstehen, untersuchten wir die Leistung 
verschiedener HLA-Klasse I-Prognoseverfahren und zeigten, dass alle führenden Methoden 
gute bis sehr gute Ergebnisse liefern können. Abschließend haben wir die ersten Algorithmen 
entwickelt, die die Interaktionen zwischen den Aminosäuren der CDR-Schleifen des T-Zell-
Rezeptors und Aminosäuren des HLA-Peptid-Komplexes vorhersagen. Diese Algorithmen 
zeigten gute Leistung unter Cross-Validierung. 
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Extended Abstract 
 
It has been shown repeatedly that infectious diseases in humans have strong 
associations with the human leukocyte antigen system, but an understanding of the basis of 
these associations remains elusive. Adaptive immune responses involving CD4 and CD8 T 
lymphocytes are dependent on (1) the appropriate and effective processing of a peptide from 
a protein source, (2) the stable binding of the peptide to the HLA molecule and (3) the 
recognition of this complex by the T cell receptor. In this thesis, we present work helping to 
better define such host-virus dynamics, examining aspects relating to each of the described 
steps. 
Viruses with high mutation rates are capable of adapting to their host‟s HLA profile if 
the fitness costs for the virus are not too high. We examined two large patient cohorts, the 
first infected with HIV-1 and the second with HCV, in order to identify viral escape 
mutations and thus potential immune epitopes which help define the host‟s adaptive immune 
response. In the case of HIV-1, we examined the persistence of HLA-associated mutations 
over time and the possible effects of HLA genotypes on the development of drug resistance 
mutations. In the case of HCV, we examined the effect of the host genetic HLA profile on the 
success of antiviral therapy. We also developed a DAS server which serves as a reference and 
annotation server for HIV-1 and HCV, targeted at the genome annotation community.  
To better understand the stable binding of peptides to HLA molecules, we evaluated 
the performance of diverse HLA class I prediction methods on large datasets which recently 
became available. Overtraining was avoided by making use of methods which had been, 
wherever possible, reimplemented. This methodology permits the control of both learning 
and testing of the prediction methods on a variety of datasets, thus allowing for a more 
accurate comparison of the methods. While all leading methods are capable of achieving 
good to excellent performance for clear binders and non-binders in cases where sufficient 
data is available, intermediate binders remain difficult to categorize. 
Finally, we examined interactions, which are still not well understood, between T cell 
receptors and the HLA-peptide complex. We identified important differences to previous 
studies and, based on the interactions found in actual experimental structures, developed the 
first algorithms which allow for the prediction of interactions between residues in the T cell 
receptor‟s CDR1, CDR2 and CDR3 loops and residues in the HLA-peptide antigen. The 
algorithms had good performance under cross-validation. 
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1 Introduction 
1.1 HIV-1 
1.1.1 The pandemic 
Human immunodeficiency virus 1 (HIV-1) is the pathogen which currently causes the 
most extreme case of immunosupression in humans. Over time, infection with HIV-1 leads to 
the gradual loss of immune competence, in the form of CD4 T cell depletion, allowing for the 
development of cancer and the infection of the host with organisms that are not normally 
pathogenic (Douek 2003; Douek et al. 2003).  
The earliest scientific reports of cases of previously healthy young homosexual men 
dying of Pneumocystis carinii pneumonia (PCP) and Kaposi's sarcoma in New York and 
California were made in mid-1981 (CDC 1981a; CDC 1981b; Hymes et al. 1981). Acquired 
immunodeficiency syndrome (AIDS) was first properly defined by the Centers for Disease 
Control (CDC) in Atlanta in September 1982 (CDC 1982c). Later that year it also became 
clear that this new disease was probably caused by an infectious agent: a 20-month old child 
receiving multiple transfusions of blood and blood products died from infections related to 
AIDS (CDC 1982a) and the first case of mother to child transmission was described (CDC 
1982b). In 1983, the virus we now call HIV-1 was first isolated. (Controversy surrounds who 
first isolated HIV-1, but many view the awarding of the Nobel Prize in Medicine or 
Physiology to Luc Montagnier and Françoise Barré-Sinoussi from the Pasteur Institute in 
Paris, France as a final scientific verdict on the matter (Lever and Berkhout 2008; Vahlne 
2009)).  
By the end of 2009, the number of people who were living with HIV-1/AIDS had 
grown to 33.3 million and more than 25 million people had died of the disease since 1981. It 
has been estimated that 2.6 million new infections and 1.8 million deaths occurred in 2009 
(Figure 1.1). Women accounted for 50% of all adults living with HIV-1 world-wide and 
Africa had 16.6 million AIDS orphans. Those given access to antiviral drugs have rose to 5.2 
million, but 10 million were still waiting for treatment in developing and transitional 
countries. At present, the virus is spreading most rapidly in Central Asia and Eastern Europe 
(UNAIDS 2009; UNAIDS 2010). 
Assuming that 80% of infected individuals receive antiviral therapy by 2012, it has 
been projected that the number of AIDS deaths will continue to rise and reach 6.5 million per 
year by 2030. This rise is due to projected demographic changes in sub-Saharan Africa, 
where population growth is highest and HIV/AIDS incidence rates are assumed to remain 
largely constant. Under this model, the total number of deaths due to AIDS is projected to be 
117 million between 2006 and 2030 (Mathers and Loncar 2006; UNAIDS 2010). The 
importance of tackling the spread of HIV-1/AIDS was already recognized by the United 
Nations in 2000 when it defined its nine most important development targets for the 21
st
 
century: one of these targets was to reduce the HIV-1 infection rates for persons 15–25 years 
of age by 25% within 10 years (Annan 2000). 
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Figure 1.1 Numbers of people living with, newly infected with, and killed by HIV-1 from 1990-2009 
(UNAIDS 2010) 
1.1.2 HIV-1 groups, subtypes and nomenclature 
HIV-1 is a retrovirus and a member of the primate lentivirus family. It is derived from 
retroviruses indigenous to African primates. Therefore, the HIV infection can be considered 
to have originally been a zoonotic disease introduced to humans by primates. HIV-1 shows 
great genetic variability and has been classified into four major groups, based on nucleotide 
sequence: M (main), O (outlier), N (non-M and non-O), and the newly identified P group. 
These groups are only distantly related to each other and therefore thought to be the result of 
four separate zoonotic transmission events from chimpanzees (M, N, O) and gorilla (P). The 
O group currently appears to be restricted to west-central Africa and the N group is extremely 
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rare and was discovered in Cameroon in 1998. The P group was identified recently in a 
woman in Cameroon (DeFranco et al. 2007; Murphy et al. 2008; Plantier et al. 2009).  
In contrast to the O, N and P groups which have essentially remained restricted to 
Africa, the M group is responsible for the global HIV-1 pandemic. The M group contains 
several lineages (also called subtypes or clades) which are designated with the letters A, B, C, 
D, F, G, H, J and K. Lineages have been known to recombine into circulating recombinant 
forms (CRFs) and, for example, the CRF A/B is a mixture of subtypes A and B. The lineages 
and CRFs are distributed unevenly across the globe, with the most widespread being A and 
C. Historically, subtype B has been the common subtype in Europe, the Americas, Japan and 
Australia (Robertson et al. 2000; Perrin et al. 2003).  
For the sake of completion, it should be noted that the second major type of HIV is 
designated HIV-2 and shares 42% sequence identity with HIV-1. HIV-2 is thought to have 
originated through a zoonotic transmission from sooty mangabeys, with eight independent 
transmission events occurring from this monkey to humans. Recombination between the two 
virus types has not been reported and probably cannot occur, because of differences in the 
RNA dimer hairpin sites. HIV-2 is also distributed worldwide, but has a lower transmission 
rate than HIV-1 and a lower rate of progeny virus production. The course of infection is also 
less pathogenic, resembling in part the infection of sooty mangabeys and African Green 
Monkeys (AGMs) with simian immunodeficiency virus (SIV) (Levy 2009; Wertheim and 
Worobey 2009). 
1.1.3 Structure and genome 
Mature virions display a broad range of diameters, but the average size is 
approximately 145 nm. A virion is generally spherical in shape and consists of a lipid bilayer 
which surrounds a cone-shaped core (also called nuleocapsid) (Figure 1.2). A core contains 
two copies of a single-stranded viral RNA genome, as well as virus-specific enzymes. Most 
virions contain a single core, but approximately one-third contain two or more such cores. 
These multi-core virions are larger in diameter. There is also a small subset of virions (about 
7%) which are not conical in shape but tubular, although it is thought that all virions share a 
similar internal organization (Briggs et al. 2003).  
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Figure 1.2 Schematic diagram of a mature HIV-1 virion (www.wikipedia.org) 
The genome of the virus is 9.2 kb in length (Ratner et al. 1985) (Figure 1.3). The three 
structural genes are gag (group-specific antigen), pol (polymerase) and env (envelope). The 
gag gene produces a precursor protein, which is processed into the matrix protein (sometimes 
also described as p17 or MA), the capsid protein (p24 or CA) and the nucleocapsid protein 
(p7 or NC). These proteins package genomic viral RNA into new virions and participate in 
viral uncoating. The pol gene encodes the protease (PR), reverse transcriptase (RT), RNAse 
and integrase (IN). These proteins are required for viral replication. The env gene encodes 
membrane-exposed proteins on the virion that mediate attachment and fusion; the precursor 
gp160 protein is cleaved into these membrane-exposed proteins which are named gp41 and 
gp120. Furthermore, tat and rev are two regulatory genes which are essential for in vivo and 
in vitro replication. And finally, the accessory genes vpu, vpr, nef and vif are important for 
viral pathogenicity in vivo. The vpu protein is required for viral assembly and budding, vpr 
protein is important for nuclear import, nef protein disturbs the morphology of the endosomal 
recycling compartment by several mechanisms and downregulates CD4 and MHC class I 
expression, and vif protein is a viral infectivity factor which acts by circumventing the potent 
antiviral activity of the host‟s APOBEC3G cell protein. Like all retroviruses, HIV-1‟s 
genome is flanked by long terminal repeats (LTRs) which are involved in viral integration 
and in the regulation of transcription (Madrid et al. 2005; DeFranco et al. 2007; Paul 2008).  
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Figure 1.3 The HIV-1 gene map of the reference strain HXB2 (www.hiv.lanl.gov) 
1.1.4 Viral replication 
HIV-1 is capable of infecting all cells which express CD4 on the cell surface. These 
cells include CD4 T cells, dendritic cells, macrophages and monocytes, but the production of 
infectious virus particles primarily occurs in activated T cells. Initially, the trimeric gp120 
subunit located on the surface of the HIV-1 virion binds to the CD4 membrane protein which 
is located on the surface of the host CD4 T cells, dendritic cells or macrophages. gp120 
subsequently undergoes a significant conformational change, which increases the interactions 
with cellular coreceptors and exposes the trimeric transmembrane fusion protein gp41. These 
cellular coreceptors can consist of different chemokine receptors, including CXCR4 and 
CCR5. This process is followed by membrane fusion (DeFranco et al. 2007).  
Upon entry into the host cell, the viral genome is converted to DNA by the viral 
reverse transcriptase: the HIV-1‟s inner core acts as a template for the reverse transcription of 
RNA into double-stranded DNA. The viral cDNA is transported into the host cell‟s nucleus 
by making use of nuclear localization signals. The proviral genome is integrated into the host 
cell‟s genome via the viral integrase, generating a provirus which becomes the primary 
template for subsequent transcription of a new generation of virions. Expression is greatly 
enhanced by the activation of host transcriptional regulators and the viral tat protein. 
Subsequently, mature viral RNAs are transported into the cytoplasm where the viral core 
proteins and the viral reverse transcriptase are synthesized. Gp120 and gp41 are synthesized 
in the endoplasmic reticulum. Membrane-associated envelope proteins recruit structural 
proteins and two copies of the full-length viral RNA genome. This is followed by membrane 
budding on the cell surface of T cells. In macrophages, mature virions assemble on 
endosomal membranes and  bud into multivesicular bodies (MBVs) which are vesicles of the 
endosomal pathway. MBVs fuse with the plasma membrane and subsequently release mature 
virions from the macrophage. The cellular endosomal sorting complex required for transport 
(ESCRT)  mediates the budding process in both cell types (DeFranco et al. 2007; Paul 2008). 
A general overview of this process can be seen in Figure 1.4. 
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Figure 1.4 The replication cycle of HIV-1 (www.wikipedia.org) 
1.1.5 Transmission 
HIV-1 is primarily transmitted by sexual contact. A further route of transmission is  
provided by the sharing of needles among intravenous drug users, particularly in Eastern 
Europe. Mother to infant transmission remains a problem in many regions world-wide, but 
intrapartum (during labor and birth) and peripartum (during the first months after birth) 
transmission can be substantially reduced by treating infected women with a short course of 
antiretroviral drugs. However, subsequent breast feeding of the infant is still a major source 
of infection in the developing world. Transmission via the transfusion of infected blood 
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products has been largely eliminated through the screening of blood products, procedures 
which were developed in the mid-1980s (Cohen et al. 2008).  
1.1.6 Course of an untreated infection 
Typically the course of an untreated infection with HIV-1 can be divided into four 
phases: (1) primary infection and the acute period, (2) the asymptomatic or clinical latency 
period, (3) the symptomatic period during which constitutional symptoms occur and (4) 
AIDS during which opportunistic diseases occur which lead to death (Figure 1.5). 
 
 
Figure 1.5 The typical course of an untreated HIV-1 infection (www.wikipedia.org) 
The CD4 T cell count (cells per µl) is shown in blue; the HIV-1 RNA copies per ml of plasma is 
shown in red. 
Subsequent to infection 50-80% of individuals have flu-like symptoms which 
clinically characterize the acute phase. There is a sharp increase in viremia (the abundance of 
the virus) and a marked decrease in the number of circulating CD4 T helper cells. In virtually 
all patients, CD8 cytotoxic T cells are activated which kill HIV-1 infected cells, leading to a 
rebound in the number of CD4 T cells. This period of acute infection typically lasts from 2 to 
6 weeks. Diagnosis of HIV-1 infection at this stage is usually missed, unless there is a 
specific cause for suspicion (Murphy et al. 2008; Paul 2008).  
Antibodies begin to be produced (seroconversion) and this characterizes the transition 
from the acute to the asymptomatic phase. A balance occurs between the level of viral 
destruction of immune cells and the host response, which is designated the viral set-point. 
This viral set-point is generally considered the best indicator of disease progression. 
Numerous viral mutants appear due to the high level of viral replication, the error-prone 
copying action of the viral reverse transcriptase and the absence of a viral nucleotide repair 
system. Specific mutations, called escape mutations, are selected for which help the virus 
evade immune recognition. This asymptomatic period can last anywhere from 6 months to 20 
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years. The number of CD4 T cells declines progressively in the asymptomatic phase, until a 
point is reached where constitutional symptoms begin to appear and the patient moves into 
the symptomatic phase. Constitutional symptoms include low grade fevers, chronic fatigue, 
general weakness (Murphy et al. 2008; Paul 2008). 
A diagnosis of AIDS can be made if the patient has fewer than 200 CD4 cells / µl, the 
patient‟s CD4 cells account for less than 14% of all lymphocytes or the patient has been 
diagnosed with one or more of 25 so called AIDS defining clinical events. Such AIDS 
defining infections include Pneumocystitis carinii pneumonica, toxoplasmosis, cryptococcal 
meningitis and Candida esophagitis. AIDS defining cancers include Kaposi‟s sarcoma and 
non-Hodgkin lymphoma (CDC 1992). The life span of a person living with AIDS who is not 
receiving specific therapy is typically less than 2 years (Vella et al. 1992). 
The course of untreated infection can vary widely; while most infected untreated 
individuals will eventually develop AIDS and die of its consequences, a small percentage of 
people seroconvert, but maintain high levels of immunocompetence and therefore do not 
develop progressive disease (such people are generally termed long-term non-progressors). 
There is also a small group of patients that remain virus-free despite repeated high levels of 
exposure to HIV-1 (Murphy et al. 2008; Paul 2008). 
1.1.7 Antiretroviral therapy 
Antiretroviral therapy is based on the hypothesis that maximal suppression of viral 
replication will prevent or delay the deterioration of the immune system, thus avoiding the 
development of later stage disease and thus morbidity and mortality. Advances in antiviral 
therapy (ART) continue to shift the balance of therapeutic risk-benefit balance to earlier 
treatment as concerns regarding the long-term risks of untreated viremia have increased. 
There have been significant advances in the areas of potency, toxicity, tolerability and pill 
burden allowing for better treatment options and compliance (Thompson et al. 2010). 
As of May 2010, 24 compounds from different mechanistic classes had been 
approved for antiretroviral therapy by the US Food and Drug Administration (FDA, 
http://www.fda.gov) (Table 1.1). A summary of the classes and their method of action 
follows: 
 
 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): This group 
of drugs consists of competitive substrate inhibitors, which are analogs of 
naturally occurring deoxynucleotides. They compete with the natural 
deoxynucleotides for incorporation into the viral cDNA by the viral reverse 
transcriptase. NRTIs do not have a 3‟-hydroxyl group and once such an analog 
has been added to a growing viral DNA chain, this chain cannot be extended 
(a process called chain termination). 
 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): This drug class 
consists of non-competitive inhibitors which bind directly to the viral reverse 
transcriptase. The movement of critical protein domains of the enzyme is 
restricted and thus the ability of the enzyme to synthesize viral cDNA is 
interrupted.  
 Protease Inhibitors (PIs): This class of drugs inhibits the activity of the viral 
protease, which cleaves protein precursors for final assembly into new virions. 
While treatment with a PI does not prevent the formation of new virions, it 
prevents the formation of mature and thus infectious virions. The already 
infected host cell is still destroyed, but the infection of new cells is prevented. 
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 Fusion or Entry Inhibitors: These drugs interfere with the ability of the virus 
to enter the host cell. By blocking extracellular rather than intracellular 
interactions, this class of drugs does not have to be transported across the cell 
membrane to operate. Drugs of this class function by preventing attachment or 
membrane fusion. 
 Integrase Inhibitors: Drugs in this group interfere with the viral integrase 
whose function is to integrate the viral cDNA into the host cell‟s genome. 
 
 
Abbreviation Generic name Brand name Date of FDA 
approval
Nucleoside/Nucleotide Reverse 
Transcriptase Inhibitors (NRTIs):
3TC lamivudine Epivir 17-Nov-95
ABC abacavir Ziagen 17-Dec-98
AZT or ZDV zidovudine Retrovir 19-Mar-87
d4T stavudine Zerit 24-Jun-94
ddI didanosine Videx EC 31-Oct-00
FTC emtricitabine Emtriva 02-Jul-03
TDF tenofovir Viread 26-Oct-01
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTIs):
DLV delavirdine Rescriptor 04-Apr-97
Sustiva (US)
Stocrin (Europe)
ETR etravirine Intelence 18-Jan-08
NVP nevirapine Viramune 21-Jun-96
Protease Inhibitors (PIs): APV amprenavir Agenerase 15-Apr-99
Lexiva (US)
Telzir (Europe)
ATV atazanavir Reyataz 20-Jun-03
DRV darunavir Prezista 23-Jun-06
IDV indinavir Crixivan 13-Mar-96
Kaletra
Aluvia (developing 
world)
NFV nelfinavir Viracept 14-Mar-97
RTV ritonavir Norvir 01-Mar-96
SQV saquinavir Invirase (hard gel 
capsule)8
06-Dec-95
TPV tipranavir Aptivus 22-Jun-05
Fusion or Entry Inhibitors: T-20 enfuvirtide Fuzeon 13-Mar-03
Celsentri (Europe)
Selzentry (US)
Integrase Inhibitors: RAL raltegravir Isentress 12-Oct-07
MVC maraviroc 18-Sep-07
17-Sep-98
FOS-APV fosamprenavir 20-Oct-03
LPV/RTV lopinavir + 
ritonavir
15-Sep-00
EFV efavirenz
 
Table 1.1 Anti-HIV-1 drugs currently approved by the FDA 
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The choice of the initial drug regimen has long-standing consequences for the patient. 
In order to optimally treat a given patient, resistance testing should be performed and thereby 
the predicted virologic efficacy assessed. Typical initial treatment regimens for adults include 
a combination of two NRTIs and a potent third agent from another class. Such a therapy has 
been commonly referred to as highly active antiretroviral therapy (HAART), although 
combination antiretroviral therapy (CART) is currently the preferred term. A common 
starting regimen is tenofovir and emtricitabine, combined with efavirenz, atazanavir/r or 
darunavir/r. Another common regimen for treatment-naïve patients is abacavir and 
lamivudine, plus one of the already mentioned third agents. For the latter regimen, it is 
important to screen for the HLA allele HLA-B*5701 in the patient to reduce the risk of 
abacavir hypersensitivity reaction (HSR), as a strong association between this HLA allele and 
abacavir HSR has been demonstrated in a number of studies. Abacavir HSR occurs in 4-9% 
of patients and is characterized by multisystem involvement and can be fatal in rare cases. 
The exact mechanism of this reaction is still unknown (Hetherington et al. 2002; Mallal et al. 
2002; Martin et al. 2004). Overall, fixed-dose formulations and once-daily regimens are 
currently generally preferred (Thompson et al. 2010). 
The HIV-1 virus mutates readily and thereby produces drug resistant variants. Three 
non-independent factors are responsible for this process (Beerenwinkel 2004):  
 
 Replication and recombination: HIV-1‟s reverse transcription is a highly error 
prone process as it lacks a proof reading mechanism. The mutation rate has 
been estimated to be 10
-4
 to 10
-6
 substitutions per base pair per replication 
cycle. This, combined with high titers of virus in untreated individuals and a 
viral generation time of 1 to 3 days, drives the development of genetic 
variation. Another source of variability is recombination, where new genomes 
are formed by template switching by the reverse transcriptase when it 
encounters two different genomes in a cell infected multiple times. 
 Diversity: Each individual HIV-1 patient has a complex mixture of genetically 
related variants.  
 Anti-HIV drug selection pressure: If the patient is not receiving antiretroviral 
therapy, the wild type virus and closely related variants are likely to dominate, 
whereas drug resistant viruses are common in patients which are being treated 
with antiretroviral therapies. If drug therapy is not successful in completely 
suppressing replication, the replicating HIV-1 quasi-species can develop new 
mutations. Some of these new variants will carry mutations which confer drug 
resistance and these will eventually predominate under drug therapy. 
 
In addition to the development of drug resistant variants, multi-drug resistance is a 
significant problem. Mutations that confer resistance to one drug are frequently likely to  
confer resistance to other drugs of that class. 
Currently, choosing a drug regimen that produces the maximal and durable 
suppression of viral replication to <50 RNA copies/ml is considered to be the most important 
therapeutic goal, as it minimizes the development of drug resistance mutations, preserves 
CD4 T cell counts and confers clinical benefits to patients (Este and Cihlar 2010). 
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1.2 HCV 
1.2.1 Discovery of the virus and current global burden 
The hepatitis C virus (HCV) has low titers in human blood, which made it difficult to 
detect using conventional methods which existed prior to the late 1980s. Additional 
complicating factors were that the virus is genetically heterogeneous and the infection has a 
long asymptomatic phase during the early years of chronic infection (Worman 2002; 
Houghton 2009). 
HCV was first discovered in 1989 using molecular biology techniques i.e. 
recombinant DNA technology; chimpanzees were infected with the virus and DNA and RNA 
was isolated from blood specimens of the infected animals. RNA was reverse transcribed to 
cDNA, a DNA library was constructed from both the DNA and cDNA. Clones of the library 
were subsequently sequenced and portions of the virus‟ genome elucidated. Initially this virus 
was termed non-A, non-B hepatitis, as it was different from both hepatitis A and hepatitis B 
which had already been described. The same group of researchers at Chiron Corporation also 
showed in a separate publication in the same issue of Science that 85% of patients diagnosed 
with non-A, non-B hepatitis had antibodies against parts of the newly discovered virus (Choo 
et al. 1989; Kuo et al. 1989; Worman 2002; Houghton 2009). 
HCV is currently recognized as being a major cause of chronic liver disease both in 
the industrialized and developing world. It has been shown to cause chronic hepatitis, liver 
cirrhosis and hepatocellular carcinoma. Available data suggests that the prevalence is 
approximately 2.2-3.0% world-wide, which is approximately 130-170 million people. The 
highest prevalence of infection is currently found in Africa and the Eastern Mediterranean. It 
should also be noted that in many countries, HCV infection rates and disease burden have not 
been examined with population-based epidemiological studies. This makes accurate 
estimations of the true world-wide impact of HCV impossible (Suzuki et al. 2007; Lavanchy 
2009). 
1.2.2 HCV genotypes, subtypes and quasi-species 
The hepatitis C virus belongs to the family Flaviviridae. More specifically, it belongs 
to the genus Hepacivirus, of which it is the only member. Although it shares a similar name 
with hepatitis A and hepatitis B viruses, HCV is genetically and clinically distinct from these 
two viruses (2006). 
HCV is classified into six major genotypes based on phylogenetic analyses. These 
genotypes are numbered 1 through 6 according to a standardized nomenclature first proposed 
in 1994 and later revised and updated (Simmonds et al. 1994; Simmonds et al. 2005). There 
are several subtypes for each genotype and these are represented by letters. Additionally, 
quasi-species have been identified based on genetic comparisons. There is substantial 
sequence variation among the different genotypes (epidemiologically distinct subtypes differ 
by 20-25%), but all of them share the same structure of linear genes which are also almost of 
identical size. 
Subtype 1a is widely distributed in Northern Europe and the USA, and subtype 1b is 
the most common world-wide. Subtypes 2a, 2b and 2c are predominantly found in older HCV 
infected individuals in countries surrounding the Mediterranean and in the Far East. Subtype 
3a is also widely distributed in Europe among intravenous drug users. Subtypes 4a and 5a are 
mainly found in the Middle East and South Africa, respectively. Finally, subtype 6a is 
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typically found among intravenous drug users in Hong Kong, Vietnam and more recently 
Australia. A number of additional subtypes have been identified, but they occur more rarely 
(Simmonds et al. 2005; Timm and Roggendorf 2007).  
1.2.3 Structure and genome 
The hepatitis C virus contains a positive-sense single-stranded viral RNA genome and 
is enveloped by a host cell derived lipid bilayer in which two envelope glycoproteins are 
anchored. The bilayer surrounds the nucleocapsid or core, which is composed of multiple 
copies of the same core protein and this core in turn contains the viral RNA genome (Figure 
1.6). Determining the size of bona fide infectious particles has been hampered by the low 
amount of virus in blood and tissues. A large number of studies have been performed in a 
variety of systems and the particle size found was typically 20-60 nm. Infectious virions are 
likely to be 50-60 nm in diameter  (Wakita et al. 2005; 2006).  
 
Figure 1.6 Structure of the hepatitis C virus (www.wikipedia.org) 
The genome of HCV is approximately 9600 nucleotides in length (Figure 1.7). It is 
structured as one long open reading frame which is flanked by 5‟ and 3‟ non-translated 
regions (NTRs). The 5‟ NTR is important for the first step of HCV polyprotein translation. It 
contains several highly structured domains which contain stem-loops and a pseudo-knot, a 
subset of which forms an internal ribosomal entry site (IRES). The IRES forms a stable pre-
initiation complex by directly binding to the cellular 40S ribosomal subunit and thus initiates 
the cap-independent translation (i.e. without the need of canonical translation initiation 
factors) of the viral RNA. The 3‟ NTR is the initiation site for the synthesis of the negative-
strand viral replication and is also involved in translational regulation (2006; Foster et al. 
2010).  
One long polyprotein is then generated which is subsequently cleaved by host-cellular 
proteases, as well as virally encoded proteases, into the individual proteins which are either 
classified as being structural or non-structural. The structural proteins encompass core (C), 
envelope 1 (E1) and envelope 2 (E2) and the non-structural proteins are p7 (only rarely called 
NS1), NS2, NS3, NS4A, NS4B, NS5A and finally NS5B (2006; Timm and Roggendorf 
2007). 
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The HCV core protein is highly basic and binds to RNA and is therefore thought to 
form the viral capsid. The envelope glycoproteins E1 and E2 are located on the surface of the 
viral particle and partially embedded in the lipid bilayer. They are necessary for viral entry 
and fusion. E1 and E2 are highly glycosylated, containing up to 5 and 11 glycosylation sites, 
respectively. E1 is thought to be involved in intra-cytoplasmic virus membrane fusion, while 
viral attachment is thought to occur via E2. The p7 protein is absolutely required for viral 
reproduction and behaves like an ion channel when reconstituted in artificial lipid 
membranes. Recent work has shown that p7 functions as an H(+) ion channel (also termed 
permeation pathway), acting to prevent acidification in otherwise acidic intracellular 
compartments (Wozniak et al. 2010). NS2 acts as a protease which cleaves the site between 
NS2 and NS3. It is a short-lived protein, which subsequently loses its protease activity and is 
degraded by the proteasome. NS3 in a multifunctional protein: the N-terminal NS3 protease 
cleaves the remaining non-structural proteins, the C-terminal RNA helicase/NTPase unwinds 
RNA and DNA. NS4A is a co-factor of NS3 protease activity. In vitro studies have indicated 
that the NS3-NS4A complex may play additional roles in the host cell. NS4B is an integral 
membrane protein which is thought to act as a scaffold for replication complex assembly, 
induce membrane association and have several other putative properties. The phosphorylated 
zinc-metalloprotein NS5A is multifunctional, playing an important role in virus replication by 
interacting with multiple partners. It is absolutely required for virus replication (Foster et al. 
2010). NS5B encodes the viral RNA-dependent RNA polymerase (RdRp) which replicates 
the viral genome (2006; Timm and Roggendorf 2007). 
 
 
Figure 1.7 The genome of the hepatitis C virus (www.wikipedia.org) 
The gene names beginning with “p” or “gp” are indicative of the predominant kDa size of the 
respective proteins and are part of an older naming system. The current naming system is shown in 
the boxed, colored genes (e.g. C). 
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1.2.4 Viral replication 
HCV interacts with a number of known and as yet unidentified cell surface receptors 
leading to binding followed by internalization of the virus particle. The E2 protein of the 
virus binds to the extracellular loop of CD81 (a tetraspanin expressed on different cell types 
including hepatocytes) with high affinity. Additionally, the scavenger receptor class-B type-I 
(SR-BI), low-density lipoprotein receptor, glycosamino-glycans and the tight junction 
proteins claudin-1 and occluin are necessary for viral entry into the cell  (Sabahi 2009; 
Gouttenoire et al. 2010). 
Once attachment has occurred, fusion takes place between the viral membrane and the 
cellular membrane. Alternatively, particles can also be internalized via endosomes, after 
which membrane fusion occurs (Figure 1.8). Decapsidation of the viral nucleocapsid occurs 
next, allowing the now free positive-strand genomic RNA to enter the cell‟s cytoplasm. 
These RNAs and newly synthesized RNAs serve as mRNAs for the synthesis of the viral 
polyprotein. The viral 5‟ NTR‟s IRES controls the translation of the HCV genome and 
recruits both cellular and viral proteins to perform this task. Once the large precursor 
polyprotein (approximately 3011 amino acids in length) has been generated, it is targeted to 
the ER membrane via an internal signal sequence located between the core and E1 proteins. 
There the ectodomain portion of E1 protein is translocated into the ER lumen. Cleavage of 
the polyprotein by cellular and viral proteases follows, producing the viral proteins. The non-
structural HCV proteins then recruit the viral genome into an RNA replication complex, 
which is associated with rearranged cytoplasmic membranes. NS4B is responsible for 
inducing a specific membrane alteration, termed the membranous web, which serves as a 
scaffold for the replication complex. The replication complex is composed of viral proteins, 
replicating RNA and altered cellular membranes and is considered to be a hallmark of all 
positive-strand RNA viruses. The precise mechanism of HCV replication is not well 
understood, but it takes place via HCV‟s RNA-dependent RNA polymerase NS5B that 
produces a negative strand RNA intermediate. This intermediate is the template for the 
generation of positive strand RNA genomes which are assembled into new viral particles or 
serve as templates for further translation or replication. The mechanisms of viral assembly 
and the release of newly formed viral particles are also poorly understood. Of the non-
structural proteins, most if not all are thought to be involved in this process. Additionally, 
lipid droplets and the very low density lipoprotein pathway have been recently shown to play 
a central role in the production of mature virus particles (2006; Gouttenoire et al. 2010).  
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Figure 1.8 Replication of the hepatitis C virus (www.wikipedia.org) 
1.2.5 Transmission 
HCV is primarily transmitted via parenteral routes, i.e. through piercing the skin or 
mucous membranes. Other methods of transmission are the mucosal exposure to blood or 
serum-derived fluids, as well as environmental sources (e.g. exposure to dried blood). Before 
1990 and the effective screening of donated blood, many cases occurred due to the 
transfusion of HCV-contaminated blood products. In some countries such as the USA, 
intravenous drug use is currently a common method of transmission. High-risk sexual activity 
has also been associated with transmission, as has mother to infant transmission. However, 
20-40% of patients do not have an identifiable risk factor for HCV (2009). 
It has been shown that different viral subtypes are associated with particular 
transmission routes. The transmission of genotypes 1b and 2 is associated with transfusions, 
1a and 3a with intravenous drug use and 4a with unsafe injections in Egypt (Magiorkinis et 
al. 2009). 
1.2.6 Chronic infection 
Most patients who contract HCV are generally asymptomatic in the phase of acute 
infection. Once the HCV RNA viremia persists for six months or more, a patient is 
considered to be suffering from a chronic infection. 54-90% of patients progress from acute 
to chronic infection (some of this variability is likely due to differences in study design). 
Patients suffering from chronic HCV infection have an increased risk of liver cirrhosis, 
hepatocellular carcinoma and death. In retrospective studies, 20-51% of patients with chronic 
HCV infection developed liver cirrhosis within 20 to 30 years of infection, 2-11% developed 
hepatocellular carcinoma and 4-15% died of liver-related causes (2009). 
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1.2.7 Antiviral therapy 
The current standard of care for treating chronic HCV infection is a combination of 
peginterferon and ribavirin. Peginterferon is an antiviral drug consisting of interferon alpha-
2a to which polyethylene glycol (PEG) has been added. The process of adding PEG (also 
termed pegylation) extends the half-life of interferon. Peginterferon acts as an antiviral, 
blocking viral entry into cells and viral replication. It also enhances the immune response. 
Ribavirin is a guanosine analog which is also thought to inhibit viral replication. However, 
the mechanism by which this combination therapy eradicates the virus is not yet well 
understood (Ghany et al. 2009; Shiffman 2010). 
Peginterferon/ribavirin combination therapy yields a sustained virologic response 
(SVR) in 40-45% of patients with HCV genotype 1a/1b and an SVR of 75-80% in patients 
with genotype 2. The other HCV genotypes have SVRs somewhere between those of 
genotypes 1a/1b and 2. As most patients are infected with genotype 1a/1b, the majority of 
patients will fail to achieve SVR using the current treatment method (Shiffman 2010).  
Today, patients are treated using response-guided therapies in which the duration of 
therapy is adjusted based on the time to response (as opposed to older dosing regimens of 
fixed-duration therapy based on genotype). For example, patients with a rapid SVR and a low 
rate of relapse can be treated with peginterferon/ribavirin for 24 weeks irrespective of viral 
genotype. Patients that take longer to respond receive a longer duration of therapy. Non-
responders can be identified after 12 weeks and their treatment stopped (2009; Shiffman 
2010). 
Currently, two protease inhibitors are being evaluated in phase 3 clinical trials and a 
large number of both protease and polymerase inhibitors are in phase 2 clinical trials. While 
protease inhibitors are highly potent and frequently reduce RNA viremia by 3 to 6 logs, the 
rate of viral resistance is high. In contrast, polymerase inhibitors reduce viremia by 2 to 4 
logs and have a lower rate of viral resistance when used as monotherapy. It is anticipated that 
a protease or polymerase inhibitor (also termed direct-acting antiviral agent or DAA) will 
receive US FDA approval in mid to late 2011. It is likely that patients will then begin to 
receive triple therapy consisting of peginterferon, ribavirin and a DAA as a first line therapy. 
It is expected, based on current data and data from ongoing clinical trials, that an SVR of 
70% will be achievable with triple therapy (Shiffman 2010). 
1.3 MHC molecules 
In the aftermath of World War II, the need to treat extensively burned airmen kick-
started the modern era of transplantation biology. It was observed that the second graft from a 
given donor (allograft) was rejected more rapidly and vigorously by its host than the first 
graft, whereas skin transplanted from a new donor would be rejected with the kinetics of a 
first set reaction (Delves et al. 2006). A number of scientists, most notably Peter Medawar, 
began to investigate the immunological basis of this process (Male et al. 2006). This 
eventually led to the discovery that a family of molecules existed which were so variable that 
it was unlikely that two unrelated individuals would have the same combination of variants. 
The human major histocompatibility complex (MHC) is called the human leukocyte antigen 
(HLA) system and is used by the immune system to recognize non-self, to which it generally 
responds with great ferocity (DeFranco et al. 2007).  
The HLA system consists of a 4-Mb gene region on the short arm of chromosome 6 
(6p21.3) which contains over 220 genes of diverse function (Stephens et al. 1999; Horton et 
al. 2004; Robinson et al. 2009). These genes encode proteins which display antigen to T 
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lymphocytes. Of central importance in the protection against pathogens are the MHC class I 
genes (particularly HLA-A, HLA-B and HLA–C) and MHC class II genes (particularly HLA-
DR, HLA-DQ and HLA–DP). Class I genes encode molecules that are expressed on the 
surface of all nucleated cells at varying levels. These molecules bind peptide fragments of 
cytoplasmic and secreted proteins (Figure 1.9) and present them to CD8 T cells, leading to a 
cytotoxic T cell response. An important function of these MHC molecules is to signal viral 
infection.  
 
 
Figure 1.9 The process by which peptides are generated, loaded onto and presented by MHC class I 
molecules (www.wikipedia.org) 
Cytoplasmic protein degradation by the proteasome, transport into endoplasmic reticulum by the TAP 
complex, loading on MHC class I molecules, and transport to the surface for presentation to CD8 T 
cells 
MHC class II molecules are mainly expressed on antigen presenting cells (APCs) 
such as B lymphocytes, macrophages and dendritic cells. Class II molecules are specialized 
to sample the endosomal-lysosomal system and therefore present peptides of extracellular 
origin to CD4 T cells, resulting in cytokine production and T cell help in antibody production 
(Figure 1.10). Supporting the activities of these molecules are the class III complement 
proteins and the inflammatory cytokine genes, which are also located in the HLA region in 
humans (Beerenwinkel et al. 2007; DeFranco et al. 2007). 
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Figure 1.10 MHC class II activation of CD4 T helper cells (www.wikipedia.org) 
As already noted, HLA class I and class II genes are extremely polymorphic 
(Robinson et al. 2009). As of July 2010, 3,937 class I alleles and 1,253 class II alleles have 
been named and the growth in the total number of observed alleles is projected to continue 
for some time. Additionally, HLA-B has been confirmed as the most polymorphic gene in the 
human genome (Mungall et al. 2003). Allelic variation occurs both within and between 
different ethnic groups (Middleton et al. 2003; Solberg et al. 2008). Linkage disequilibrium, 
where the alleles at one HLA locus are not randomly distributed with respect to the alleles at 
another HLA locus, has been described between different loci in the HLA region (Miretti et 
al. 2005; Beerenwinkel et al. 2007).  
Due to the high number of polymorphisms in the HLA genes, most individuals are 
likely to be heterozygous at most polymorphic loci. The expression of HLA alleles is co-
dominant, as both alleles of a locus are expressed on a cell‟s surface and each allele is able to 
present peptides to T cells (Figure 1.11). Polymorphisms in HLA molecules are primarily 
concentrated among amino acids which are responsible for the binding of the foreign peptide. 
These amino acids are located on the floor or on the inner walls of the peptide-binding cleft. 
The polymorphisms cause the clefts to have different sizes and chemical characteristics in 
different allele variants. Therefore, although all HLA molecules can bind large and diverse 
sets of peptides, different HLA molecules have preferences in their binding affinities and 
specificities (Beerenwinkel et al. 2007; Murphy et al. 2008).  
Groups of HLA-A, -B and -DR alleles, termed supertypes, have been identified which 
share specific binding preferences for peptides or supermotifs of a similar size, charge and 
amino acid composition. Clustering HLA molecules into such supermotifs facilitates epitope 
identification and vaccine design (Sette and Sidney 1999; Lund et al. 2004; Sidney et al. 
2008). 
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Figure 1.11 The co-dominant expression of MHC alleles (www.wikipedia.org) 
1.4 T Cell Receptors and T Cell Development 
1.4.1 Lymphocyte development 
In mammals, lymphocyte development mostly occurs in specialized areas called the 
central lymphoid organs: bursa-dependent (B) cells develop in the bone marrow and in the 
liver of fetuses, thymus-dependent (T) cells develop in the thymus (Murphy et al. 2008). 
Bursa-dependent refers to the bursa of Fabricius in birds, which is an outpouching of the 
cloaca, where these cells were originally described. Both fetuses and juvenile mammals 
produce large numbers of lymphocytes which move into peripheral lymphoid tissues and 
populate them. In adult mammals, B cells are still continually formed in the bone marrow, but 
T cells are only formed at a much reduced rate in the thymus. T cell numbers in adults are 
instead maintained by mature T cells dividing outside of the central lymphoid organs (Paul 
2008).  
T cell precursors originate in the bone marrow where they develop from a common 
lymphoid progenitor, which also gives rise to B cells (Murphy et al. 2008). Subsequently, 
these T cell precursors move from the bone marrow to the thymus, where they eventually 
mature (von Boehmer et al. 2003; Werlen et al. 2003; Hogquist et al. 2005; Siggs et al. 2006). 
The thymus contains a network of epithelia called the thymic stroma, which provides a 
microenvironment for the developing bone marrow-derived T cell precursors which are 
committed to the T cell lineage. These T cell precursors, having arrived in the thymus, 
undergo differentiation for one week prior to undergoing a period of intense proliferation. 
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Only a small proportion of these cells (less than 1-3%) survive apoptosis and leave the 
thymus as mature T cells (Scollay et al. 1980; Egerton et al. 1990; Goldrath and Bevan 1999); 
the vast majority are ingested by macrophages in the thymic cortex. This widespread 
apoptosis is a crucial aspect of T cell development, as it represents the process of negative 
selection (also called clonal deletion). During this process, double-positive (having the 
surface markers CD4 and CD8) or single-positive (having only the surface marker CD4 or 
CD8) thymocytes which express T cell receptors (TCRs) with a high affinity for self antigens 
are eliminated (Starr et al. 2003; Klein et al. 2009). Contact occurs between the TCRs of the 
developing thymocytes and the cortical stroma, which is composed of epithelial cells with 
long branching processes that express both MHC class I and MHC class II molecules on their 
surface. This intense screening allows each new T cell to be tested for its ability to recognize 
MHC-self peptide complexes and if the affinity is too strong the cell is destroyed, thereby 
building self tolerance. Additionally, thymocytes which express TCRs with little or no 
affinity for MHC-self peptide complexes die of neglect. Therefore, only thymocytes with 
TCRs which have an intermediate affinity allow for positive selection: immature double-
positive thymocytes with intermediate affinity and/or avidity for self-peptide-MHC 
complexes are induced to differentiate into mature single positive thymocytes (DeFranco et 
al. 2007; Paul 2008).  
Commitment to the CD4 or CD8 lineage is accompanied by commitment to either the 
helper or cytotoxic T cell function, which occurs due to the differential expression of the T-
helper-inducing POZ/Kruppel-like factor (Th-POK) or runt-related transcription factor 
(RUNX) transcription factors (Collins et al. 2009). After CD4 or CD8 lineage commitment, 
where double positive thymocytes become single positive thymocytes, cells are exported 
outside of the thymus. Cells of the CD4 helper T cell lineage recognize MHC class II 
molecule complexed with antigenic peptides, whereas the CD8 cytotoxic T cell lineage 
recognizes MHC class I molecule peptide complexes. Each lineage therefore retains the co-
receptor necessary for recognizing the type of MHC molecule preferentially bound by the 
TCR of that cell type. When cells of both lineages are exported to the periphery they become 
part of the peripheral T cell repertoire. The time period between the entry of the progenitor T 
cells into the thymus and the export of mature cells into the periphery has been estimated to 
be 12 days (DeFranco et al. 2007). 
Recent work suggests that maturing thymocytes need to have repeated engagements 
with antigen presenting cells (APCs) as they travel through the thymus. Positive selection 
occurs in cases where there is continuous low-level stimulation through a series of brief 
encounters with MHC-self peptide complexes presented by the thymic stromal cells. This 
way, developing thymocytes sample many cell surfaces, increasing the chance that they may 
encounter a negatively selecting ligand (Ebert et al. 2008).  
1.4.2 Gene segment rearrangements in maturing T cells 
Each mature T cell expresses a unique antigen receptor on its surface; during the 
maturing of the cells in the thymus, a sequential rearrangement of antigen receptor gene 
segments occurs which ultimately generates this unique antigen receptor. All jawed 
vertebrates appear to contain the same four homologous TCR isotypes: TCRα, TCRß, TCRγ 
and TCRδ (Rast et al. 1997). There are two subsets of T cells, differentiated by the exact pair 
of receptor chains that they express. These are either the TCRα and TCRß pair or the TCRγ 
and TCRδ pair. Most cells express the α:ß heterodimeric receptor and hence the focus of this 
work will be on this more common receptor type. Cells expressing the α:ß TCR typically 
recognize peptide antigens which are presented on the MHC encoded molecules, while cells 
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expressing the γ:δ heterodimer are thought to be either restricted to non-classical MHC class I 
molecules or bind free antigen, such as invariant molecules released by damaged cells 
(Brenner et al. 1986; Clevers et al. 1988; Hayday 2000). 
The human loci which encode the T cell receptor subunits consist of separate variable 
(V), diversity (D), joining (J) genes, as well as constant (C) genes. The locus for human 
TCRα is located on chromosome 14q11.2 and spans 1000 kb. The germline organization 
consists of 54 V genes, of which only 44 to 47 genes are functional. Further 3‟ in the locus, a 
cluster of 61 J genes exists, followed by a single C gene. The genes of  TCRδ are nestled 
within the TCRα locus, located between the V and J genes (Lefranc 2001; Giudicelli et al. 
2005).  
The locus for TCRß is located on 7q35 and spans 620 kb. The germ-line organization 
of the TCRß locus is somewhat different from TCRα: 76 V genes exist, not all of which are 
functional, followed by a single D gene, 7 J genes, a single C gene, another D gene, 7 J genes 
and finally a single C gene. The C genes of the TCRß locus consist of separate exons which 
encode a number domains. The genes of  TCRδ are nestled within the TCRα locus, located 
between the V and J genes. (Lefranc 2001; Giudicelli et al. 2005). 
The nomenclature for human T cell receptor genes which will be used here is 
consistent with that proposed by the developers of the International IMmunoGeneTics 
database (IMGT) (Lefranc 2001; Giudicelli et al. 2005) and which was also approved by the 
Human Genome Organization (HUGO) Nomenclature Committee in 1999. For example, 
TRAV7 indicates V gene 7 of TCRα, whereas TRGC1 indicates C gene 1 of TCRγ. 
In both human and mice, TCRδ is the first locus to rearrange during the maturation of 
T cells in the thymus. This is closely followed by the rearrangement of TCRγ and TCRß loci 
and finally TCRα rearranges (Blom et al. 1999; Livak et al. 1999; Joachims et al. 2006).  
A mature T cell expresses either α:ß or γ:δ TCR heterodimers on its surface and the 
process by which a bipotent precursor cell commits to one of these two lineages is termed 
lineage commitment. The exact process through which this occurs is unknown and a number 
of models have been proposed to explain it (Joachims et al. 2006). These models include 
instructive model in which precursor cells are bipotent, but the development of a functional 
γ:δ TCR leads to the development of a cell with the γ:δ heterodimer on its surface. 
Alternatively, if a so-called pre-TCR complex forms, the cell becomes a α:ß cell (Dudley et 
al. 1995; Livak et al. 1999). In the stochastic or separate lineage model, the commitment is 
thought to precede gene rearrangement (Winoto and Baltimore 1989; Kersh et al. 1995; Sim 
et al. 1995). And finally, the more recent signal strength model states that the type of cell 
which develops is determined by the strength of signals transduced by TCRs: weak signals 
lead to the development of α:ß cells and strong signals produce γ:δ cells (Haks et al. 2005; 
Hayes et al. 2005). 
Once germline rearrangement is completed the TCRα locus consists of a V gene, a J 
gene and C gene, which produces the mRNA encoding the TCRα chain. The rearranged 
TCRß consists of V, J, D and C genes which also produce one mRNA encoding the TCRß 
(Krangel 2009). The hypervariable regions in both TCRα and TCRß are known as CDR1, 
CDR2 and CDR3, where CDR stands for complementarity determining region. These 
hypervariable regions participate in antigen binding and determine the structural 
complementarity of the receptor to the antigen. CDR1 and CDR2 are encoded by the V gene,  
whereas CDR3 is encoded by the J gene (TCRα) or the D and J genes (TCRß). The constant 
region (encoded by the C gene) does not participate in antigen binding and does not vary 
between cells which have different antigen specificities (DeFranco et al. 2007).  
TCR diversity is generated in a number of different ways, one of which is the 
assembly of different V-J or V-D-J combinations. Also, the dimerization of different TCRα 
and TCRß chains is promiscuous, although not all TCRα  and TCRß isotypes are able to form 
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dimers due to structural constraints. However, the most significant source of TCR diversity is 
a process by which the sequences at the junctions of the V, D and J genes are partially 
digested and random nucleotide sequences of variable length are inserted during junction 
assembly via an enzyme complex called the V(D)J recombinase. Proteins that make up the 
V(D)J recombinase complex and that are important for this process are RAG-1 and RAG-2, 
which are specifically found in lymphoid cells (Melek et al. 1998; Gellert 2002; Krangel 
2009).  
Interestingly and controversially, some authors believe that TCR revision is possible 
once the mature T cells have left the thymus. TCR revision is the process by which mature 
peripheral self-reactive T cells (which are thought to only exist in very small numbers, having 
escaped the selection process in the thymus) lose surface expression of their TCR, reinduce 
the expression of the recombinase machinery, then rearrange the genes which encode 
extrathymically generated TCRs for antigen and finally express these new receptors on the 
cell surface (Hale and Fink 2010).  
1.4.3 Antigen binding 
Because the activation of naïve T cells in the face of infection requires sustained  
signaling from the TCR, the TCR must bind the MHC-peptide complex with high enough 
affinity to ensure such sustained signaling is possible (Carreno et al. 2006). A number of 
structures of TCRs bound to their MHC-peptide ligands have been reported, where the 
interaction occurs between the MHC-peptide and CDR loops of the TCR: the CDR1α, 
CDR2α, CDR1β and CDR2β loops which are germ-line encoded and the CDR3α and CDR3β 
loops, which are only partially germ-line encoded. TCRs often lie in a diagonal, across the 
face of the MHC-peptide antigen with the interaction partners typically being as follows: 
CDR1α, CDR2α are usually located facing the α2 helix of the MHC class I or the β1 helix of 
the MHC class II molecules; CDR1β and CDR2β are usually located facing the α1 helix of 
the MHC class I or MHC class II molecules; CDR3α and CDR3β have interactions with the 
peptide. The angle and pitch of the TCR versus the MHC-peptide varies because of the 
differing bound peptides and the variable CDR3 sequences (Marrack et al. 2008). 
The interaction sites between the TCR and MHC-peptide are inherently flexible and 
can be difficult to identify. Rules that govern the reactions between TCR and MHC-peptide, 
apart from the usual diagonal orientation and the placement of the TCR V region loops over 
the α-helices of the MHC, have not been apparent. In a detailed study of CDR1 and CDR2 
loops in human and mouse complexes, Marrack et al., identified built-in biases in the TCR 
variable regions which bind to MHC-peptide antigens. The authors state that nearly all 
structures in the analysis would have been subjected to normal negative selection and 
therefore unlikely to demonstrate all their built-in abilities to react to MHC-peptide. Fourteen 
MHC class I complexes (8 human and 6 mouse) were examined, as were 8 MHC class II 
complexes (4 human and 4 mouse). This dataset included all structures which were available 
at the time, excluding duplicates of particular TCR-MHC-peptide combinations and ones 
analyzed in a previous publication (Feng et al. 2007). The dataset was also heavily biased 
with respect to the use of specific TCRβ subunits, both in the case of human (TRBV6 or 
Vβ13 using an older nomenclature system) and mouse (Vβ8), which can be expected to skew 
the identified similarities. Positions in the TCR CDR loops which commonly interacted with  
the MHC-peptide commonly were: 
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 CDR1α amino acid positions 28, 29 (frequently Y), 31 (frequently Y/F) 
 CDR2α amino acid positions 50 (frequently Y), 51 (frequently S), 52  
 CDR1β amino acid positions 28, 29 (frequently N/Y) 
 CDR2β amino acid position 46, (frequently Y/F), 48 (frequently Y), 54 
(frequently D/E) 
 
Marrack et al. also observed that some of these TCR amino acids tended to interact 
with particular MHC class I amino acids: 
 
 CDR1α amino acids positions 29, 31 tended to interact with MHC class I α2 
domain‟s amino acid in position 158 
 CDR2α amino acids positions 50, 51 tended to interact with MHC class I α2 
domain‟s amino acid in position 158 
 CDR1β amino acids positions 28, 29 tended to interact with MHC class I α1/α 
domain‟s amino acid in position 69 
 CDR2β amino acids positions 46, 48 tended to interact with MHC class I α1/α 
domain‟s amino acid in position 69 
 
For MHC class II amino acids the pattern was similar: 
 
 CDR1α amino acids positions 29, 31 tended to interact with MHC class II β1 
domain‟s amino acid in position 73 
 CDR2α amino acids positions 50, 51 tended to interact with MHC class II β1 
domain‟s amino acid in position 73 
 CDR1β amino acids positions 28, 29 tended to interact with MHC class II α1 
domain‟s amino acid in position 64 
 CDR2β amino acids positions 46, 48, 54 tended to interact with MHC class II 
α1 domain‟s amino acid in position 64 
 
The authors theorized that the rules did not apply consistently in all cases due to 
differences in the CDR3 regions of the TCR (which were not included in the study). 
The roughly diagonal binding orientation (±75º) of α:β TCR on the surface of the 
MHC-peptide is similar in most structures that have been crystallized so far. However, 
because  there is some variation in the binding angle it has been difficult to identify all 
residues involved in the interaction of the complex (Wucherpfennig et al. 2010). Yet some 
researchers believe that gaining such an understanding may not even be necessary, as some 
TCR V genes may have coevolved with MHC genes and thus the TCR V-domains contain 
residues which have preferred contacts with the MHC molecule. This hypothesis has been 
around for some time (Jerne 1971) and a number of cellular, functional and biochemical 
studies support it, yet it remains controversial.  
It is thought that invariant germ-line V genes, which encode both CDR1 and CDR2, 
are involved in such germ-line encoded recognition, while somatically rearranged CDR3, 
which is encoded by the J gene (TCRα) or the D and J genes (TCRß), is not. Thus, both 
CDR1 and CDR2 are susceptible to evolutionary selection, unlike the somatically generated 
CDR3 loops; the “invariant” regions of the TCR and MHC are paired, as are the “variable” 
regions of the CDR3 and the peptide. It has been calculated that 75-80% of the binding 
surface involves contacts between CDR1, CDR2 and the MHC which may also have 
encouraged such a coevolution (Garcia et al. 2009). 
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Garcia et al. analyzed structures produced by two previous studies (Feng et al. 2007; 
Dai et al. 2008). They examined the seven complexes: 
 
 3 Vβ8.2 TCRs complexed with mouse I-A
u
 MHC molecules 
 2 Vβ8.2 TCRs complexed with mouse I-A
b
 MHC molecules 
 1 Vβ8.1 TCR complexed with mouse I-A
b
 MHC molecule 
 1 Vβ8.2 TCR complexed with mouse I-A
k
 MHC molecule 
 
Not only do the MHC alleles vary, as described above, but there are different peptides 
(MPB1-11, Con A and 3K) and the TCR Vα chains (Vα4.2,  Vα4.1,  Vα3.1 and Vα2.3) in the 
complexes differ as well. The Protein Data Bank accession numbers of six structures in the 
study were 1U3H, 2Z31, 2PXY, 1D9K, 3C60 and 3C61 (one structure did not have its 
accession number specified). Superposition shows close conversion of the CDR1β and 
CDR2β contacts with the I-A α1 chain helix. All complexes show a similar “knob-in-the-
hole” complementarity in which the Y48 of CDR2β occupies a depression in the α1 helix of 
the I-A MHC molecule. This interaction is surrounded by a halo of side-chain interactions 
and the authors found this coincidence very striking, despite the differences in the Vα chain, 
the peptides and the differing MHC alleles in each complex. Garcia et al. consider this to be 
the strongest evidence to date that this interaction is encoded at the level of pair-wise 
interactions. 
Work confirming this hypothesis was performed in mice which expressed a single 
rearranged TCRβ chain with individual mutations of the Y46, Y48 and E54 residues (Scott-
Browne et al. 2009). Mutations of these residues into alanine substantially reduced the 
development of the entire T cell repertoire. The phenotype was particularly strong in the case 
of the Y46 or Y48 mutations. Interestingly, the lower binding affinity of the Vβ segment led 
to the pairing of TCRβ chains with higher affinity TCRα chains. The authors conclude that 
their work demonstrates that thymic selection is controlled by specific germ-line encoded 
contact points in the MHC and that the near obligate requirement for these amino acids 
indicate that these amino acids might confer “generic” MHC reactivity to TCRs. 
1.4.4 T cell receptor cross-reactivity 
It has been shown that there are far more potentially immunogenic peptides in the 
environment than there are T cells in an individual at any point in time (Mason 1998). The 
stringent positive selection process in the thymus of developing T cells leads not only to the 
survival of cells which have maximum sensitivity for recognizing non-self peptides, but also 
to T cells which have a low affinity for MHC molecules bearing peptides derived from host 
proteins (Starr et al. 2003). Therefore the mechanism of TCR cross-reactivity (also 
sometimes referred to as alloreactivity or degeneracy) was proposed to explain the greater 
effective size of the TCR repertoire (Yin and Mariuzza 2009).   
There are currently five conceptually distinct mechanisms which have been identified, 
which help explain how cross-reactivity works at the atomic level (Yin and Mariuzza 2009): 
(1) induced fit where the binding site is conformationally flexible allowing it to bind to 
multiple MHC peptide antigens (Mazza et al. 2007), (2) differential TCR docking where the 
same TCR binds to different MHC-peptide antigens using different docking orientations 
(Colf et al. 2007), (3) structural degeneracy where suboptimal complementarity between the 
TCR and peptide can be improved by variations in the peptide (Li et al. 2005), (4) molecular 
mimicry where different MHC-peptide ligands with very similar interfaces can be bound by a 
cross-reactive TCR (Harkiolaki et al. 2009; Macdonald et al. 2009) and (5) antigen-dependent 
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tuning of MHC-peptide flexibility where the conformational dynamics in the ligand allow for 
it to be recognized upon TCR binding (Borbulevych et al. 2009). 
The “codon hypothesis” (Garcia et al. 2009) states that germ-line TCR-MHC 
interactions can occur in two ways. First, each TCR can bind to different MHCs with low 
affinity, yet in a specific manner and therefore the binding orientation can differ, dependent 
on the binding partner; a TCR gene product (Vx) can bind multiple MHC molecules (Y, X or 
Z) and engages them in different highly specific ways. Second, a given TCR can bind to the 
same MHC molecule with entirely unrelated chemistries; a TCR gene product (Vx) can bind 
to the same MHC (Y) using several distinct codons (A, B or C) and this is thought to be 
influenced by the CDR3 sequence and the peptide. This would explain how different peptides 
bound to the same MHC, produce very different docking footprints with the same TCR (Feng 
et al. 2007; Dai et al. 2008). In this manner, the peptide is involved in determining the final 
docking geometry as it selects from a limited menu of predefined codons. 
1.4.5 TCR/MHC-peptide binding geometry 
In MHC class I and class II structures, the peptides are presented in an extended 
conformation in a vice-like groove. The bound peptides are flanked by two α-helices and the 
floor of the binding groove is composed of an anti-parallel β-strand. The ends of the peptide 
binding groove are closed in class I structures, limiting the length of the peptide which can be 
bound, while in class II structures the groove is open, which allows for much longer peptides 
to be bound (Murphy et al. 2008). The TCR heterodimer is generally oriented diagonally 
relative to the long axis of the MHC peptide binding groove (Garboczi et al. 1996; Garcia et 
al. 1996). The Vα of the TCR is positioned above the N-terminal half of the peptide and the 
Vβ of the TCR is located above the C-terminal half of the peptide. Previous analyses have 
shown that most contacts between the TCR and the peptide occur via the highly variable 
CDR3 loops. Contacts between the TCR and MHC are mediated mostly through the CDR1 
and CDR2 loops (especially those of  the Vα domain), whereas  CDR3 make a smaller 
contribution in the number of conserved contacts. The binding orientation is thought to be 
driven through long-range electrostatic steering or through a low-affinity binding event, 
subsequent to which the CDR loops maximally mold to the MHC-peptide providing the final 
docking orientation (Rudolph et al. 2006).  
There has been a number of different approaches for describing the TCR to MHC-
peptide binding orientation or how the TCR crosses the MHC binding platform (also referred 
to as the crossing angle). One widely applicable recent approach has been proposed by 
Rudoph et al. in which relative rather than absolute values are used in the calculations to 
define the general principles. The crossing angle is determined by calculating a vector along 
the MHC axis, drawing a best-fit straight line through the Cα atoms of the two MHC α-
helices. For MHC class I, these are the Cα atoms A50-A86 and A140-A176. A second vector 
describing the long axis of the TCR binding site is calculated by constructing a vector 
between the centroids of the conserved Ig disulfide-forming sulfur atoms in TCR α:β 
heterodimers  (L22-L90 and H23-H92). The crossing angle between the MHC and TCR 
vectors is the dot product of the two vectors. Using the described method, the crossing angles 
in TCR-MHC class I peptide complexes were found to be roughly diagonal and range from 
21º to 70º. Additionally, there is also significant variation in the tilt and role of the TCR on 
top of the MHC (Rudolph et al. 2006). 
CHAPTER 1. INTRODUCTION 
 
 
 
 
26 
 
  
1.4.6 T cell activation 
T cell activation occurs in the secondary lymphoid tissue, where recirculating naïve T 
cells bind to mature activated dendritic cells. Dendritic cells are specialized cells which ingest 
debris and infectious agents in peripheral tissues and then migrate into the lymphoid tissue. 
Some dendritic cells are resident in the lymphoid tissue and function as phagocytes before 
maturing into APCs (DeFranco et al. 2007). 
Once TCR ligation has occurred an intracellular signaling cascade is initiated; several 
pathways are activated within the T cell leading to T cell activation and proliferation (Smith-
Garvin et al. 2009). The exact mechanism of initial TCR triggering is unknown and is still 
hotly disputed (Fooksman et al. 2010; Ma and Finkel 2010). Subsequent to initial triggering, 
TCR signaling is mediated via the immunoreceptor tyrosine-based activation motifs (ITAMs) 
located in the cytoplasmic tails of the CD3 molecule. Then, several major pathways in the T 
cell are activated: (1) the protein tyrosine kinase Lck phosphorylates the ITAM tyrosines, 
which then recruit and phosphorylate the zeta chain associated protein of 70 kDa (ZAP70), 
eventually leading to the assembly of a large protein complex built on the linker for 
activation of T cells (LAT) protein (2) an increase in the intracellular calcium levels and (3) 
the production of diaglycerol (DAG) followed by the activation of pathways involving the 
key signaling molecule Ras and protein kinase C isoforms (PKCθ). Subsequently, a 
proliferation of activation and a clonal expansion of the T cells occurs via the induction of 
cytokine gene transcription. CD8 cytotoxic T cells mature and acquire the capacity to lyse 
target cells through the release of cytotoxic molecules. CD4 helper cells activate other cells 
including  phagocytes, mast cells, basophiles, eosinophils and B cells, which then go on to 
differentiate into antibody producing cells (Murphy et al. 2008). 
1.4.7 Modeling the thymic selection of T cell receptors 
T cell immune responses are dependent on the appropriate and effective processing of 
peptides from a protein source, the stable binding of the peptide to the MHC molecule and 
recognition of this complex by the TCR. Of these three steps, the binding of the peptide to the 
MHC is the most selective event. There is a large body of work from last 20 years, which has 
examined MHC-peptide binding (Lafuente and Reche 2009). The study of a representative 
cross-section of such methods has been shown them to have high prediction accuracies 
(Roomp et al. 2010).  
However, there is still a significant proportion of stable MHC peptide complexes 
which elicit no TCR response. Comparatively little work has been performed on predicting 
which TCR will bind to MHC-peptide complexes. Simplified representations of amino acids, 
represented as a string of numbers or bits, have been used to study negative selection and 
TCR cross-reactivity (Detours et al. 1999; Detours and Perelson 1999; Chao et al. 2005).  
A more recent approach has been developed in which the problem was studied 
numerically but still in a significantly simplified form (Kosmrlj et al. 2008; Kosmrlj et al. 
2009; Kosmrlj et al. 2010) . The TCR and MHC plus peptide (subsequently referred to as 
MHC-peptide) complexes are each modeled numerically as strings of amino acids. The 
strings (typically both 10 amino acids in length) represent the amino acids at the interface 
between the TCR and MHC-peptide complex and the model assumes that only one site on the 
TCR interacts with a corresponding site which consists of the bound peptide. Both the 
segment of the TCR and the segment of the peptide are modeled as being of equal sequence 
length. The TCR segment represents the highly variable CDR3 and interactions between the 
TCR and MHC are not explicitly considered.  
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Subsequently, in silico thymic selection experiments were carried out where an HLA-
dependent number of thymic self-peptides where chosen, according to their frequency of 
appearance in the human proteome. Similarly, immature thymocytes (CD8 T cells) were 
generated by choosing amino acids which contacted the peptide according to the probabilities 
with which amino acids appear in the human proteome. A mature T cell emerged from the 
thymus only when its TCR had bound to at least one self-peptide with an affinity that 
exceeded the positive selection threshold, but did not exceed the negative selection threshold. 
After emergence from the thymus, the mature T cell was challenged by a viral peptide bound 
to the same MHC type (which, as already noted, was not explicitly considered). If the 
interaction strength exceeded that of the negative selection threshold the TCR was considered 
to successfully recognize the peptide. Additionally, TCR cross-reactivity was assessed by 
mutating each TCR contact residue to the other 19 amino acid types. Sites on the viral 
peptide were considered to be important, if half or more of the mutations caused the 
recognition by the TCR to be abrogated. The authors concluded that negative selection skews 
the mature T cell repertoire to TCRs composed of peptide contact residues enriched in amino 
acids that bound weakly to amino acids in the peptide.  
The authors (Kosmrlj et al. 2008) also qualitatively compared their in silico results 
with those of 18 unspecified crystallized TCR-MHC-peptide complexes from the PDB: the in 
silico predictions were assessed for their strength of interaction with other amino acids and 
compared to the strength of such interactions in solved crystal structures, which were divided 
into two classes (weak and strong). The authors assert that data obtained from the crystal 
structures was in qualitative agreement with the theoretical prediction that weakly interacting 
amino acids on the TCR are enriched, whereas strongly interacting amino acids are 
attenuated. Overall, it can be said that the current in silico approaches predicting which TCR 
residues are likely to interact with the MHC-peptide antigen are still highly simplified, but 
the models do give important insights into the population dynamics of the T cell repertoire 
and its interaction with viruses such as HIV-1 (Kosmrlj et al. 2010).  
1.5 Host-Virus Dynamics: The Interplay of Host Genetic Factors and 
Viruses 
The most common recurring infections in humans are due to viruses. The major innate 
response to viruses is by type 1 interferons, complement and natural killer (NK) cells. The 
major adaptive protection against viruses is via antibodies and cytotoxic T cells. CTLs are 
able to recognize infected host cells because these cells present viral protein fragments in the 
form of peptides bound to HLA class I molecules on their cell surface. Once the HLA/peptide 
complex has been recognized by the CTL‟s T cell receptor, the CTL will release cytokines, 
chemokines and molecules such as perforin and granzyme that result in the lysis and 
apoptosis of the infected cell (DeFranco et al. 2007). 
 Host genetic profiles play an important role in the course and outcome of viral 
diseases. These genetic profiles have a significant impact on the susceptibility or resistance to 
infection, the rate of disease progression and therefore the clinical manifestations of the 
disease. However, the rapid rate of viral evolution in viruses such as HIV-1 and HCV allows 
the virus to adapt to specific host genetic profiles. The increased understanding of the 
interplay between the host and the virus has provided important insights into the large 
variation in responses to viral infection, where some patients are resistant to infection  
whereas others progress to more advanced forms of disease in a very short time period. 
Genetic resistance is an important aspect of the viral adaptation to the host and its analysis is 
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an important aspect of the treatment of viral disease. The HLA genotype of an individual 
appears to play an important role in the progression of the disease (Beerenwinkel et al. 2007).  
When regions of viral proteins are presented as epitopes by HLA molecules, an 
immune response may be triggered. Therefore, the less likely it is for a particular peptide to 
be presented by an HLA molecule, the lower the overall immune response of the patient 
against that particular peptide will be. In certain HLA genotypes, a mutation away from the 
viral consensus sequence might be beneficial in promoting immune escape. The ability of the 
viruses such as HIV-1 and HCV to mutate rapidly enables them not only to develop 
resistance mutations to anti-retroviral therapy, but also to adapt to the HLA genotype of the 
infected individual. This type of mutation is frequently termed an escape mutation (Perelson 
et al. 1996; Beerenwinkel et al. 2007; Bostan and Mahmood 2010). 
Once such an escape mutation has occurred it has three potential evolutionary fates. It 
may revert to the wild-type amino acid on transmission to an individual of another HLA 
genotype. In this case, the wild-type amino acid will remain a target for the immune system. 
Alternatively, the escape mutation might be stable and the epitope that contains it will no 
longer be a target for the immune system. Such an escape mutation will reach fixation in a 
population over time as all other amino acid variants at that position are eliminated leaving 
only the escape mutation. The original epitope therefore also no longer exists and has become 
extinct. Finally, the escape mutation might not revert to wild-type, but could still be 
contained in a recognized epitope. In this case, the frequency of the mutation will equilibrate 
in the population and thus continue co-exist with the wild-type amino acid (Leslie et al. 2005; 
Beerenwinkel et al. 2007). 
A number of large, population-based HLA class I association studies have been 
conducted with HIV-1. Studies were performed on cohorts of differing ethnicity and focusing 
on differing HIV-1 subtypes. They have associated some HLA molecules with better 
responses to viral infection (e.g. HLA-B*27) and others to faster progression of disease (e.g. 
HLA-B*3502). Several smaller studies have been performed analyzing the effects of HLA 
class II genes on disease progression. Also, numerous distinct viral epitopes have been 
identified which contain viral escape mutations (Kaur and Mehra 2009; Kawashima et al. 
2009; Ferre et al. 2010a; Shankarkumar et al. 2010). 
An analysis of the percentages of viral amino-acid positions, at which polymorphisms 
away from population consensus were significantly associated with the HLA-A, -B and -C 
allelic groups, found that there is great variability across the HIV-1 genome. Some viral 
genes have no statistically significant associations, whereas others have over 2% of their 
amino acids involved in significant associations (Kiepiela et al. 2004). Other work has shown 
that defined CTL epitopes tend to cluster in regions with distinct characteristics: conserved 
regions appear to have more epitopes, highly variable regions that lack epitopes bear 
cumulative evidence of past immune escape that may make them relatively refractive to CTL 
cells, and epitopes are more highly concentrated in α-helical regions of HIV-1 proteins 
(Yusim et al. 2002).  
The association between immune control of HIV-1 and the HLA genotype of an 
individual is particularly striking for alleles of the HLA-B locus. The alleles HLA-B*27, 
HLA-B*51 and HLA-B*57 have been associated with the control of infection, the alleles 
HLA-B*58 and some HLA-B*35 alleles lead to more rapid disease progression. The HLA-B 
locus is not only the most polymorphic of the three major HLA class I loci, but also the most 
polymorphic in the human genome. Work showing the critical factor linking the protective 
HLA-B alleles is that they present a relatively large number of HIV-1 Gag protein epitopes, 
whereas the HLA-B alleles that lead to a more rapid progression of disease present few to no 
Gag protein epitopes. Further population-based studies have shown that an increased breadth 
of Gag-responses in patients is correlated with decreased viral load and therefore effective 
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control of infection, and such a correlation has not been seen with other non-Gag-responses. 
It is thought that there are several reasons why Gag protein epitopes are important for 
immune control of HIV-1. Firstly, the Gag protein displays very little inter-individual 
sequence variation when compared to other HIV-1 proteins, which implies that sequence 
changes in this gene are not well tolerated because they lead to significant reduction in fitness 
cost for the virus. And secondly, Gag is considered to be highly immunogenic probably 
because of its high abundance in cells infected by the virus (Matthews et al. 2008; Webster 
2009). 
A recent comparison of elite HIV-1 controllers (viral load of fewer than 75 
copies/ml), viremic controllers (viral load of 75 to 2000 copies/ml) and non-controllers (viral 
load of more than 10,000 copies/ml) showed that HIV-specific CD8 T-cell responses are 
common to both blood and mucosa, but that Gag-specific responses dominate in the rectal 
mucosa of  controllers. Controllers had responses to both HLA-B*27- and HLA-B*57-
restricted epitopes in both tissues and the magnitude of the response, measured by testing the 
spot-forming cells (SFC) per million, was greater than those epitopes recognized by other 
alleles. In contrast, the responses of non-controllers were more evenly distributed among the 
HIV-1 genes examined (Gag, Env and Nef) (Ferre et al. 2010b). 
An important new study has examined host genetic effects on the outcome of chronic 
HIV-1 infection. The authors performed a genome-wide association study comparing HIV-1 
controllers and progressors of multiple ethnic groups. Controllers were defined as having had 
their plasma viral load measured at least three times and the resulting levels measured fewer 
than 2000 RNA copies/ml over at least a one year in the absence of antiviral therapy (median 
viral load 241 copies/ml, CD4 count 699 cells/mm
3
, disease duration 10 years). Such 
individuals also typically maintained stable CD4 cell counts, did not develop clinical disease 
and were less likely to transmit disease to others. Progressors were chronically infected 
treatment-naïve individuals with a median viral load of 61,698 copies/ml and CD4 count 224 
cells/ mm
3
. In the largest ethnic group, which consisted of individuals of European ancestry, 
313 single nucleotide polymorphisms of genome-wide significance were identified (i.e. the 
P-values for these SNPs remained significant after correction for multiple testing and  
applying other experimental quality control measures). Every one of these SNPs was located 
in the MHC region of chromosome 6. The African American and Hispanic ethnic groups had 
similar results. Specific examination of the CCR5-CCR2 locus, which had been associated 
with HIV-1 disease progression in previous studies, only showed nominal (uncorrected) 
statistical significance in this new analysis. This work underscores that HLA-viral peptide 
interaction is the major factor modulating durable control of HIV-1 infection (Pereyra et al. 
2010). 
It is well established that MHC class II alleles bind epitopes promiscuously (Panina-
Bordignon et al. 1989; O'Sullivan et al. 1991). More recent work, systematically examining a 
broad selection of HIV-1 and EBV epitopes known to bind to MHC class I alleles, was also 
able to show that there is significant promiscuity for this allele class (Frahm et al. 2007). This 
confirmed work which examined small numbers of epitopes that had been evaluated in the 
context of HLA supertypes i.e. the identified epitopes bound to differing alleles which 
belonged to the same supertype (Threlkeld et al. 1997; Burrows et al. 2003; Masemola et al. 
2004), but also showed that certain epitopes are capable of binding diverse alleles which do 
not belong to the same supertype. Of the 242 well-defined viral epitopes tested in 100 
individuals, half of all detected responses were in the absence of the originally described 
allele. In fact, only three percent of epitopes were exclusively recognized in the presence of 
the original allele. 
In comparison to HIV-1, relatively little work has been invested analyzing the impact 
of host genetic profiles on HCV at a population level. In the studies so far (HLA class I and 
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class II), conflicting results have been obtained which are probably due to the small sample 
size of some of the cohorts studied. Recent work in a large multi-racial cohort in the United 
States showed that certain HLA alleles are associated with increased clearance (DRB1*0101, 
HLA-B*5701, HLA-B*5703, and HLA-Cw*0102) and another allele was associated with 
HCV RNA positivity (HLA-DRB1*0301) (Kuniholm et al. 2010).  
TCR cross-reactivity has interesting implications for the ability of the immune system 
to fight infections. Experiments (Huseby et al. 2005; Huseby et al. 2006) and simulation 
studies (Kosmrlj et al. 2008; Kosmrlj et al. 2009) have shown that T cells that develop in 
mice only expressing one type of MHC-bound peptide in the thymus are more cross-reactive 
to point mutants of peptide epitopes, when compared with the T cells of mice which express 
diverse self peptides. Additionally, predictions have been made helping to explain the 
differences in the ability of different MHC molecules to bind to peptides (Kosmrlj et al. 
2010): of the ~10
7
 peptides in the human proteome which can be bound by various MHC 
molecules, only 70,000 peptides were predicted to bind to HLA-B*5701 and 180,000 
peptides were predicted to bind to HLA-B*0701. Therefore, humans expressing HLA alleles 
such as HLA*B-5701 that bind fewer peptides are expected to have more cross-reactive 
TCRs and therefore a better immune response. This is indeed the case for HIV-1, where the 
HLA-B*5701 allele has been found to be enriched in elite controllers, i.e. patients who 
maintain very low levels of HIV-1 RNA without therapy, while HLA-B*0701 has not been 
found be not protective against HIV-1 (Kosmrlj et al. 2010). 
Due to the critically important influence of host genetic profiles on the level of viral 
control achieved by a patient, future treatment strategies for patients infected with such 
viruses as HIV-1 and HCV should not only involve the analysis of drug resistance mutations 
in order to help define treatment options, but to also take into account patient HLA profiles as 
host genetic effects can also play a causal role in the loss of immune control. 
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2 Selective Pressures of HLA Genotypes and Antiviral Therapy on 
HIV-1 Sequence Mutation at a Population Level1  
2.1 Introduction 
Human immunodeficiency virus infection has become a major global human health 
issue and a major challenge to natural or vaccine-induced immune control of HIV-1 is the 
ability of the virus to mutate rapidly when it comes under the pressure of the host‟s immune 
system (Koenig et al. 1995; Borrow et al. 1997; Goulder et al. 1997; Barouch et al. 2002). 
Antiviral cytotoxic T lymphocytes kill HIV-1 infected cells upon recognition of specific viral 
epitopes. HIV-1 escape mutations interfere with processing of viral antigens by proteasomes 
(Allen et al. 2004; Yokomaku et al. 2004; Zimbwa et al. 2007) or evolve at critical binding 
sites within the human leukocyte antigen restricted CTL epitope, thereby abrogating binding 
to the HLA molecule or inhibiting efficient recognition by the T cell receptor (McMichael 
and Rowland-Jones 2001; Draenert et al. 2004). Thus, HIV-1 escapes antiviral immune 
responses and eradication by the host‟s immune system. Such selection pressure as well as 
viral adaptation to antiretroviral drugs should lead to consistent changes in the amino acid 
sequence of the proteins expressed by dominant subpopulation of the viral quasispecies.  
Moore et al. studied the selection pressure exerted by HLA restricted immune 
responses on the evolution of the HIV-1 sequence at the population level (Moore et al. 2002). 
A cohort of 473 HIV-1 infected patients was genotyped for the HLA-A and HLA-B loci. The 
most recent sequence of the HIV-1 reverse transcriptase between amino acid positions 20 and 
227 was aligned to an HIV-1 consensus sequence and viral mutations were identified. These 
mutations were then tested for association with distinct HLA-A or -B alleles. The authors 
identified 64 positive and 17 negative associations, although only 12 remained after 
correction for multiple testing. Several of these mutations were located in known CTL 
epitopes. In a second study of the same cohort, the aforementioned group identified 
interactions between antiretroviral drugs, HLA alleles and diversity in the RT and protease 
viral sequences (John et al. 2005). These interactions led to higher frequencies of antiviral 
drug resistance mutations in patients with certain HLA alleles in some cases, but also to 
lower frequencies in other cases. This indicates that HLA dependent specific immune 
responses can support, but also prevent the evolution of drug resistance. 
The previous studies have analyzed the HLA-driven evolution of HIV-1 in only a 
fragment of the RT and protease. Therefore we wanted to examine if this phenomenon can be 
confirmed in the entire first half of the RT.  
We were also interested in extending the analysis to include the MHC class II locus 
HLA-DRB1 to better understand selection pressure by CD4 T helper cells at the population 
level. MHC class II molecules are specialized to monitor the endosomal-lysosomal system of 
cells which in turn are specialized to internalize extracellular antigen (i.e. phagocytes, 
dendritic cells and B cells). MHC class II molecules display peptides derived from these 
antigens to CD4 T cells and may thus produce a different form of immune pressure against 
HIV-1 infection (DeFranco et al. 2007). 
                                                 
1
 The work reported in this section was performed in collaboration with Golo Ahlenstiel and Ulrich 
Spengler (University of Bonn, Germany) and Martin Däumer and Rolf Kaiser (University of Cologne, 
Germany). It has been published in the journal Clinical and Vaccine Immunology, appearing in this thesis with 
the journal‟s permission (Ahlenstiel et al. 2007). My own contribution to the publication comprises the 
construction of the HLA-HIV database, identification of escape mutations and their analysis and the 
phylogenetic analysis resulting 4 of the 4 published tables (Tables 2.1, 2.2, 2.3 and 2.4) and 1 of 1 published 
figures (Figure 2.3). 
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In order to minimize the influence of founder effects on the HLA associations found 
(Bhattacharya et al. 2007), we the analysis to only those patients infected by clade B HIV-1 
viruses. Previously, viral lineage effects in studies encompassing more than just one HIV-1 
clade led to the identification of escape mutations which were in reality related to the viral 
clade and thus not true escape mutations. Also, we performed an analysis of potential viral 
linage effects within the cohort. 
Furthermore, we wanted to assess for “hot spots,” where the sequence mutates more 
easily/rapidly due to immune pressure and how mutations persist over time. 
Finally, to understand the clinical significance of our findings we analyzed whether 
HLA-driven mutations in the RT and/or protease sequence of HIV-1 lead to antiviral drug 
resistance and if the patient‟s HLA-type has an impact on whether drug resistance mutations 
are accumulated in a specific order in the case of thymidine analogue mutations. 
2.2 Patients and Methods 
2.2.1 Patients 
We studied 179 clade B HIV-1 positive patients being treated at a single hospital in 
Bonn, Germany. The patients were monitored every three months and any complications 
were recorded and classified according to the European modification of the 1986 Centers for 
Disease Control and Prevention staging (CDC 1986). Antiviral therapy was advised 
according to updated recommendations on antiretroviral treatment for HIV-1 infection by the 
International AIDS Society panel. HIV-1 sequence data was collected between March 1999 
and May 2003, with some patients having sequences collected at more than one time point. 
Additional information on HIV-1 transmission, ethnicity, sex and HBV and HCV infection 
status was also acquired (Table 2.1).  
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Description Number (% )
Total number of patients 179
Age Average 42
Range 22 - 70
Female / Male 15 / 164
Ethnicity Caucasian 161 (90.0%)
Other 13 (7.3%)
Unknown 5 (2.7%)
Risk Code Homosexual 99 (55.3%)
Heterosexual 12 (6.7%)
IV drug abuse 12 (6.7%)
Residency in epidemic region 3 (1.7%)
Exposure to blood products 1 (0.5%)
Haemophelia 40 (22.3%)
Unknown 12 (6.7%)
HIV-1 Viral Subtype B 179 (100%)
HCV Status (Chronic) 55 (30.7%)
HCV Virus Type 1 29 (16.2%)
2 8 (4.5%)
3 10 (5.6%)
4 2 (1.1%)
Multiple 1 (0.5%)
Unknown 5 (2.7%)
HBV HBs antigen + 15 (8.4%)
Anti-HBs-, Anti-HBc+ 23 (12.8%)
Anti-HBs+, Anti-HBc+ 45 (25.1%)
Anti-HIV Therapy Naive 14 (7.8%)
ART (< 3 antiviral drugs) 18 (10.1%)
HAART (>= 3 antiviral drugs) 147 (82.1%)  
Table 2.1 Characteristics of the patient cohort 
For the laboratory methods used for HLA genotyping and HIV-1 sequences, see 
Appendix A. 
2.2.2 Database design 
An extensive and diverse dataset was accumulated for the patient cohort, which 
included personal patient data, therapy histories, virologic and immunologic data, further 
clinical test data derived from patient tissues, and sequence data. The HIV-1 sequences are 
clinically derived and thus sequenced with population-based or bulk approaches. The initial 
database schema was based on that of the HIV-1 Arevir database (Roomp et al. 2006), in 
which the data is captured in different modules consisting of a few tables each. These Arevir 
modules include, for example, “Patients” which contains personal patient data, treatment 
location and diagnoses. 
The schema of the Arevir database was significantly expanded to include data on the 
HLA-typing of patients, HLA genes, alleles, supertypes, haplotypes, motifs, known epitopes, 
etc. Additionally, tables were added to reflect the complex medical histories of patients which 
were often co-infected with viruses such as HCV and HBV. Therefore, a data model was 
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developed which is specifically tailored to analyze host immune responses to viruses (Figure 
2.1). 
 
 
Figure 2.1 Database diagram of the HLA-HIV-1 database  
Dependencies between important database tables are shown, as well as all primary and foreign keys.  
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The data model was implemented in the relational database management system 
(RDBMS) Microsoft SQL Server. It was chosen because rich features in manipulating, 
securing and managing data and ease of use.  
2.2.3 HLA-associated mutations in the reverse transcriptase and protease 
All amino acids in the complete HIV-1 protease and between positions 1 and 330 in 
the viral reverse transcriptase were examined in the most recent sequences from all patients 
and compared to population consensus sequences (see Appendix B). As a first step, we 
analyzed each amino acid position using Fisher‟s exact test for associations with HLA alleles 
(Mehta and Patel 1986). In order to raise the power of the calculations, very rare alleles (less 
than or equal to 4% of the cohort) were excluded from the analysis. All HLA allele covariates 
with P-values of less than 0.05 were identified and fitted in a subsequent multivariate 
analysis to logistic regression models. We used binomial models, where the linear predictor 
consisted of all significant alleles and the response was a factor, in which variant amino acids 
were classified as successes. Correction for multiple-testing used the false discovery rate 
(FDR) method (Benjamini and Hochberg 1995). Due to the low numbers of deletions and 
insertions in the sequences, no separate analysis was done to take these into account. 
2.2.4 Distribution and persistence of HLA-associated mutations 
A previous study has described CTL-epitope “hotspots,” in which immunodominant 
epitopes cluster within distinct regions of the HIV-1 gp120 protein (Brown et al. 2005). The 
CTL epitopes collected in the HIV Molecular Immunology Database at Los Alamos also 
appeared to be localized in particular regions of HIV-1 proteins (2005). We were interested in 
determining, if the distribution of HLA-associated mutations was uniform across the RT and 
protease. Therefore, the distribution of known mutations was compared to 10,000 randomly 
generated distributions according to the uniform model, each with an equal number of 
sequence mutations and tested for statistical significance. 
We also analyzed the persistence of HLA-associated mutations over time in our 
cohort. For 70 patients, HIV-1 sequences were available for at least two individual time 
points that were a minimum of 6 months apart (the sequences of 50 patients were collected 
more than 1 year apart). None of these sequences was acquired during the acute stage of 
HIV-1 infection, but rather at a later time point. Persistence of mutations was examined at 
each of the already identified positions. 
2.2.5 Impact of HLA on drug resistance mutation pathways 
During antiretroviral therapy the virus is exposed to strong selective pressure, which 
can result in an accumulation of mutations conferring drug resistance. These mutations are 
usually persistent, provided that there is continuous drug-induced selection pressure (Shafer 
et al. 2000). Therefore, the development of resistance within the HIV-1 genome can be 
regarded as the accumulation of such mutations. This accumulation has been modeled by 
weighted branchings or directed trees, which provide an intuitive model of directed 
dependencies between events and their time of occurrence. The single tree model has been 
extended to mixtures of trees (so-called mutagenetic trees mixture models) in order to capture 
more complex evolutionary scenarios, for which the software package Mtreemix has been 
developed (Beerenwinkel et al. 2005). 
Of particular interest were the thymidine analogue mutations (TAMs) in the RT that 
can arise after treatment with nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, 
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stavudine and abacavir. Studies have suggested that HIV-1 develops TAMs by one of two 
distinct pathways TAM1 (41L, 210W and 215F/Y) or TAM2 (67N, 70R and 219E/Q) (Hanna 
et al. 2000).  
We identified all patients in our cohort that had undergone NRTI treatment and 
examined their HIV-1 sequences for TAM mutations to determine, whether particular HLA 
alleles can be associated with either the TAM1 or TAM2 pathway.  
2.2.6 HLA-driven selection at antiretroviral drug resistance sites 
Several HLA allele-specific mutations have been reported to be located in positions of 
known drug resistance mutations (John et al. 2005; Johnson et al. 2005). An analysis of the 
sequences of our patient cohort was performed in order to determine whether similar 
associations could be identified. 
2.2.7 Phylogenetic analysis 
In order to explore the impact of viral lineage founder effects, we have applied 
ProtTest version 1.3 (Drummond and Strimmer 2001; Guindon and Gascuel 2003; Abascal et 
al. 2005) to find the best-fitting model of protein evolution for the HIV-1 sequence alignment 
of the cohort (the alignment was made using the bulk/consensus sequences generated for each 
patient). The best-fitting model according to both the Akaike Information Criterion (AIC) and 
the Bayesian Information Criterion (BIC) (Hastie et al. 2001) was the JTT model (Jones et al. 
1992) with gamma rates, variable amino-acid frequencies and invariable sites. We then used 
PhyML (Guindon and Gascuel 2003) for estimating a maximum-likelihood phylogeny for the 
given protein evolution model and performed 100 bootstrap replicates in order to obtain 
bootstrap support values. Subsequently, we used neighbor-net (Bryant and Moulton 2004; 
Huson and Bryant 2006) to get a better visualization of the noise in the phylogenetic signal.  
2.3 Results 
2.3.1 Patients 
During the observation period, 147 (82.1%) patients were treated with highly active 
anti-retroviral therapy (HAART), which was based on a protease inhibitor (PI; indinavir, 
saquinavir, nelfinavir, amprenavir or ritonavir) in 117 patients and a non-nucleoside reverse-
transcriptase inhibitor (NNRTI; nevirapine, efavrienz, or delavirdine) in 30 patients. HAART 
was the first-line treatment in 61 patients, and 86 had previously had therapy with nucleoside 
analogues. HAART was changed to different drug combinations in 85 of 117 patients who 
received HAART based on PIs and in 23 of 30 patients who received HAART based on 
NNRTIs, to address side-effects or emerging viral resistance.  
The antiretroviral-treatment group consisted of 18 (10.1%) patients who received 2 or 
fewer antiretroviral drugs. One patient received zidovudine monotherapy and 17 were treated 
with several nucleoside analogues (zidovudine, didanosine, zalcitabine, stavudien or 
laminvudine). The remaining 14 patients (7.8%) did not receive any retroviral drugs. 
With regard to the length of treatment, 18 patients had been treated for less than 1 
year, 62 patients had been treated between 1 and 5 years, and 88 patients for more than5 
years. The staging of HIV-1 disease according to the European modification of the 1986 
Centers for Disease Control and Prevention staging (CDC 1986) in the cohort was A in 58 
patients, B in 59 patients and C in 57 patients. Five patients were not classified. 
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2.3.2 HLA-associated mutations in the reverse transcriptase and protease 
HIV-1 RT sequences (amino acid positions 1 to 330) were initially aligned with the 
reference sequence HXB2 (2005). Associations were subsequently confirmed using the 
population consensus sequence, which was generated by assigning the most common amino 
acid for each position of all sequences pooled from the cohort. Overall, 15 associations with 
uncorrected P-values of less than 0.005 were found, which also had P-values of less than 0.05 
in the logistic regression models (Table 2.2). Ten of these associations had P-values of less 
than 0.05 after correction for multiple-testing.  
We were able to confirm four of the associations that Moore et al. reported as 
significant after correction for the total number of residues examined across the entire region 
(Moore et al. 2002): HLA-B*51 at amino acid position 135, HLA-B*07 at position 162, 
HLA-A*11 at position 166 and HLA-B*35 at position 177. We also found a number of novel 
HLA allele-specific associations with 4 of those associations lying outside the part of the RT 
sequence analyzed by Moore et al. Seven of the mutations in the RT sequence are located in 
previously defined epitopes with six of these being located in known epitope anchor 
positions. 
Interestingly, six of the identified associations were negative associations indicating 
that mutations in the RT were less likely, if the patient carried that particular allele: amino 
acid position 177 was negatively associated with HLA-B*35, position 178 with HLA-B*35, 
position 188 with HLA-DRB1*12, position 207 with HLA-B*15, position 277 with HLA-
A*03 and position 291 with HLA-B*27. A possible explanation for such negative 
associations was given by Leslie et al: a negative association can arise as a result of positive 
selection of an escape mutation by high frequency alleles, which is stably transmitted, 
accumulating in the population to the point at which it defines the consensus sequence (Leslie 
et al. 2005). 
In the protease, we found HLA-associated mutations at seven positions with an 
uncorrected P-value of less than 0.005, which also had P-values of less than 0.05 in the 
logistic regression models (Table 2.3). Four associations had P-values of less than 0.05 after 
correction for multiple-testing, with three of these associations being previously defined 
epitopes. No negative associations were found. 
For the two HLA-DRB1 associated mutations in the RT (position 67 for HLA-
DRB1*08 and position 188 form HLA-DRB1*12), the alleles are not known to be in linkage 
disequilibrium with any class I alleles which were included in the multivariate analysis at 
each position. 
Overall, HLA-B alleles were involved in more associations (n = 15 or 68%) than 
alleles from either the HLA-A (n = 5 or 23%) or HLA-DRB1 (n =2 or 9%). 
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Polymorphism HLA type Absent 
(n)
Present 
(n)
OR P-value
(unadjusted)
P-value
(adjusted, FDR)
Known Epitopes Persistent? New?
1 E6x HLA-B*40 23 11
Non-HLA-B*40 139 6
2 V35x HLA-A*24 19 17
Non-HLA-A*24 112 31
3 D67x HLA-DRB1*08 1 6
Non-HLA-DRB1*08 120 52
4 V75x HLA-B*57 6 5
Non-HLA-B*57 154 14
5 I135x HLA-B*51 2 22
Non-HLA-B*51 97 58
6 E138x HLA-A*24 31 5
Non-HLA-A*24 143 0
7 S162x HLA-B*07 21 27
Non-HLA-B*07 108 23
8 K166x HLA-A*11 13 7
Non-HLA-A*11 152 7
9 D177x HLA-B*35 16 18
Non-HLA-B*35 125 20
10 I178x HLA-B*35 22 12
Non-HLA-B*35 129 16
11 Y188x HLA-DRB1*12 5 3
Non-HLA-DRB1*12 167 4
12 Q207x HLA-B*15 10 20
Non-HLA-B*15 111 38
13 K277x HLA-A*03 1 38
Non-HLA-A*03 89 51
14 K277x HLA-B*44 26 9
Non-HLA-B*44 64 80
15 E291x HLA-B*27 10 3
Non-HLA-B*27 163 3
y
0.23 0.00125 0.04121
B*3501/B35
aa175-aa183: NPDIVIYQY
aa175-aa183: HPDIVIYQY
persistent: 5
multiple pops: 0
definite change: 0
n
0.00314
0.06 0.00534 >0.05
persistent: 10
multiple pops: 0
definite change: 1
y
persistent: 4
multiple pops: 0
definite change: 0
y
persistent: 14
multiple pops: 1
definite change: 1
y
persistent: 12
multiple pops: 2
definite change: 1
y
0.02 <<0.00001 <<0.00001
A3
aa269-aa277: QIYPGIKVR
3.61 0.00225 0.02616
persistent: 6
multiple pops: 1
definite change: 1
11.69 0.00016 0.00521
A*1101/A11
aa158-aa166: AIFQSSMTK
aa158-aa166: SIFQSSMTK
persistent: 14
multiple pops: 1
definite change: 3
persistent: 7
multiple pops: 0
definite change: 1
18.40
6.04
B*5101/B51
aa128-aa135:TAFTIPSI
persistent: 8
multiple pops: 0
definite change: 1
<0.00001 0.00004
B7
aa153-aa165: WKGPAIFQSSMT
aa153-aa165: WKGSPAIFQSSMT
aa156-aa164: SPAIFQSSM
aa156-aa165: SPAIFQSSMT
- 0.00026 0.00859
persistent: 4
multiple pops: 2
definite change: 1
y
persistent: 10
multiple pops: 0
definite change: 1
n
n
y
n
9.17 0.00244 >0.05
0.14 <0.00001 0.00013
B*3501/B35
aa175-aa183: NPDIVIYQY
aa175-aa183: HPDIVIYQY
<0.00001 0.00002
0.17 0.00003 0.00090
persistent: 8
multiple pops: 1
definite change: 2
y
y
3.23
11.08
>0.05
persistent: 3
multiple pops: 0
definite change: 1
y0.04 0.00191 >0.05
0.00001 0.00047
B*4001
aa5-aa12: IETVPVKL
persistent: 9
multiple pops: 3
definite change: 0
y
13.85 0.00501 >0.05
persistent: 3
multiple pops: 2
definite change: 0
 
Table 2.2 HIV-1 sequence mutations in the HIV-1 reverse transcriptase. 
Polymorphism shows the variant position with the wild type amino acid; HLA type the specific HLA 
type for which a mutation was found; Absent (n) the number of patients with the wild type amino 
acid; Present (n) the number of patients with the HIV-1 sequence mutation; OR the odds ratio; P-
value (unadjusted) the unadjusted P-value of the contingency table using Fisher‟s Exact Test; P-value 
(adjusted) the adjusted P-value using FDR; Known Epitopes any known epitopes for the HLA-allele 
and their sequences (2005); Persistent? the persistence of the HIV-1 sequence mutation in individual 
patients at a minimum of two different time points (persistent = all dominant viral sequences from a 
patient were identical at the different time points, multiple pops = dominant viral sequences identified 
in a patient were different at the various time-points without a consistent change from one type to 
another, definite change = the patient's dominant viral sequence showed a clear switch at this position 
from one amino acid to another amino acid); New? indicates whether the HIV-1 sequence mutation is 
new or has already been described in the literature.  
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2.3.3 Distribution and persistence of HLA-associated mutations 
The HLA-associated mutations that have been identified in our patient cohort do not 
appear to be uniformly distributed across the protease and RT, but are more frequent in 
regions known to have many epitopes. However, an analysis of the non-random distribution 
of the HIV-1 sequence mutations showed only a weak level of significance in the protease (P-
value equal to 0.06) and none in the RT (data not shown). 
In most patients, sequence mutations were consistently found in all available 
sequences. In relatively few cases, the mutations were not persistent with the wild type amino 
acid being substituted by a variant amino acid in most cases (Tables 2.2 and 2.3). Drug 
therapy did not appear to influence the gain or loss of HIV-1 sequence mutations, as most 
patients had HAART composed of diverse drug combinations, and yet their mutations have 
remained stable throughout. 
 
 
Polymorphism HLA type Absent 
(n)
Present 
(n)
OR P-value
(unadjusted)
P-value
(adjusted, 
FDR)
Known Epitopes Persistent? New?
1 E35x HLA-B*44 11 24
Non-HLA-B*44 120 24
2 E35x HLA-A*68 11 13
Non-HLA-A*68 120 35
3 N37x HLA-B*44 9 26
Non-HLA-B*44 98 46
4 I54x HLA-B*57 5 6
Non-HLA-B*57 145 23
5 V82x HLA-B*57 5 6
Non-HLA-B*57 142 26
6 Q92x HLA-B*15 22 8
Non-HLA-B*15 146 3
7 I93x HLA-B*15 11 19
Non-HLA-B*15 101 48
y
0.03922 y
10.91 <0.00001 <0.00001
persistent: 7
multiple pops: 0
definite change: 0
B*44 
aa34-aa42: EEMNLPGRW
persistent: 14
multiple pops: 1
definite change: 0
persistent: 11
multiple pops: 3
definite change: 1
y
4.05 0.00238
B*44 
aa34-aa42: EEMNLPGRW
6.15 <0.00001 0.00022
A*6802 
aa30-aa38: DTVLEDINL
aa30-aa38: DTVLEEMNL
aa30-aa38: DTVLEEWNL
7.57 0.00285 >0.05 y
6.55 0.00499 >0.05
persistent: 10
multiple pops: 0
definite change: 1
y
persistent: 4
multiple pops: 0
definite change: 3
persistent: 10
multiple pops: 1
definite change: 0
persistent: 5
multiple pops: 1
definite change: 1
y
y17.70 0.00003 0.00099
3.63 0.00184 >0.05
 
Table 2.3 HIV-1 sequence mutations in the HIV-1 protease 
Polymorphism shows the variant position with the wild type amino acid; HLA type the specific HLA 
type for which a mutation was found; Absent (n) the number of patients with the wild type amino 
acid; Present (n) the number of patients with the HIV-1 sequence mutation; OR the odds ratio; P-
value (unadjusted) the unadjusted P-value of the contingency table using Fisher‟s Exact Test; P-value 
(adjusted) the adjusted P-value using FDR; Known Epitopes any known epitopes for the HLA-allele 
and their sequences (2005); Persistent? the persistence of the HIV-1 sequence mutation in individual 
patients at a minimum of two different time points (persistent = all dominant viral sequences from a 
patient were identical at the different time points, multiple pops = dominant viral sequences identified 
in a patient were different at the various time-points without a consistent change from one type to 
another, definite change = the patient's dominant viral sequence showed a clear switch at this position 
from one amino acid to another amino acid); New? indicates whether the HIV-1 sequence mutation is 
new or has already been described in the literature.  
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2.3.4 Impact of HLA on drug resistance mutation pathways 
Of our patient cohort, 165 patients were treated with an NRTI regimen containing 
zidovudine, stavudine or abacavir before the sequence used for analysis was generated. Of 
these patients, 72 had no TAM mutations reported. For TAM1 (41L, 210W and 215F/Y), 9 
patients matched the pathway, and 25 had either one mutation too few or too many. For 
TAM2 (67N, 70R and 219E/Q), 10 patients had matching mutations and 10 patients had 
either one mutation too many or one too few. The remaining patients had even rarer 
combinations of these mutations.  
We looked for associations between either the TAM1 or TAM2 pathway and a 
particular HLA type using Mtreemix. This also allowed for imperfect matches to a particular 
pathway, because the software supports the analysis of complex evolutionary scenarios. The 
optimal number of trees was estimated to be k = 3 (Figure 2.2). However, no significant 
associations were found, i.e. patients belonging a particular tree could not be associated with 
also having particular HLA allele. We suspect that a large part of the difficulty of performing 
this analysis stems from the fact that such a large proportion of patients (72 of 165 treated 
with the NRTI regimen) had no TAM mutations whatsoever. 
 
 
Figure 2.2 Mtreemix analysis, optimal number of trees 
2.3.5 HLA-driven selection at antiretroviral drug resistance sites 
We examined all associations in our cohort, which are also known drug resistance 
mutations (Table 2.4). Our results differ somewhat from those of John et al. (John et al. 
2005), who reported drug resistance mutations at protease amino acid residues 20, 32, 36 and 
48 to have positive HLA associations. In our cohort we could not confirm any of these 
associations. John et al. also reported the RT amino acid residues 41, 67, 70, 118, 210 and 
215 to have positive HLA associations matching NRTI-associated mutations. Of these, only 
residue 67 was associated with HLA-DRB1*08 in our cohort (HLA-A*10 in John et al).  
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Drug or Reistance Type Polymorphism HLA type Absent 
(n)
Present 
(n)
Patients who 
received drugs
New?
1 Tipranavir/Ritonavir PRO-E35x HLA-B*44 11 24 0 of 24 (0%)
Non-HLA-B*44 120 24 0 of 155 (0%)
2 Tipranavir/Ritonavir PRO-E35x HLA-A*68 11 13 0 of 35 (0%)
Non-HLA-A*68 120 35 0 of 144 (0%)
3 Many currently used PIs PRO-I54x HLA-B*57 5 6 10 of 11 (90.9%)
Non-HLA-B*57 145 23 117 of 168 (69.6%)
4 Many currently used PIs PRO-V82x HLA-B*57 5 6 10 of 11 (90.9%)
Non-HLA-B*57 142 26 117 of 168 (69.6%)
5 Atazanavir PRO-Q92x HLA-B*15 22 8 0 of 30 (0%)
Non-HLA-B*15 146 3 0 of 149 (0%)
6 multi-nRTI Resistance RT-D67x HLA-DRB1*08 1 6 7 of 7 (100%)
Non-HLA-DRB1*08 120 52 158 of 172 (91.8%)
7 multi-nRTI Resistance RT-V75x HLA-B*57 6 5 11 of 11 (100%)
Non-HLA-B*57 154 14 154 of 168 (91.6%)
8 NNRTIs RT-Y188x HLA-DRB1*12 5 3 5 of 8 (62.5%)
Non-HLA-DRB1*12 167 4 84 of 171 (49.1%)
y
y
y
y
y
y
y
y
 
Table 2.4 HIV-1 sequence mutations at positions which are also known drug resistance mutations, and 
the number of patients of the HLA-type which received the drug type 
Drug or Resistance Type shows the drug or drug resistance type; Polymorphism the HIV-1 sequence 
mutation in the protease or RT; HLA type the specific HLA type for which the mutation was found, 
Absent (n) the number of patients with the wild type amino acid; Present (n) the number of patients 
with the HIV-1 sequence mutation; Patients who received drugs the counts and percentages of 
patients who received the drug(s); New? indicates whether the association is new or was previously 
described in the literature.  
We also found eight new associations, five in the protease and three in the RT. For 
three of the associations in the protease (residue 35 for HLA-A*68 and HLA-B*44, residue 
92 for HLA-B*15), none of the patients in our cohort had ever been treated with the relevant 
antiviral therapy (tipranavir/ritonavir or atazanavir). In contrast, for the remaining five 
associations (residues 54 and 82 in the protease, residues 67, 75 and 188 in the RT), most 
patients were treated with the relevant antiviral therapy. These residues are associated with 
resistance against most currently available PIs, NNRTIs or multi-nucleoside and nucleotide 
reverse transcriptase inhibitors. However, statistically significant differences in patients 
taking these drugs could not be found between individuals with or without the HLA allele.  
We observed that hepatitis C co-infected patients were less likely to have received 
antiretroviral therapy, which included PIs.  
2.3.6 Phylogenetic analysis 
The shape of the maximum-likelihood phylogeny of the viral sequences is almost star-
like: the sequence diversity within clusters is higher than the diversity between clusters. 
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Another indicator for the star-likeness is the low bootstrap support for all branches in the 
interior of the phylogeny. The resulting neighbor-net network (Figure 2.3) shows a lot of 
netting in the center of the phylogeny and rejects a clustering into distinct groups. Hence, the 
neighbor-net method also suggests a star-like shape for the phylogeny. Given that the 
sequences evolved along a star-like phylogeny, we can rule out founder effects or other 
artifacts due to a shared evolutionary history. 
 
Figure 2.3 Neighbor-net network of the viral sequences drawn from the cohort  
The network illustrates a star-like shape and a high level of netting in the center of the phylogeny. 
2.4 Discussion 
Selection of the dominant HIV-1 population among the viral quasispecies is likely to 
reflect the combined effects of viral adaptation to the host's immune response and 
antiretroviral drugs. MHC class I alleles have been described to affect the evolution of the 
HIV-1 sequence on the population level in a single previous cohort from Western Australia 
(Moore et al. 2002; John et al. 2005). We were interested in examining whether these 
findings could be confirmed in our Western European cohort.  
Four out of a total of twelve significant associations previously reported in the RT 
were confirmed in our cohort, all of which corresponded to known epitopes (Table 2.2). 
Moreover, we describe 11 new associations with four of these lying outside the region of the 
RT analyzed previously (Moore et al. 2002). Several of these associations also correspond to 
known T cell epitopes.  
The identified CTL escape mutations, for which known epitopes exist, do not 
consistently lie in known anchor positions. Due to the complex pathway by which an epitope 
is processed before being displayed on the cell surface by the HLA-molecule and the 
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incompletely understood nature of T cell receptor binding and T cell activation, HIV-1 
sequence mutations in non-anchor positions could very well still have a negative impact on 
the recognition of such epitopes and hence be beneficial for the virus. 
These data support the hypothesis that the associations found are indeed epitopes 
targeted by CTL and that continuous pressure by CTL responses leads to the selection of 
survival strains that have mutations in these regions. The fact that we cannot reproduce all 
associations described in the previous publications and that we found a number of additional 
associations may be due to several reasons: the first cohort consisted of patients from 
Western Australia, whereas our patients are mainly Caucasians from Germany. Thus, the 
respective collected HLA sequences may differ and the access to and type of antiviral drugs 
may be different. However, the fact that we were able to confirm a number of associations 
despite these differences proves that our main conclusions, although affected by local factors, 
are generally true. Furthermore, HLA-associated mutations, once acquired, were stable and 
found in later viral isolates from the same patient. This supports the hypothesis that the 
continuing selection pressure by T cell recognition prevents the virus from reverting back 
despite changes in the antiviral drug regimen.  
MHC class I dependent CTL responses shape the viral sequence by direct killing of 
infected cells that present the right epitope in their HLA molecules. So far, the impact of 
MHC class alleles II on viral evolution has only been studied in a small patient group 
(Harcourt et al. 1998). Harcourt et al. described HIV-1 sequence variation in the p24 GAG 
epitope of HLA-DR1. Our data from a large patient cohort support their observation of a role 
of MHC class II alleles and CD4 T cell responses in the evolution of the HIV-1 sequence. We 
found two associations in the RT region, also demonstrating that even class II alleles can 
exert selection pressure on viral sequences. 
We also studied the effect of MHC class I and class II on the evolution of the full-
length protease sequence. Interestingly, we did not find any of the associations which were 
described in the Western Australian cohort (John et al. 2005). The underlying reason for this 
is unclear. However, since most patients in our cohort and the Western Australian cohort 
were undergoing drug treatment it is possible that the type, time point and length of use of 
certain protease inhibitors may have affected the results in our study as well those in the 
previous studies. Nevertheless, three associations were found within previously described 
epitopes for the same HLA allele and four associations remained significant after correction 
for multiple testing, supporting the validity of the associations reported. 
Although we were not statistically able to confirm the existence of “hotspots,” as the 
effect reached only a weak level of statistical significance (P-value equal to 0.06), it appears 
that certain regions in the RT and protease are targeted by a greater number of epitopes and 
therefore CTLs, thus driving viral evolution in this region. 
A study by Kiepiela et al. reported that the relative contribution of HLA-B alleles 
outweighs the contribution of HLA-A alleles in influencing HIV-1 disease outcome (Kiepiela 
et al. 2004). This is also reflected in our results, as more significant associations were found 
with HLA-B alleles (n = 15 or 68%) than with HLA-A (n = 5 or 23%) alleles or HLA-DRB1 
alleles (n = 2 or 9%).  
In most patients HLA-associated HIV-1 sequence mutations were consistently found 
in all sequences of that patient, while only relatively few cases had HLA-associated 
mutations that were not stable. These changes were generally from a wild type amino acid to 
the variant amino acid in the subsequent sample. This observation is consistent with other 
studies showing that CTL escape mutations develop soon after infection (Jones et al. 2004). 
We also analyzed whether these HLA-associated mutations were influenced by drug 
therapy, and found that the impact of drug therapy on the associations in our patient cohort 
was not statistically significant. In some cases, patients in the cohort had not received a 
particular drug treatment (tipranavir or atazanavir), yet had HLA-associated mutations at 
positions where known drug resistance mutations to these particular drugs can also occur. As 
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tipranavir and atazanavir were first approved for antiviral therapy shortly after our patients‟ 
viral sequences were acquired, it is not possible for these patients to have been infected with 
an already resistant viral strain. This indicates that either these mutations have become locked 
in our population, so that the virus cannot revert back, or HLA-driven selection of mutations 
may predispose some patients to the development of some drug-resistance mutations. In order 
to optimize the therapy of patients carrying particular HLA-types, the choice of future 
therapy regimens should take into account the fact that some patients are more likely to 
develop particular HLA-associated mutations, which co-exist at residues of drug resistance 
mutations. This consideration could be made for positions in the protease that are linked to 
specific drugs (tipranavir and atazanavir), but not the majority of PIs, NRTIs or NNRTIs. 
In summary, we were able to confirm immune-driven selection pressure not only by 
MHC class I alleles, but also by MHC class II alleles on the development of escape mutations 
at a population level. Further, we have described a number of HLA-associated mutations in 
the RT as well as protease and, finally, have analyzed their possible impact on the success of 
antiviral drug treatment. 
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3 HLA Class I Allele Associations with HCV Polymorphisms and 
Outcome of Antiviral Therapy in Patients with Chronic Hepatitis C2 
3.1 Introduction 
HCV is currently recognized as being a major cause of chronic liver disease both in 
the industrialized and developing world and thus is a significant global health problem. The 
virus has been shown to cause chronic hepatitis, liver cirrhosis, hepatocellular carcinoma and 
is a leading cause of liver transplantation worldwide. Available data suggest that the 
prevalence is approximately 2.2-3.0% world-wide, which is approximately 130-170 million 
people (McHutchison 2004; Suzuki et al. 2007; Lavanchy 2009). 
A number of factors are thought to contribute to failure of the host to control 
infection. These include the impairment of cellular effector functions, suppression of antigen-
specific cells by regulatory T cells, dendritic cell dysfunction, T cell exhaustion and the 
deletion of antigen-specific cells in the liver (Timm et al. 2007). Additionally, in the 
chimpanzee model, a further mechanism has been described leading to the failure of the host 
to control infection: the development of escape mutations in HCV led to viral persistence 
(Weiner et al. 1995; Erickson et al. 2001). Early evidence for such viral escape in humans 
came from chronically infected patients (Chang et al. 1997). 
Studies suggest that immune control of HCV in humans is possible and that host 
factors play an important role in the ability of a host to mount a sufficient immune response 
against the virus. A response against a broad spectrum of viral epitopes by CD4 and CD8 T 
cells is necessary for viral clearance, but most patients are only able to provide a narrow 
repertoire of T cells specific for HCV antigens (Lechner et al. 2000; Lauer et al. 2004; Timm 
et al. 2007; Thimme et al. 2008).  
The repertoire of T cells targeting differing viral epitopes in patients critically 
depends on the patient‟s HLA profile. HLA class I molecules are expressed on the surface of 
every nucleated cell in the human body and their role is to present fragments of cytosolic 
proteins eliciting a CD8 T cell response. While CD8 T cells do not respond to peptide 
fragments from healthy cells, they will recognize and respond to foreign protein fragments 
from viruses or cancers. HLA class I genes are highly polymorphic and thus there is 
enormous intra- and inter-individual allelic diversity. Differing HLA molecules have 
different peptide binding grooves which lead to a different composition of the HCV-derived 
epitope antigens presented to CD8 T cells by different patients. Patients with alleles such as 
HLA-A*03 and HLA-B*27 seem to have an advantage in clearing HCV by being able to 
produce a strong immune response, while HLA-B*08 appears to occur more often in those 
with chronic infections (McKiernan et al. 2004). The identification of specific sequence 
positions associated with viral escape may be used to identify new potential HCV epitopes, 
particularly for HCV genotypes such as 1b were little experimental work has yet been done.  
While the HLA class II allele profile of patients infected with HCV has been 
correlated with aspects of disease outcome such as viral persistence, RNA viral load or liver 
                                                 
2
 The work reported in this section was performed in collaboration with Christian Lange and Christoph 
Sarrazin (University of Frankfurt, Germany).  Most of the work has been published in the Journal of Hepatology 
and appears in this thesis with the journal‟s permission (Lange et al. 2010).  My own contribution to the 
publication comprises the identification of escape mutations, the association of HLA alleles with clinical 
parameters and the analysis of phylogenetic relatedness resulting in 2 of the 3 published tables (Tables 3.2 and 
3.3). 
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fibrosis progression, the influence of HLA class I alleles has been less clearly defined (Jiao 
and Wang 2005; Hraber et al. 2007; Wang et al. 2009).  
Studies examining CD8 escape mutations have generally been limited in the terms of 
the cohort sizes and also in the number of HCV proteins/epitopes examined (Seifert et al. 
2004; Timm et al. 2004; Cox et al. 2005; Ray et al. 2005; Tester et al. 2005; Urbani et al. 
2005; Timm et al. 2007; Neumann-Haefelin et al. 2008a; Salloum et al. 2008). Rauch et al. 
were the only group so far to examine a large cohort of patients infected with HCV genotype 
1a or 3 showing substantial differences between the two genotypes (Rauch et al. 2009). 
In this study, one goal was to identify novel associations between HLA alleles and 
polymorphisms within the HCV genes which encode the proteins E2, NS3 and NS5B in a 
large patient cohort where patients were infected with either HCV genotype 1a or 1b. These 
escape mutations are thought to negatively influence the binding strength of the peptide to the 
HLA allele and therefore reduce the potential immune response against the virus; a detailed 
analysis was performed to analyze the binding strength of identified potential variant 
epitopes. Furthermore, it has been hypothesized that certain HLA alleles may be associated 
with successful antiviral therapy and therefore, treatment success was also correlated with the 
host HLA type. It was possible to show for the first time that the sustained virologic response 
rates of patients differed substantially between patient groups and some HLA alleles are 
associated with a successful antiviral therapy.  
3.2 Patients and Methods 
3.2.1 Patients 
The cohort examined in this study consisted of 159 adult patients of both sexes 
monoinfected with HCV genotype 1 and suffering from chronic hepatitis C. They were 
selected before the initiation of antiviral therapy and had never received antiviral therapy 
before.  
Patients whose liver disease was caused by other factors were excluded from the 
study. All patients had compensated (stable) liver disease. A liver biopsy was performed in 
146 of 159 patients, prior to the initiation of treatment in order to grade and stage the level of 
chronic hepatitis. Serum aminotransferase (both aspartate and alanine aminotransferase) 
levels were also determined prior to antiviral therapy to assess liver function. 
Antiviral therapy consisted of pegylated interferon alpha-2b combined with ribavirin 
within a randomized controlled treatment study (Berg et al. 2009). Patients received 1.5 
µg/kg body weight pegylated interferon alpha-2b per week in addition to 800-1,400 mg 
ribavirin daily for 24 to 48 weeks. Close monitoring of patients occurred for safety, tolerance 
and efficacy of the antiviral therapy. All patients were outpatients. The treatment protocol 
was approved by a review board and all patients gave written informed consent. 
A number of further variables were examined in the cohort: 
 
 Inflammation indicates the degree of inflammation of the patient‟s liver. It is 
graded by a scoring system (Berg et al. 2009) where a score of 0 indicates no 
inflammation, 1 indicates minimal inflammation, 2 indicates mild 
inflammation and  3 indicates severe inflammation.  
 Fibrosis indicates the degree of liver fibrosis. It is also graded by a scoring 
system where a score of 0 indicates no fibrosis, 1 indicates minimal fibrosis 
(only portal fibrosis), 2 indicates intermediate fibrosis (portal fibrosis with few 
septa), 3 indicates advanced fibrosis (severe portal fibrosis and many septa) 
and 4 indicates cirrhosis. 
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 Baseline is the viral load measured prior to beginning antiviral therapy and the 
unit of measurement is IU/ml. 
 Basl8 is the initial viral load prior to treatment under or over 800,000 IU/ml.  
 Basl4 is the initial viral load prior to treatment under or over 400,000 IU/ml. 
400,000 IU/ml is currently considered to be the optimal baseline viral load 
cut-off to predict response in treatment-naive patients with genotype 1 HCV 
and thus differentiate relatively high and low viral loads. 
 Early treatment response (ETR): the patient responds quickly and tests 
negative for HCV RNA in week 12 of the therapy.  
 Sustained virologic response (SVR): the patient tests negative for HCV RNA 
48 weeks after completing therapy.  
3.2.2 HLA genotyping 
HLA antigens were determined for all patients prior to beginning antiviral therapy. 
For the methods used to HLA genotype the patients, see Appendix C. 
3.2.3 HCV RNA detection, quantification and genotyping  
Before antiviral therapy was initiated, HCV RNA was quantified and the HCV 
genotyping was performed. For the methods used to genotype the HCV viruses, see 
Appendix C.  
3.2.4 HCV gene sequencing 
For the methods used to generate HCV gene sequences, see Appendix C. 
3.2.5 HLA-associated mutations in the E2, NS3 and NS5B 
All patient data, as well as HCV sequence data were entered into the database 
described in Section 2.2.2. 
For the E2 protein, amino acid positions 464 to 576 (112 amino acids) were 
examined, for the NS3 protease amino acid positions 1026 to 1221 (195 amino acids) were 
examined and in NS5B RNA-dependent RNA polymerase amino acid positions 2670 to 2987 
(317 amino acids) were examined in the sequences from all patients for which they were 
available.  
Patients were separated into two groups for this analysis, depending on whether they 
were infected with HCV subtype 1a or 1b. Patients who were coinfected with HCV subtype 
1a and 1b simultaneously were excluded from this analysis. The population consensus 
sequence of each genotype was used as reference sequence. The population consensus 
sequence was generated by assigning the most common amino acid for each position of all 
sequences pooled from the cohort of the indicated genotype (Yusim et al. 2005). HCV E2, 
NS3 and NS5B protein sequences from the patients were then aligned with the appropriate 
consensus sequence. The position of the identified polymorphism was then indicated by using 
the reference sequence H77 from the Los Alamos HCV Sequence Database (Kuiken et al. 
2005; Kuiken et al. 2006; Kuiken et al. 2008). See the Appendix  D and E for consensus 
sequences and the alignments of these protein sequences with reference sequences. 
We analyzed each amino acid position using an extension of Fisher‟s exact test for 
associations with HLA alleles. As it requires very strong statistical power to make statements 
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about associations with rare alleles and our cohort was relatively small, we excluded very 
rare alleles from our analysis (less than or equal to 4% of the cohort). All HLA allele 
covariates with P-values of less than 0.05 were identified and fitted in a subsequent 
multivariate analysis to logistic regression models. We used binomial models, where the 
linear predictor consisted of all significant alleles and the response was a factor, in which 
variant amino acids were classified as successes. Correction for multiple-testing used the 
false discovery rate (FDR) method. Due to the low numbers of deletions and insertions in the 
sequences, no separate analysis was done to take these into account. 
3.2.6 Association of HLA alleles with clinical parameters 
Testing for significant associations between specific HLA alleles and a variety of 
clinical parameters was performed in which the parameters were treated as categorical data: 
inflammation, fibrosis, viral load less than 400,000 IU/ml before treatment, viral load less 
than 800,000 IU/ml before treatment, viral load greater than 800,000 IU/ml before treatment, 
achievement of SVR and EVR. Each case was assigned to one cell in a 2x2 contingency table 
and Fisher‟s exact test was used to identify significant differences.  
3.2.7 Assessment of phylogenetic relatedness 
An assessment for the presence of a founder effect type bias in the cohort was made, 
where an HLA allele is overrepresented in subgroup of individuals that have viral sequences 
sharing a recent common ancestor. We identified clusters of possibly related sequences and 
assessed the potential impact of such relatedness by performing analyses stratified by clusters 
(similar to Rauch et al. (Rauch et al. 2009)). In a cohort where no founder effect exists, the 
distributions of HLA alleles should be random across clusters of relatively homogeneous 
possibly related sequences. Protein sequences were aligned, sequence similarity scores were 
calculated, and subsequently a dissimilarity matrix, using the Euclidean metric, was 
generated. We used a robust generalization of k-means clustering known as partitioning 
around medoids (PAM) (Kaufman and Rousseeuw 1990). Optimal clustering was determined 
by assessing the silhouette widths for 2-20 medoids and selecting the maximal average 
silhouette width. For NS3, the maximal average silhouette width was 8, and for E2 it was 16 
(Figure 3.1). NS5B was not included in the analysis because not all patients were sequenced 
for the gene (86 of 159 patients were sequenced). Individuals were assigned to their nearest 
cluster and the proportion of HLA alleles in the clusters was assessed using Fisher‟s exact 
test. Genotype 1a was aligned against genotype 1b to maximize comparability between 
genotypes. There were no statistically significant associations found, indicating that in this 
cohort there is a random distribution of HLA alleles across clusters of relatively homogenous 
sequences. 
The method for assessing the phylogenetic relatedness of the HCV cohort differed 
from the method used for the HIV-1 cohort in Section 2.2.7. The reason for this change in 
approach were recommendations made by a reviewer of the manuscript, as the approach used 
here has been used in previous HCV studies and thus may be more easily understood by the 
medical community. 
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Figure 3.1 Silhouette widths for  2-20 clusters for NS3 and E2 gene sequences calculated using PAM 
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3.3 Results 
3.3.1 Patient characteristics 
The demographic and baseline characteristics of the cohort are summarized in Table 
3.1. Although there is no specific data on ethnicity, the physicians involved in the study assert 
that most of the patients were Caucasian and representative of a Western European 
population. Most patients were male and the mean age of the cohort was 43 years. In the 
cohort, 43% were infected with HCV genotype 1a, 55% with genotype 1b and 2% were 
coinfected with both subtypes. During antiviral treatment, 68% achieved an early treatment 
response and after treatment 50% achieved a sustained virologic response. 
 
Description Number (% )
Total number of patients 159
Age Mean 43
Range 18-68
Female / Male 75 / 84
HCV Genotype 1a 69 (43%)
1b 87 (55%)
1a/1b 3 (2%)
HCV RNA, log10 IU/ml Mean 5.74
Range 2.79-6.90
ETR 108 (68%)
SVR 80 (50%)
Inflammation Stage 0 12 (8%)
1 64 (40%)
2 55 (34%)
3 11 (7%)
Unknown 17 (11%)
Fibrosis Stage 0 26 (16%)
1 61 (38%)
2 36 (23%)
3 21 (13%)
4 1 (1%)  
Table 3.1 Baseline characteristics of the cohort  
Abbreviation: SVR, sustained virologic response. 
3.3.2 HLA distribution of the cohort 
The frequencies of the HLA-A and HLA-B alleles in the cohort were examined 
(Figure 3.2). Of the most frequently occurring HLA-A alleles were broadly representative of 
Western European population studies found in the dbMHC database (Sayers et al. 2010), with 
the HLA-A*01 allele being slightly underrepresented and HLA-A*24 being somewhat 
overrepresented. Of the HLA-B alleles, HLA-B*07 was somewhat overrepresented and 
HLA-B*08 was somewhat underrepresented.  
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The highly polymorphic nature of the HLA-B locus is reflected by the large number 
of alleles occurring at a very low frequency. Previous work associated a number of alleles 
with viral clearance in patients with acute hepatitis C: HLA-A*03, HLA-B*27 and HLA-
B*54. The frequency of these alleles in the cohort examined here was similar to the previous 
study (Neumann-Haefelin et al. 2008a).   
 
 
Figure 3.2 HLA distribution in the cohort  
3.3.3 HLA-associated sequence polymorphisms in HCV proteins E2, NS3 and 
NS5B 
Genes encoding the HCV proteins E2, NS3 and NS5B were directly sequenced from 
159 patients with chronic hepatitis C. Sequences of genotype 1a and 1b isolates were 
independently aligned by using the population consensus sequence of each genotype 
(Appendix D). Overall, nine associations of HLA class I alleles with polymorphisms within 
HCV genotype 1a sequences and six associations with polymorphisms within HCV genotype 
1b sequences were identified all with uncorrected P-values less than 0.05 (Tables 3.2 and 
3.3). Associations were identified for HLA-A alleles with polymorphisms within E2 and NS3 
and for HLA-B alleles with polymorphisms within E2, NS3 and NS5B. Only one of these 
associations had a P-value of less than 0.05 after correction for multiple testing.  
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# Gene Amino 
Acid 
Position
Polymorphism HLA type Absent 
(n)
Present
(n)
OR Fisher's P-value 
(unadjusted)
Cutoff <0.01
Fisher's P-value 
(adjusted with 
FDR)
B*18 1 8
non-B*18 36 24
A*25 0 3
non-A*25 59 7
A*11 4 6
non-A*11 49 10
B*13 1 5
non-B*13 47 16
A*24 13 0
non-A*24 32 24
A*11 7 3
non-A*11 58 1
B*07 15 6
non-B*07 46 2
A*68 0 3
non-A*68 54 12
B*15 1 2
non-B*15 32 0
0.0087
473
E2
E2
>0.05
>0.05
>0.05
>0.05
>0.05
0.00 0.0027
12.00 0.0096
0.0023
7.35 0.0077
14.69 0.0086
9
7
8
570E2
NS3-T1087x
NS3-Q1115x
NS3-T1211x
2690
1211
1087
>0.05NS5B NS5B-R2690x
>0.05NS3
>0.05
1115 >0.05
0.0050
9.20 0.0080
24.86 0.0084
1
2
3
4
5
6
E2-V570x
E2-D466x
E2-S473x
E2-A475x
E2-K492x
NS3
NS3
475
492
E2
E2
466
 
Table 3.2 Positive HLA class I associated sequence polymorphisms, genotype 1a 
OR = odds ratio 
 
# Gene Amino 
Acid 
Position
Polymorphism HLA type Absent 
(n)
Present
(n)
OR Fisher's P-value 
(unadjusted)
Cutoff <0.01
Fisher's P-value 
(adjusted with 
FDR)
A*01 9 4
non-A*01 71 3
A*03 16 4
non-A*03 67 0
A*24 9 16
non-A*24 42 20
B*44 9 2
non-B*44 27 49
B*44 5 6
non-B*44 67 9
B*15 5 4
non-B*15 41 1
10.52 0.0085 >0.05
5
4
3
2
1
>0.05
E2 492 E2-R492x 3.73 0.0086 >0.05
E2 483 E2-R483x 0.0022
32.80 0.0023 0.0486
>0.05
E2 538 E2-L538x 8.93 0.0028 >0.05
E2 522 E2-F522x 0.12 0.0065
NS5B 2758 NS5B-V2758x
E2 474 E2-Y474x
 
Table 3.3 Positive HLA class I associated sequence polymorphisms, genotype 1b 
OR = odds ratio 
Overall, it can be said that HCV genotype 1b is relatively poorly represented in 
epitope databases and therefore the potential for prediction servers to have large enough 
datasets for accurate learning is relatively low. In November 2010, the IEDB contained 311 
binders and 535 non-binders for HCV genotype 1b. This database explicitly excludes HIV 
epitopes (Vita et al. 2010). HIV epitopes can be found in the Los Alamos HIV Molecular 
Immunology Database; there 2398 binders are identified as being derived from HIV-1 
subtype B, non-binders are not specifically identified. Both HIV-1 and HCV genomes have 
CHAPTER 3. HLA-RESTRICTED IMMUNE PRESSURE ON HCV 
 
53 
 
  
similar lengths (9.2 kb vs. 9.6 kb) and should thus contain, roughly, similar numbers of 
potential epitopes.  
The number of patients in our cohort was small and some of the associations were 
borderline significant after correction for multiple testing. Therefore an additional method for 
validating the identified associations was chosen. The web-based prediction servers NetMHC 
(Lundegaard et al. 2008) and SYFPEITHI (Rammensee et al. 1999) were used to identify 
possible HCV CD8 epitopes, because there is a relative lack of experimentally verified HCV 
epitopes available in public databases. (This contrasts markedly with HIV-1 were many 
experimentally verified epitopes are available, see Section 2.3.2). The rationale for using 
NetMHC was the excellent performance of this prediction method in a number of comparison 
studies, and SYFPEITHI was chosen because it has been used in a number of previous studies 
examining escape mutations in HCV. Additionally, the HCV Immunology Database at Los 
Alamos was examined for known CTL epitopes; this database contains the same HCV data as 
the Immune Epitope Database (IEDB), but is structured in a more user friendly manner. 
Of the 15 predicted epitopes, seven overlapped with previously described epitopes 
indicating that the epitopes are located in highly immunogenic regions (Tables 3.4 and 3.5). 
Of the 15 epitopes, seven were identified as potential weak binders by NetMHC, and a further 
epitope had what can be described as an intermediate binding affinity (778 nM). The 
SYFPEITHI prediction server uses a scoring system in which a score of greater than or equal 
to 20 indicates a high likelihood of being a true epitope. This was the case for five epitopes 
and in three further epitopes, the associated mutation was located in anchor residue positions. 
Overall, eight of the 15 identified polymorphisms have a score of at least 20 using 
SYFPEITHI or an affinity of less at most 500 nM using NetMHC. Larger patient datasets are 
required to add sufficient power to the associations, with the exception of  HLA-B*15 
RVFTEAMTRY2757-2766 which already showed an adjusted P value of less than 0.5. 
Additionally, it should be noted again that there is a lack of experimental data identifying 
epitopes for HCV genotype 1b making the verification of the identified 1b epitopes difficult. 
 
 
# Gene Allele Amino Acid 
Position
Amino 
Acid
SYFPEITHI 
Prediction
Score NetMHC 
Prediction 
Affinity 
(nM)
HCV Immunology 
Database CTL Epitope
Allele
1 E2 B*18 466 D DQGWGPISY 17 DQGWGPISY 127 (WB) RPLTDFDQGW B53
2 E2 A*25 473 S - - - - DFAQGWGPISYANGS human
3 E2 A*11 475 A ANGSGPDHR 13 - - DFAQGWGPISYANGS human
4 E2 B*13 492 K - - - - YPPKPCGI B51
5 E2 A*24 570 V VCGAPPCVI 13 - - CVIGGAGNNT B53
6 NS3 A*11 1087 T GTRTIASPK 25 GTRTIASPK 94 (WB) TRTIASPKGPVIQMY human
7 NS3 B*07 1115 Q APQGARSLT 21 APQGARSLT 183 (WB) DLVGWPAPQGSRSLT human
8 NS3 A*68 1211 T TTMRSPVFT 13 TTMRSPVFT 84 (WB) - -
9 NS5B B*15 2690 R NSRGENCGY 11 NSRGENCGY 414 (WB) - -
 
Table 3.4 Putative epitopes associated with sequence polymorphisms identified in the cohort, 
genotype 1a 
The identified polymorphisms are indicated in red. 
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# Gene Allele Amino Acid 
Position
Amino 
Acid
SYFPEITHI 
Prediction
Score NetMHC 
Prediction 
Affinity 
(nM)
HCV Immunology 
Database CTL Epitope
Allele
1 E2 A*01 474 Y AQGWGPITY 17 - - - -
2 E2 A*03 483 R DQRPYCWHY 12 - - - -
3 E2 A*24 492 R HYAPRPCGI 23 HYAPRPCGI 319 (WB) - -
4 E2 B*44 522 F VVVGTTDRF 12 - - - -
5 E2 B*44 538 L GENETDVLL 22 GENETDVLL 778 - -
6 NS5B B*15 2758 V RVFTEAMTRY 23 SLRVFTEAM 91 (WB) - -
 
Table 3.5 Putative epitopes associated with sequence polymorphisms identified in the cohort, 
genotype 1b 
The identified polymorphisms are indicated in red. 
The statistically most significant association in this study occurred in the NS5B gene 
at position V2758 and was associated with HLA-B*15. This polymorphism has not been 
described before. In the analysis of putative epitopes, both SYFPEITHI and NetMHC 
predicted an epitope in this region, of a score of 23 and a 91 nM binding affinity respectively. 
However, the exact position of the predicted epitopes were different with each method (Table 
3.5). In the case of SYFPEITHI, V2758 is located at a main anchor position for HLA-B*15 
(Prilliman et al. 1999), whereas, interestingly, in the case of NetMHC the variant is located 
neither at a known primary nor secondary anchor position. However, escape mutations at 
non-anchor residue positions have been described before and probably, in these cases, have a 
greater impact on CTL binding than on MHC binding (Moskophidis and Zinkernagel 1995). 
The potential existence of a founder effect in the cohort was also evaluated by 
performing a phylogenetic analysis of cohort (Figure 3.3). The analysis revealed high 
phylogenetic distances between different patients. Therefore a shared evolutionary history of 
the viruses infecting the cohort being responsible for the identified HLA-restricted 
polymorphisms is unlikely. Also, a further assessment of phylogenetic relatedness (Section 
3.2.7) was unable to determine the existence of a founder effect. 
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Figure 3.3 Phylogenetic tree of the viral sequences drawn from the cohort 
Clusters representing HCV subtypes 1a and 1b are indicated. Lengths of branches represent 
phylogenetic distances between HCV isolates of different patients. The tree reveals high phylogenetic 
distances between isolates from different patients. 
3.3.4 Association of HLA alleles with outcome of antiviral therapy 
The sustained virologic response rate of the cohort was, with 50%, in the expected 
range of patients infected with HCV genotype 1 under controlled trial conditions. In order to 
investigate whether particular HLA-A or HLA-B alleles were associated with a higher or 
lower chance of successful treatment, patient allele types were associated with achieving 
SVR (Table 3.6). In the case of patients with the allele HLA-B*07 which were infected with 
HCV genotype 1a, the allele was associated with treatment success (for patients with HLA-
B*07, SVR was 66%, for patients negative for HLA-B*07, SVR was only 33%, P-value less 
than 0.05). However, patients carrying the HLA-B*44 allele had a reduced chance of 
treatment success when infected with HCV genotype 1a (for patients with HLA-B*44, SVR 
was only 20%, but for patients negative for HLA-B*44, SVR was 55%, P-value less than 
0.01). Finally, patients infected with HCV genotype 1b carrying the HLA-A*-02 allele had a 
better treatment response (for patients with HLA-A*02, SVR was 65%, for patients negative 
for HLA-A*02, SVR was only 41%, P-value less than 0.05). 
 
CHAPTER 3. HLA-RESTRICTED IMMUNE PRESSURE ON HCV 
 
56 
 
  
HCV Genotype Allele SVR no SVR P-value
1a B*07 14 7
non-B*07 17 31
1a B*44 4 16
non-B*44 27 22
1b A*02 31 17
non-A*02 16 23
0.0201
0.0088
0.0299
 
Table 3.6 Association of HLA class I alleles and sustained virologic response or treatment success  
The overall SVR rate was 50%, which is in the expected range for patients infected with HCV 
genotype 1 under control trail conditions. 
The stage and grade of chronic hepatitis C was also associated with patients carrying 
particular HLA alleles (Tables 3.7 and 3.8). In particular, patients infected with HCV 
genotype 1a and carrying allele HLA-A*26 had higher levels of both liver inflammation and 
fibrosis (P-value less than 0.05). In contrast, patients infected with HCV genotype 1b, had 
lower levels of liver fibrosis (HLA-A*02 and HLA-A*68) and lower levels of inflammation 
(HLA-A*24). HCV RNA viral load or early treatment response was not correlated with the 
presence of any HLA allele. 
 
HCV Genotype Allele Inflamation Stage <= 1 Inflammation Stage > 1 P-value
1a A*26 2 8
non-A*26 36 19
1a B*08 9 1
non-B*08 29 26
1b A*24 8 16
non-A*24 34 22
0.0124
0.0370
0.0299
 
Table 3.7 HLA class I alleles associated with degree of liver inflammation 
HCV Genotype Allele Fibrosis Stage <= 1 FIborsis Stage > 1 P-value
1a A*26 3 7
non-A*26 39 15
1b A*02 29 14
non-A*02 15 22
1b A*68 7 0
non-A*68 37 36
0.0246
0.0239
0.0147
 
Table 3.8 HLA class I alleles are associated with degree of liver fibrosis 
3.4 Discussion 
In this study, the HLA class I phenotype of patients with chronic HCV genotype 1 
infection was shown to be correlated with viral polymorphisms and the outcome of antiviral 
therapy consisting of pegylated interferon alpha-2b and ribavirin. It was possible to (1) 
identify several as yet unknown HLA class I-associated viral escape mutations in both HCV 
genotype 1a and 1b quasispecies located within novel CD8 T cell epitopes. Additionally, (2) 
it was possible to associate certain HLA class I alleles with successful antiviral treatment. 
Overall, we were able to identify 15 HLA-restricted HCV polymorphisms in viral 
genotypes 1a and 1b. Our cohort size, while larger than almost all previous studies, still 
suffered from being relatively small with only 69 patients infected with HCV genotype 1a 
and 87 patients infected with HCV genotype 1b. This led to relatively small statistical power 
and only one of the polymorphisms withstood correction for multiple testing.  
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For this reason we performed a detailed epitope analysis using a variety of web-based 
prediction servers and epitope databases. Of the identified 15 HLA-restricted polymorphisms, 
12 either scored highly (greater than or equal to 20) with SYFPEITHI, were identified as a 
weak binder with NetMHC (binding affinity between 50-500 nM) or lay within an 
experimentally identified epitope in the Los Alamos HCV Immunology Database. Also, six 
polymorphisms were located in putative anchor positions in the HLA peptide groove. It  is 
thought that mutations in epitopes which are located in such primary anchor positions are 
particularly disruptive to HLA-peptide complex formation and hence substantially reduce the 
likelihood of effective TCR recognition (Rammensee et al. 1999). To our knowledge, only 
four of the identified putative HCV CD8 T cell epitopes overlap with previously described 
epitopes, but these have been described to be associated with other HLA alleles (Thimme et 
al. 2002; Wertheimer et al. 2003; Lauer et al. 2004; Timm et al. 2007; Neumann-Haefelin et 
al. 2008b; Thimme et al. 2008). This observation indicates that a high level of 
immunogenicity originates from these HCV protein regions, as individuals of different HLA 
phenotypes present only slight different epitopes. This data confirms the need for further 
immunological studies in larger chronically infected patient cohorts and substantially 
extended in vitro binding affinity studies to identify both HCV peptides which are binders or 
non-binders, especially in the case of as yet poorly studied HCV genotypes such as 1b. 
Recent work has shown that there are substantial differences in the adaptation of HCV 
genotypes 1a and 3 to immune pressure. In this study, it was possible  to independently 
analyze the quasispecies of HCV genotype 1a and 1b infected patients and show that there 
are even significant differences at the viral subtype level (Rauch et al. 2009). 
The putative epitope in the NSB5 protein of  HCV genotype 1b was identified as 
RVFTEAMTRY2757-2766  by SYFPEITHI and SLRVFTEAM2755-2763  by NetMHC. Due to the 
relatively low amount of experimental binding affinity data available for HCV genotype 1b in 
the publically available databases, it can be assumed that there is currently insufficient data 
available to train prediction algorithms to perform with high levels of accuracy. In particular, 
since the polymorphism located within this particular eptiope,V2758X, showed the highest 
level of significance after correction for multiple testing lends support to this polymorphism 
being located in a highly immunogenic region. Also, since as of yet no potential epitopes  
have been described within this region for genotype 1b infected patients, there appear to be 
immunogenic differences between the virus quasispecies in this region (Kuiken et al. 2005; 
Yusim et al. 2005; Kuiken et al. 2006).   
Prior studies that examined HLA type and treatment success in chronically infected 
patients concentrated on HLA class II alleles or were performed prior to the widespread 
availability of pegylated interferon alpha-2b (Jiao and Wang 2005; Patel et al. 2006; Gaudieri 
et al. 2009). Therefore, this study provides novel information on the role of HLA class I 
alleles in response to current state-of-the-art therapies. It should be noted however, that the 
while the differences in SVR with alleles HLA-B*07, HLA-B*44 and HLA-A*02 are 
striking they are lower than recently identified correlations of treatment success with 
polymorphisms near the IL-28B gene (Ge et al. 2009; Thomas et al. 2009).  
In summary, it was possible to identify several unknown HLA class I-restricted 
polymorphisms located within putative CD8 T cell epitopes and show substantial differences 
between differences between the viral quasispecies genotype 1a and 1b. Furthermore, the 
treatment success with pegylated interferon alpha-2b and ribavirin is significantly increased 
in patient groups of particular HLA genotypes. 
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4 ViralDAS3 
4.1 Introduction to BioSapiens and DAS 
BioSapiens was a Network of Excellence funded by the European Union‟s 6th 
Framework Program from 2004 to 2009 (http://www.biosapiens.info/page.php). The goal of 
the network was to provide a large scale, concerted effort to annotate genome data. Included 
in the network were 25 institutions from 14 countries, including the Max Planck Institute for 
Informatics, which was involved in Work Package 15 entitled “Thematic Work Package on 
Infectious Diseases.” 
The method chosen to make such a large scale annotation possible was through the 
Distributed Annotation System (DAS, see description below). The annotations are available 
in public domain and easily accessible through a single portal called the DAS Registry 
(http://www.dasregistry.org). 
DAS is a network protocol which was developed to enable the exchange of biological 
data (Dowell et al. 2001; Prlic et al. 2007). The protocol was originally targeted to the 
genome annotation community to solve the problem of “the frustration of integration.” 
Genomic sequence, protein sequence or structure annotations are decentralized and stored by 
third-party annotators and integrated on an as-needed basis by client-side software. 
Therefore, there is no dependency on particular database schemas or technologies or client-
side technologies, and thus an uncoupling of reference and annotation servers occurs. 
DAS consists of three parts: (1) centralized database resources such as Entrez (Sayers 
et al. 2010), Ensembl (Flicek et al. 2010) and Interpro (Hunter et al. 2009) which perform the 
function of reference servers and provide genomic and protein sequence as well as structure 
data, (2) various annotation servers using such software packages as LDAS (2001) and 
ProServer (Finn et al. 2007) which supply specialized annotation for the data provided by the 
reference servers and (3) a client viewer such as Dasty (Jones et al. 2005) or SPICE (Prlic et 
al. 2005) which displays sequence or structure information from the reference servers and 
various user-selected annotation layers. Communication between the client layer and the 
servers is defined by the DAS XML specification. 
4.2 Implementation of ViralDAS 
As there were no reference servers available for virus genomes such as HIV-1 or 
HCV, a reference server using the GBrowse software package was designed and 
implemented (Stein et al. 2002): the ViralDAS server for HIV-1 and HCV is the first DAS 
Server for viral genomes (Marcus 2008). It was specifically adapted from the default DAS 
server type to meet the requirements posed by a viral genome. The DAS server configuration 
that has been developed can easily be extended to other viruses which have similar features. 
In order to implement ViralDAS, several new feature types had to be created and 
existing feature types had to be adapted. The current DAS server now supports the feature 
types transcripts, polyproteins, cleaved proteins and accessory proteins (Figure 4.1). For 
example, the seven most common transcripts of HIV-1 were annotated (over 30 are known, 
but many occur only rarely). The three polyproteins of HIV-1 are shown in a separate track. 
                                                 
3
The work described in this section was performed as part of BioSapiens Network of Excellence 
(http://www.biosapiens.info/page.php). My own contribution comprises designing and implementing the 
ViralDAS server. ViralDAS is described in internal reports for BioSapiens and mentioned in a book on 
collaborative research and resources in bioinformatics (Marcus 2008). 
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Below the polyprotein track, one can see the track which shows the proteins produced by the 
cleavage of the polyproteins, as well as other accessory proteins. Over each transcript, 
polyprotein or protein, the gene name is shown as the three-letter abbreviation e.g. ENV. The 
protein glyphs are all in “musical staff notation” thus displaying the correct reading frame of 
each protein. For HIV-1 HXB2 strain numbering has been used (Korber et al. 1998).  
The server can be reached via the following URLs:  
 
 http://viraldas.bioinf.mpi-inf.mpg.de 
 http://www.dasregistry.org 
 
 
Figure 4.1 Screenshot of the main HIV-1 ViralDAS page 
4.3 Outlook 
Future possible developments, which would provide more annotation tracks that are 
specific to the viral genomes, are numerous. HIV-1 develops a large number of resistance 
mutations which reflect the HAART (combination drug therapy) therapy that the infected 
individual has undergone. Currently, the drugs which are widely used target several viral 
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proteins and cause the viral genome to develop resistance mutations in them. Additionally, 
the virus adapts to the HLA-immune profile of the host and has been shown to produce 
escape mutations which prevent the host‟s immune system from recognizing the virus 
effectively and combating the infection. In fact, particular regions of the virus, known as 
epitopes, are particularly prone to developing escape mutations depending on the HLA-
profile of the host. Finally, there are also a number of HIV-1 viral subtypes and viral 
recombinant forms, which vary in their prevalence in different regions of the globe. All these 
aspects could also be implemented for HCV as well. 
Linkage to the annotation of the human genome in context with the viral infection still 
has to be conceptualized and implemented.  
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5 Predicting MHC Class I Epitopes in Large Datasets4 
5.1 Introduction 
A precise understanding of host immune responses is crucial for basic immunological 
studies as well as for designing effective disease prevention strategies. Epitope-based analysis 
methods are effective approaches at assessing immune response, allowing for the 
quantification of the interaction between a host and pathogen, of vaccine effectiveness or 
other prevention strategies. 
MHC class I molecules deliver peptides from the cytosol and are recognized by CD8 
T cells. The binding of antigenic peptides from pathogens to MHC class I molecules is one of 
the crucial steps in the immunological response against an infectious pathogen (Paul 1998). 
While not all peptides that bind MHC molecules become epitopes, all T cell epitopes need to 
bind to MHC molecules. Therefore, deciphering why certain peptides become epitopes and 
others do not is central to the development of a precise understanding of host immune 
responses.  
The Immune Epitope Database and Analysis Resource (IEDB) (Peters et al. 2005a; 
Peters et al. 2005b) is a central data repository and service, containing MHC binding data 
relating to B cell and T cell epitopes from infectious pathogens, experimental pathogens and 
self-antigens (autoantigens). In most cases, T cell epitopes are defined as peptides that are not 
only presented to T cell receptors on the cell surface by specific MHC molecules, but that 
also trigger an immune response. IEDB encompasses patent data from biotechnological and 
pharmaceutical companies, as well as direct submissions from research programs and 
partners. Within the database, epitopes are linked with objective and quantifiable 
measurements with regard to their binding affinity to specific, well defined immune system 
receptors. 
IEDB is not the first database to store such information, as there are a number of 
databases which include similar information. However, although most of the components of 
IEDB can be found in other resources, none contains them all. For example, SYFPEITHI 
(Rammensee et al. 1999) contains carefully mapped epitopes or naturally processed peptides, 
but unlikely IEDB, does not annotate the context in which they are immunogenic. The Los 
Alamos HIV Molecular Immunology Database (2007), focuses on a restricted dataset. FIMM 
(Schonbach et al. 2002), is of modest size and solely focuses on cellular immunology and 
MHCPEP (Brusic et al. 1998), while still widely used, has not been updated since 1998. 
While MHCBN (Lata et al. 2009) and AntiJen (Blythe et al. 2002; Toseland et al. 2005) 
contain peptide entries that are not contained in IEDB, IEDB has more entries than any other 
existing database in this field. 
While IEDB is the first epitope database of significant size, the experimental 
screening of large sets of peptides with respect to their MHC binding capabilities is still very 
demanding due to the large number of possible peptide sequences and the extensive 
polymorphism of the MHC proteins. Therefore, there is significant interest in the 
development of computational methods for predicting the binding capability of peptides to 
MHC molecules, as a first step towards selecting peptides for actual screening.  
                                                 
4
 The work reported in this section was performed in collaboration with Iris Antes (MPI for 
Informatics/TU Munich, Germany).  It has been published in the journal BMC Bioinformatics and appears in 
this thesis based on the permissions granted by BioMed Central's Open Access Charter (Roomp et al. 2010).  
My own contribution to the publication comprises selecting the datasets for the analysis, performing the 
prediction analysis (including robustness and generalizability) resulting in 4 of the 4 published tables (Tables 
5.1, 5.2, 5.3 and 5.4) and 3 of 3 published figures (Figures 5.1, 5.2 and 5.3). 
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Sequence- and structure-based methods, as well as combinations thereof, have been 
developed and were used for both classification and regression. Classification models aim to 
distinguish binding from non-binding peptides, whereas regression methods attempt to 
predict the binding affinity of peptides to MHC molecules. As the quantity of publicly 
available binding data has been limited until recently, most methods focus on classification. 
A review of previous methods can be found in Tong et al. (Tong et al. 2007). 
Sequence-based methods are computationally more efficient than structure-based 
methods. However, they are hampered by the need for sufficient experimental data and 
therefore only achieve high performance on already intensively investigated MHC alleles. 
Additionally, sequence-based methods do not provide a structural interpretation of their 
results, which is of importance for designing peptidic vaccines and drug-like molecules. 
Structure-based methods have the advantage of being independent of the amount of available 
experimental binding data, but are computationally intensive and therefore not suited for the 
screening of large datasets.  
A recent approach (Antes et al. 2006) performs a combined structure-sequence-based 
prediction by incorporating structural information obtained from molecular modeling into a 
sequence-based prediction model. This method therefore not only allows for the fast 
prediction of MHC class I binders, but also for the efficient construction of docked peptide 
conformations. This approach is the only prediction method available today, which also 
allows for the construction of such conformations. We have evaluated this approach for MHC 
class I alleles of the HLA-A and HLA-B loci for which extensive datasets were available in 
IEDB and compared it to two sequence-based prediction methods from the literature. These 
two sequence-based prediction methods are the same as examined in Antes et al. (Antes et al. 
2006) and were chosen here as well for comparison reasons. In addition, we have evaluated 
the prediction server NetMHC which has shown to be among the best predictors in recent 
comparison tests (Lin et al. 2008). 
A major focus of this study is on testing the dependency in performance of well 
established methods on the use of different training and testing datasets. The four methods we 
have chosen span a representative cross section of available methodology for MHC-peptide 
binding predictions, from simple binary (SVMHC) to rather sophisticated encoding 
(DynaPred
POS
). The chosen methods include advanced learning strategies such as support 
vector machines (SVM) (DynaPred
POS
 and SVMHC) and artificial neural networks (ANN) 
(NetMHC), as well as the more straightforward quantitative matrix based prediction (YKW).  
Lin et al. (Lin et al. 2008) performed a comparative evaluation of thirty prediction 
servers developed by 19 groups using an independent dataset. Each server was accessed via 
the Internet and the predictions were recorded, normalized, and compared. Peters et al. 
(Peters et al. 2006) performed an extensive analysis of predictors, in which they trained and 
tested their in-house methods, but did not reimplement any of the external methods used. 
Instead, web interfaces were used for the external methods. Zhang et al. (Zhang et al. 2009) 
evaluated five prediction methods using public web interfaces with the default parameters of 
the methods in question. Three of these methods were in-house and two were external. The 
authors discarded all peptides used for training their own methods for subsequent testing, but 
there was some concern that there was some overlap between evaluation and training data 
sets for one of the external methods. They also trained their own predictors on a dataset of 
binders and non-binders for a wide variety of alleles, testing on a second set of binders and 
non-binders which were released at a later point in time. The goal of this analysis was to 
examine the performance of these predictors on alleles for which little or no data was 
available (which were described as pan-specific predictors). The alleles for which such pan-
specific analyses were performed were not identified and only limited information on the 
methods performance was available.  
Work by other groups which preceded the study by Zhang et al. (Zhang et al. 2009), 
included a support vector machine based approach (Jacob and Vert 2008), which was trained 
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and tested on a relatively small datasets, where different predictive models are estimated for 
different alleles, using training data from „similar‟ alleles. The notion of allele similarity is 
defined by the user therefore requiring human intervention which is not a systematic 
procedure. A binding energy model (Jojic et al. 2006), which was trained and tested on very 
small datasets, was used to make pan-specific predictions for only two alleles. A further study 
(Zhang et al. 2005), which utilized hidden Markov models and artificial neural networks as 
predictive engines, was again trained on relatively small datasets. The system was used to 
identify so-called promiscuous peptides, which bind well to a number of diverse alleles. 
In this study, we reimplemented the external methods YKW and SVMHC and trained 
and tested them along side our in-house method DynaPred
POS
 on a wide variety of datasets. 
This allows for a more objective comparison of the performance of these methods. We also 
tested NetMHC in all the tests where training was not necessary; this server is only available 
via a web interface and thus could not be reimplemented for this study. In contrast to the 
previous work described, we perform a detailed analysis of the performance of predictors 
trained on one allele and their ability to accurately predict other alleles. 
5.2 Methods 
5.2.1 Datasets with complete peptides 
In this section we describe the datasets we use that contain data incorporating full 
peptides, i.e. information on all nine residues. IEDB was mined for allele/peptide data on 
May 16th, 2007. Only alleles with a significant number of 9-mer binding and non-binding 
peptides (the total number being greater than 200) where included in the analysis (Table 5.1). 
The data was imported into a local relational database to allow for efficient analysis.  
Three datasets were generated for each allele: all peptides available in IEDB (the full 
dataset or Dataset F), all peptides with an available quantitative laboratory test result (IC50 or 
in rare cases EC50), but including only those with a binding affinity between 50 nM and 1000 
nM, i.e. including only weak binders and non-binders (the intermediate dataset or Dataset I) 
and all peptides with an IC50, but excluding those with a binding affinity between 10 nM and 
10,000 nM, i.e. including only very strong binders and very clear non-binders (the strong 
dataset or Dataset S). Alleles with less than 200 peptides in total (binders and non-binders) 
were excluded from the analysis in all datasets. IC50 measures the half maximal (50%) 
inhibitory concentration (IC) of a radioactive isotope labeled standard peptide to MHC 
molecules, whereas EC50 measures the half maximal effective concentration (EC) of such a 
reference peptide (Peters et al. 2005a; Peters et al. 2005b). For Dataset F, in cases where a 
peptide with a particular sequence had more than one entry in IEDB for a particular allele (for 
example the peptide was tested with same allele by two different laboratories, resulting in 
two separate IEDB entries), this peptide was included only once. If no binding constant was 
available, the peptide was also only included once in Dataset F. If a peptide was described as 
a binder by one laboratory and a non-binder by another laboratory, it was included both as a 
binder and non-binder in Dataset F. For Datasets I and S, in cases where peptide-allele 
complexes had duplicate entries in IEDB and the binding affinities differed, resulting in at 
least one entry with a binding affinity which fell within the ranges used in Datasets I and S, 
this peptide was included in the respective dataset. If, for a particular allele, there was more 
than one binding affinity measurement made that fell into one of the ranges used in the 
analysis, an average binding affinity was calculated and used for that peptide in that 
particular range. Any peptides annotated in IEDB as binders with IC50 values greater than 
500 nM, and peptides annotated as non-binders with IC50 values less than 500 nM were 
discarded. We have made the three datasets available:  
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 http://www.mpi-inf.mpg.de/~roomp/benchmarks/list.htm 
 
We also tested an independent dataset recently published by Lin et al. (Lin et al. 
2008), derived from the tumor antigen survivin and the cytomegalovirus internal matrix 
protein pp65. This data was not used for training any of the four prediction methods in this 
study and therefore serves as an independent test set. 
5.2.2 Prediction methods 
Four prediction methods were evaluated with respect to their ability to correctly 
classify binders and non-binders in the datasets described above. As already described in the 
introduction, the chosen methods span a representative cross-section of available 
methodology for MHC binding predictions. 
The first prediction method used (DynaPred
POS
) was developed in our laboratory 
(Antes et al. 2006). The general strategy followed to generate this prediction model, involves 
as a first step molecular dynamics simulations from which energetic information for all 20 
amino acids in each of the nine binding pockets of the binding groove of HLA-A*0201 was 
extracted. The algorithm is based on the assumption that the total binding affinity of a peptide 
can be approximated by the sum of the binding affinities of its individual amino acids, 
neglecting the effect of interactions between neighboring residues. Therefore, each amino 
acid was simulated individually in each binding pocket; initial conformations were 
constructed from available crystal structures and, in order to stabilize the peptide 
conformations, the single so-called pivot amino acid was extended by a glycine residue on 
both sides (for terminating residues on the non-terminating side only) resulting in pseudo-
dimers or -trimers which were used in the simulations. For amino acids with no available 
experimental structures, existing residues were mutated to the corresponding amino acid 
using the program SCWRL3 (Canutescu et al. 2003). Subsequently, a binding-free-energy-
based scoring matrix (BFESM) was constructed which included important energy terms 
reflecting the binding properties of the amino acids derived from the simulations. Each entry 
in the matrix represented one feature (energy term) of a particular amino acid in a particular 
binding pocket.  
The BFESM is used to generate a feature vector for each given peptide in the training 
dataset; all vectors together produce a feature matrix for model generation and prediction. A 
local feature matrix is constructed from the BFESM which uses all residue and binding 
pocket positional information from the scoring matrix. This matrix provides a basis for 
logistic regression and SVM training (Team 2003) of the final model (DynaPred
POS
). 
One feature unique to DynaPred
POS
 is the ability to construct bound peptide 
conformations for all predicted sequences. The bound conformations are generated by 
connecting the saved residue conformations for the simulation runs and performing a short 
energy minimization. In a detailed analysis (Antes et al. 2006), the constructed peptide 
structures were refined within seconds to structures with an average backbone RMSD of 1.53 
Å from the corresponding experimental structure. 
Additionally, we evaluated two sequence-based prediction methods from the 
literature. The first method is SVMHC from Dönnes et al. (Dönnes and Elofsson 2002), which 
is based on SVMs and was implemented using the software package SVM-LIGHT (Joachims 
1999). For this method, SVM kernels and trade offs were optimized by systematic variation 
of the parameters and evaluation of prediction performance was made using Matthews 
Correlation coefficients (Matthews 1975), which were used as the main measure of 
performance for parameter optimization. The second sequence-based prediction method we 
evaluated is YKW from Yu et al. (Yu et al. 2002), which is based on data-derived matrices. 
The matrix is generated using logarithmized propensities for occurrence in binding vs. 
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nonbinding peptides of amino acids at specific positions within the peptide training set to 
generate an initial matrix. The final matrix was derived by a position dependent weighting of 
the initial matrix which was derived by an analysis of binding data. The SVMHC and YKW 
methods were re-implemented for this study using the methodology reported in the original 
publications. 
The fourth and final method we evaluated is an artificial neural network based 
approach (Nielsen et al. 2003) (Buus et al. 2003), which was developed using ANN which are 
capable of performing sensitive, quantitative predictions. Such quantitative ANN were shown 
to be superior to conventional classification ANNs which have been trained to predict 
binding versus non-binding peptides. NetMHC has recently been shown to be among the best 
predictors in an extensive comparison of prediction servers whose performance was 
evaluated with 176 peptides derived from the tumor antigen survivin and the cytomegalovirus 
internal matrix protein pp65 (Lin et al. 2008). NetMHC is available via 
http://www.cbs.dtu.dk/services/NetMHC/. NetMHC could not be trained for this study as it 
was only accessible via with web interface, and was therefore used for testing purposes only. 
Also, it is probable, that at least some of the data used to train the NetMHC server was the 
same data which was retrieved from IEDB for this study. 
For Datasets F, I and S, training and testing of the prediction models for SVMHC, 
YKW, and DynaPred
POS 
was performed for each HLA-A and HLA-B allele separately. In the 
case of DynaPred
POS
, the same BFESM generated from the molecular simulations on HLA-
A*0201 was used to generate each new feature matrix for each allele separately. For 
NetMHC, the peptide sequences from Dataset F, I and S were submitted to the prediction 
server and the prediction results were recorded. 
The accuracy of the methods was assessed by generating areas under the curve (AUC, 
see ROC analysis (Fawcett 2004)), which is a widely used non-parametric performance 
measure. ROC analysis tests the ability of models to separate binders from non-binders 
without the need of selecting a threshold. The values AUC ≥ 0.90 indicate excellent, 0.90 > 
AUC ≥ 0.80 good, 0.80 > AUC ≥ 0.70 marginal and 0.70 > AUC poor predictions (Swets 
1988).  
We used 10-fold cross validation to assess the accuracy of the predictions. 
5.2.3 Datasets excluding anchor positions  
Additionally, datasets were generated from the complete peptide datasets F, I, and S 
from several alleles which excluded the primary anchor positions in the 9-mer. In these new 
datasets, which we called F1,3-8, I1,3-8 and S1,3-8, the primary anchor positions P2 and P9 were 
replaced by glycine residues. Training and testing of the prediction models YKW, SVMHC 
and DynaPred
POS
 was performed for each HLA-A and HLA-B allele separately. NetMHC 
was not included in this analysis, because we were only able to access the predictor via the 
online server and were thus unable to retrain the statistical model. 
5.2.4 Robustness 
In order to determine how dependent the reproducibility of the results of the 
prediction methods YKW, SVMHC and DynaPred
POS
 are on the size of the available allele 
datasets (a phenomenon that we call robustness), we tested the methods' performance with 
randomly selected balanced datasets of different sizes, selected from all peptides available in 
IEDB for a particular allele (Dataset F). NetMHC was not included in this analysis, because 
we were unable to retrain the statistical model.  
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The alleles examined were HLA-A*0201, HLA-A*3101 and HLA-B*0702. The 
training was performed on each allele separately, followed by testing using 10-fold cross 
validation. The smallest balanced dataset for each allele consisted of 50 randomly selected 
binders and 50 randomly selected non-binders and the size of the largest dataset depended on 
the overall number of binders or non-binders available for the allele. All prediction methods 
were run on four randomly selected balanced datasets in each size category for each allele. 
5.2.5 Generalizability 
By this test, we assess the ability of the statistical models (YKW, SVMHC and 
DynaPred
POS
), trained for the allele HLA-A*0201, to generalize to other alleles. NetMHC 
was again not included in this analysis, because we were unable to retrain the statistical 
model. Training was performed on Dataset F of HLA-A*0201, followed by testing on 
Datasets F of all other alleles. This generalization ability is essential for epitope prediction 
models as there are many alleles with insufficient data for training an allele-specific model. 
5.3 Results 
5.3.1 Datasets with complete peptides 
In this section we examine the dependency of the performance of the four prediction 
methods on the selection criteria of the used training dataset. 
If all available peptides for an allele are used for the prediction (Table 5.1, Dataset F), 
NetMHC performs particularly well, achieving the highest AUC for all 24 alleles examined. 
All four methods had a predictive performance of good or excellent for 20 or more of the 24 
alleles. NetMHC significantly outperforms the three other methods (Wilcoxon Rank Sum 
Test, P-value < 0.001) and no statistically significant difference between the other three 
methods could be detected. Therefore, the ranking of the methods can be described as 
NetMHC > (DynaPred
POS
, SVMHC, YKW). 
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Allele 
Name
Binders Non-
Binders
Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0101 163 1316 1479 0.93 0.98 0.95 0.94
2 A*0201 1544 1929 3473 0.93 0.96 0.92 0.91
3 A*0202 723 697 1420 0.88 0.93 0.85 0.85
4 A*0203 732 685 1417 0.88 0.95 0.86 0.84
5 A*0206 633 782 1415 0.88 0.95 0.87 0.86
6 A*0301 637 1618 2255 0.89 0.96 0.88 0.8
7 A*1101 816 1279 2095 0.92 0.96 0.9 0.91
8 A*2402 202 464 666 0.8 0.85 0.78 0.81
9 A*2601 69 885 954 0.84 0.93 0.83 0.84
10 A*3101 510 1480 1990 0.89 0.95 0.89 0.88
11 A*3301 203 994 1197 0.88 0.96 0.89 0.88
12 A*6801 578 620 1198 0.85 0.92 0.82 0.81
13 A*6802 439 980 1419 0.84 0.93 0.85 0.83
14 B*0702 238 1110 1348 0.94 0.98 0.94 0.93
15 B*0801 23 687 710 0.82 0.99 0.78 0.79
16 B*1501 182 836 1018 0.86 0.97 0.89 0.9
17 B*2705 81 917 998 0.93 0.97 0.9 0.94
18 B*3501 273 578 851 0.83 0.93 0.84 0.85
19 B*4001 94 1112 1206 0.9 0.97 0.93 0.91
20 B*4402 76 136 212 0.77 0.84 0.75 0.76
21 B*4403 71 142 213 0.68 0.81 0.65 0.7
22 B*5101 108 249 357 0.82 0.93 0.8 0.81
23 B*5301 127 228 355 0.86 0.95 0.85 0.87
24 B*5801 78 893 971 0.9 0.99 0.93 0.93
Average 
AUC
0.86 0.94 0.86 0.86
 
Table 5.1 Prediction accuracies for the full dataset 
Alleles included in the study with the number of binders and non-binders available; all available 
binders and non-binders were included in the analysis irrespective of whether quantitative laboratory 
test data was available or not (Dataset F). Only unique peptide sequences were included in the counts; 
all peptides with more than one entry for a particular allele in IEDB were counted once only. The 
overall performance of the three prediction models on different alleles is shown; AUC = area under 
the curve (ROC analysis). The average AUC for each method is included at the bottom of each 
column. 
The results are dependent on the size of the datasets: for good results (AUC greater 
than 0.85), an allele's dataset generally has to contain more than 100 binders and more than 
100 non-binders (preferably more than 200 binders and more than 200 non-binders). Also, 
datasets for which the number of binders and non-binders are relatively balanced produced 
larger AUCs (i.e. better performance). Unbalanced datasets in IEDB generally have a 
substantially lower number of binders than non-binders. For YKW, SVMHC and DynaPred
POS 
better results were achieved for HLA-A than HLA-B. This probably is due to the lower 
number of epitopes which are available for HLA-B in IEDB and, in the case of DynaPred
POS
, 
due to the fact that the BFESM was generated using HLA-A*0201 simulation results. 
NetMHC however achieved comparable results for both HLA-A than HLA-B.  
Intermediate binders (Table 5.2, Dataset I) were difficult to classify. NetMHC had the 
best performance for 10 out of 11 alleles. However, all methods showed at best marginal 
prediction performance (the largest achieved AUC was 0.79) and in most cases the 
predictions were poor. 
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Allele
Name
Binders Non-
Binders
Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0201 616 135 751 0.67 0.77 0.65 0.66
2 A*0202 286 87 373 0.53 0.7 0.41 0.54
3 A*0203 261 126 387 0.58 0.79 0.58 0.6
4 A*0206 264 74 338 0.56 0.73 0.57 0.57
5 A*0301 335 106 441 0.58 0.7 0.6 0.59
6 A*1101 374 91 465 0.56 0.69 0.62 0.63
7 A*3101 278 103 381 0.42 0.69 0.48 0.56
8 A*3301 129 72 201 0.62 0.52 0.39 0.63
9 A*6801 273 96 369 0.54 0.68 0.44 0.57
10 A*6802 227 123 350 0.52 0.74 0.5 0.5
11 B*1501 169 33 202 0.59 0.79 0.49 0.59
Average
AUC
0.56 0.71 0.52 0.59
 
Table 5.2 Prediction accuracies for the dataset containing only weak binders and non-binders 
Results from Dataset I, in which only weak binders (50 nM to 500 nM binding affinity) and non-
binders (500 nM to 1000 nM binding affinity) were included. Alleles included in Dataset F, which 
had fewer than 200 binders and non-binders in total in Dataset I, were no longer included in the 
analysis. The average AUC for each method is included at the bottom of each column. 
Restricting the datasets to peptides which were either very strong binders or clear 
non-binders substantially improved the results in most cases (Table 5.3, Dataset S); with 
thirteen of fourteen alleles the best method, NetMHC, achieved AUC equal to or greater than 
0.99. With the exception of allele HLA-A*2402, all methods had an excellent predictive 
performance (AUC greater than 0.90). Despite a substantially lower number of data points in 
Dataset S, a higher accuracy was found for the best method for all alleles when compared 
with the Datasets F. A typical ROC plot comparing the performance of the four prediction 
methods for Dataset S is shown in Figure 5.1. 
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Allele 
Name
Binders Non-
Binders
Total DynaPredPO
S
NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0101 34 284 318 0.96 1.00 0.96 0.97
2 A*0201 549 503 1052 0.97 0.99 0.97 0.95
3 A*0202 290 267 557 0.98 1.00 0.97 0.97
4 A*0203 273 255 528 0.97 0.99 0.96 0.96
5 A*0206 216 371 587 0.97 0.99 0.96 0.95
6 A*0301 123 332 455 0.93 1.00 0.94 0.95
7 A*1101 228 269 497 0.95 1.00 0.94 0.97
8 A*2402 69 272 341 0.88 0.84 0.84 0.85
9 A*2601 15 256 271 0.97 1.00 0.94 0.97
10 A*3101 114 349 463 0.96 1.00 0.96 0.97
11 A*3301 36 620 656 0.95 1.00 0.94 0.93
12 A*6801 155 235 390 0.95 1.00 0.94 0.94
13 A*6802 95 440 535 0.96 1.00 0.97 0.94
14 B*0702 45 161 206 0.95 1.00 0.96 0.93
Average
AUC
0.95 0.99 0.95 0.95
 
Table 5.3 Prediction accuracies for the dataset containing only strong binders and clear non-binders 
Results from Dataset S, in which only strong binders (less than 10 nM binding affinity) and very clear 
non-binders (greater than 10,000 nM binding affinity) were included. Alleles included in Dataset F, 
which had fewer than 200 binders and non-binders in total in Dataset S, were no longer included in 
the analysis. The average AUC for each method is included at the bottom of each column. 
 
Figure 5.1 Overall performance evaluation 
ROC plot for the overall performance evaluation of SVMHC, YKW , DynaPredPOS and NetMHC 
with models that are trained and tested on Dataset S pertaining to allele HLA-A*0201. 
Overall, the best performance was achieved in cases where Dataset S was used, the 
number of binders in the dataset was large (more than 200 binders and more than 200 non-
binders), the dataset was relatively well balanced, the NetMHC method was used, and the 
allele was of the HLA-A*02  type.  
CHAPTER 5. PREDICTING MHC CLASS I EPITOPES IN LARGE DATASETS 
 
72 
 
  
For the independent dataset of 176 peptides (Table 5.4), while NetMHC was the best 
method for five of the seven alleles tested there was no significant difference in the 
performance of the methods. For all alleles, with the exception of HLA-A*1101, at least one 
method had excellent predictive performance (AUC greater than 0.90); generally at least two 
methods showed excellent predictive performance.  
 
Allele 
Name
Binders Non-
Binders
Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0201 33 143 176 0.92 0.94 0.82 0.93
2 A*0301 11 165 176 0.77 0.92 0.70 0.85
3 A*1101 17 159 176 0.84 0.89 0.72 0.83
4 A*2402 37 139 176 0.90 0.78 0.90 0.64
5 B*0702 9 167 176 0.86 0.98 0.72 0.68
6 B*0801 10 166 176 0.97 0.92 0.97 0.61
7 B*1501 14 162 176 0.71 0.92 0.71 0.80
Average
 AUC
0.85 0.90 0.79 0.76
 
Table 5.4 Prediction accuracies for an independent dataset 
A set of 176 novel peptides, generated and tested by Lin et al. (Lin et al. 2008), were used to test the 
prediction accuracy of the four methods in this study. The average AUC for each method is included 
at the bottom of each column. 
5.3.2 Datasets excluding anchor residues 
We examined the possible impact of non-anchor amino acid residues on peptide 
binding by measuring the prediction accuracy of YKW, SVMHC and DynaPred
POS
 on datasets 
in which the primary anchor position amino acids P2 and P9 of the peptides were removed 
and replaced by glycine residues. The best AUC of the performing method is listed for each 
dataset Table 5.5. If the anchor positions were excluded from the analysis, it was found that 
the AUCs from Dataset S1,3-8 were generally largest. This is consistent with the results 
obtained from the datasets containing complete peptides. The predictive performance results 
were generally good for HLA-A alleles and excellent for HLA-A*02 type alleles, but 
marginal to poor for Dataset F1,3-8 and Dataset I1,3-8. 
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Allele
 Name
Dataset Binders Non-
Binders
Total AUC Best
Method(s)
(n) (n) (n)
A*0101 F1,3-8 161 1312 1473 0.67 SVMHC
I1,3-8 106 35 141 0.66 SVMHC
S1,3-8 34 281 315 0.80 SVMHC
A*0201 F1,3-8 1475 1888 3363 0.80 SVMHC
I1,3-8 601 134 735 0.56 YKW
S1,3-8 540 494 1034 0.93 SVMHC
A*0203 F1,3-8 701 657 1358 0.81 SVMHC
I1,3-8 252 105 357 0.56 YKW
S1,3-8 270 252 522 0.92 SVMHC
A*1101 F1,3-8 841 1275 2116 0.73 SVMHC/YKW
I1,3-8 374 91 465 0.61 SVMHC
S1,3-8 226 267 493 0.82 SVMHC
A*3101 F1,3-8 509 1471 1980 0.75 SVMHC
I1,3-8 278 103 381 0.49 YKW
S1,3-8 114 342 456 0.85 SVMHC
B*0702 F1,3-8 230 1093 1323 0.73 SVMHC
I1,3-8 122 44 166 0.44 SVMHC
S1,3-8 43 160 203 0.68 YKW
B*3501 F1,3-8 257 566 823 0.70 YKW
I1,3-8 131 39 170 0.61 SVMHC
S1,3-8 38 131 169 0.73 YKW  
Table 5.5 Prediction accuracies for datasets which excluded anchor positions 
The prediction accuracy on datasets F1,3-8, M1,3-8, C1,3-8 and S1,3-8 where the primary anchor-
position amino acids P2 and P9 of the peptides were replaced by glycine residues. 
5.3.3 Robustness  
In this test we examined the dependency of the quality of the obtained prediction 
models (YKW, SVMHC and DynaPred
POS
) on the size of the training sets used. NetMHC was 
not included in this analysis as the predictor is only available online and therefore could not 
be trained by the authors. We found that in most cases the AUCs stabilized at or close to their 
maximum level, when the size of the randomly selected balanced dataset consisted of more 
than 200 binders and 200 non-binders (Figure 5.2). This effect was observed with all three 
prediction methods and for all three alleles included in the study. SVMHC performance was 
less stable for small datasets, which might be due to its simple encoding method and is a 
significant drawback of this method. 
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Figure 5.2 Robustness analysis 
The reproducibility of the results of the prediction methods and their dependence on the size of the 
available dataset was examined in selected alleles. Box plots of randomly selected balanced sets of 
binders and non-binders from Dataset F for the alleles HLA-A*0201, HLA-A*3101, and HLA-
B*0702 are shown. The smallest dataset for each allele consisted of 50 binders and 50 non-binders. 
The size of the largest dataset for each allele depends on the total number of binders or non-binders 
available for that particular allele. NetMHC was not included in this analysis as the predictor is only 
available online and could therefore not be trained by the authors. 
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5.3.4 Generalizability 
Last, we evaluated the generalizability of YKW, SVMHC and DynaPred
POS
 on all 
HLA-A and HLA-B alleles for Datasets F. NetMHC was again not included in this test 
because the model could not be trained by the authors. In Figure 5.3 the AUCs for the models 
trained on the HLA-A*0201 dataset is given for different alleles. It can be seen that 
DynaPred
POS
 outperforms the other models for alleles of the HLA-A*02 type, but for the 
other alleles the performance of the three methods is very similar. The prediction capabilities 
are good to marginal for some alleles implying that cross-allele prediction is feasible in some 
cases.  
 
 
 
Figure 5.3 Performance Comparison on Dataset F 
The performance of the three prediction models, trained on Dataset F of HLA-A*0201 and tested on 
Dataset F of all alleles (AUCs). NetMHC was not included in this analysis as the predictor is only 
available online and therefore could not be trained by the authors. 
The MHC supertype classifications schemes generate clustered sets of molecules with 
largely overlapping peptide repertoires (Reche and Reinherz 2007; Sidney et al. 2008). These 
classification schemes generally depend on features such as published motifs, binding data 
and the analysis of shared repertoires of binding peptides, etc. There has been interest in the 
development of pan-specific algorithms that can predict peptide binding to alleles for which 
limited or even no experimental data is available. This would, in contrast to the typical 
supertype classification scheme which depends on the availability to such data, allow for the 
prediction of binding in cases where no such data is available. 
In recent work by Zhang et al. (Zhang et al. 2009), their predictor was trained on a 
dataset of binders and non-binders for a wide variety of alleles, and tested on a second set of 
datasets which consisted of binders and non-binders which were released at later point in 
time. While the study claims to analyze performance on alleles for which no or only limited 
data is available, these alleles are never identified and only very limited information on the 
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results is given. Also, the performance on alleles for which no data was available for training 
was poor. In contrast, we have performed a detailed analysis of the performance of predictors 
trained on one allele, and their ability to accurately predict other alleles. 
There have been several papers defining supertypes using a number of different 
approaches (Doytchinova et al. 2004; Sidney et al. 2008). Generally HLA-A*02 alleles and 
HLA-A*24 alleles are not clustered in the same supertype. Our generalizability work was 
however able to make reasonable predictions for HLA-A*2402 (the only allele in our study 
of this supertype), using a predictor trained on allele HLA-A*0201. 
5.4 Discussion 
Until the creation of IEDB, the available peptide sequence datasets were small and 
spread over many separate efforts. In addition the datasets consisted predominantly of 
binding sequences, so that most prediction models based on these data used random non-
binding data for training purposes. Through the IEDB database a sufficiently large number of 
experimentally verified non-binders have become available for learning for the first time. 
Therefore, the prediction models evaluated here could not only be tested on a substantially 
larger number of binders, but in addition experimentally verified non-binders could be 
included in the training datasets and alleles that have previously not been analyzed due to 
insufficient dataset sizes could be included in the study. 
As expected, Dataset S, which consisted only of peptides for which a quantitative 
laboratory result was available in IEDB and which were either strong binders or clear non-
binders, performed better than Dataset F. As the binding affinity at which a binder becomes a 
non-binder has a threshold of 500 nM in IEDB, removing all peptides from the dataset which 
we described as so-called intermediate binders (50 nM to 1000 nM) improved the 
performance of the methods (results not shown), as did using a subset of data containing only 
the very strongest binders and clearest non-binders. Due to the error involved in experimental 
binding affinity analysis (Kessler et al. 2003), we suggest using a cutoff of 500 nM may 
incorrectly categorize a weak binder as a non-binder or vice versa. Perhaps adding a category 
containing such intermediate binders, in addition to the already existing categories binder and 
non-binder, would be a useful addition to IEDB. 
The excellent performance of NetMHC, on Dataset S in particular where it performs 
with an AUC of 1 for many alleles, may be in part due to the fact that this method could not 
be trained for the purposes of this study as NetMHC was only accessible via a web interface. 
It should also be noted that some of the data used to train NetMHC was probably identical to 
that extracted from IEDB for this study. This conjecture is also supported by the prediction 
results of the methods on the independent, novel dataset, which showed no statistically 
significant results between the methods (Table 5.4). 
Peters et al. (Peters et al. 2006) performed an extensive analysis in which they trained 
and tested their own in-house methods, but external methods were not reimplemented by the 
authors. Instead, the available web interfaces for external methods were used with the default 
settings. In contrast to this, we reimplemented the external methods YKW and SVMHC to 
allow for both training and testing. 
The analysis of the reproducibility of the results of the examined prediction models 
and their dependence on the size of the available dataset (robustness) showed that all methods 
require a sufficient number of data points for reproducible results (Figure 5.2). Overall, most 
alleles appear to require a minimum of 200 binders and 200 non-binders in Dataset F before 
the AUCs stabilize at or close to their maximum level. We suggest that performing the 
analysis on alleles with too few data points (which is still unfortunately the case with many 
HLA-B alleles) can lead to unreliable results. 
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The analysis of the methods‟ generalizability showed that the prediction capabilities 
are good to marginal for some alleles, implying that cross-allele prediction is feasible in some 
cases. In other cases, the AUCs were very low. Having trained with HLA-A*0201 and then 
tested for generalizability on HLA-A and HLA-B alleles in Dataset F, a possible reason for 
certain alleles to give rise to such low AUCs may be that a particular subset of binders that 
bind well to HLA-A*0201 may be very clear non-binders for the alleles in question. 
Conversely, clear non-binders for HLA-A*0201 may be binders for the other alleles leading 
to low AUCs. 
In contrast to the former study (Antes et al. 2006), which included only binding 
sequences (as sufficient numbers of experimentally verified non-binding sequences were not 
available at that time) in testing generalizability, we observed a much improved level of 
cross-allele prediction with these newer datasets.  
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6 Insights into T Cell Receptor Binding5 
6.1 Introduction 
T cell immune responses are dependent on the appropriate and effective processing of 
peptides from a protein source, the stable binding of the peptide to the MHC molecule and 
recognition of this complex by the T cell receptor. Of these three steps, the binding of the 
peptide to the MHC is the most selective event (Yewdell and Bennink 1999). There is a large 
body of work from the last 20 years, which examines MHC-peptide binding (Lafuente and 
Reche 2009). Comparisons of methods which predict MHC-peptide binding have shown that 
the best methods have high prediction accuracies for alleles for which sufficient binding data 
are available (Lin et al. 2008; Roomp et al. 2010).  
However, there is still a significant proportion of stable MHC-peptide complexes 
which elicit no TCR response. Comparatively little work has been performed on predicting 
which TCR will bind to MHC-peptide complexes. Simplified representations of amino acids, 
represented as a string of numbers or bits (where each number or bit represents an amino 
acid), have been used to study negative selection and TCR cross-reactivity (Detours et al. 
1999; Detours and Perelson 1999; Chao et al. 2005). A more recent approach has been 
developed in which the problem was studied numerically but still in a highly simplified form 
(Kosmrlj et al. 2008; Kosmrlj et al. 2009); a single short string of amino acids represents the 
highly variable CDR3 which interacts with the peptide. Hence, interactions between the TCR 
and MHC are not explicitly considered (Kosmrlj et al. 2010). A comparison of the in silico 
results with those of 18 unspecified crystallized TCR-MHC-peptide complexes from the 
Protein Data Bank (PDB) (Berman et al. 2000) showed qualitative agreement: the theoretical 
predictions showed that weakly interacting amino acids on the TCR are enriched, whereas 
strongly interacting amino acids are present in relative low frequency. Overall it can be said 
that the current in silico approaches for predicting which TCR residues are likely to interact 
with the MHC-peptide antigen are still highly simplified, but the models provide important 
insights in to the population dynamics of the T cell repertoire and its interaction with viruses 
such as HIV-1 (Kosmrlj et al. 2010). 
We were interested in gaining a better understanding of the interaction modes of 
human TCR V regions, based on detailed analyses of the crystal structures of TCRs bound to 
MHC-peptide antigen complexes. We therefore have (1) studied the interaction of all 
available TCRs bound to HLA-A*0201 peptide complexes. The rationale for choosing 
complexes which included HLA-A*0201 stems from the fact that HLA-A2 is the most 
common HLA phenotype in many ethnic populations and HLA-A*0201 is the most common 
allele (Player et al. 1996; Shieh et al. 1996). There are more instances in PDB of TCR-MHC-
peptide complexes that include HLA-A*0201 than any other allele. Also, finding TCRs 
which interact with one specific HLA allele reduces the variability of one of the components 
of the analysis, allowing for more reliable comparisons of the interaction patterns between 
different complexes. Based on these results (2), we have developed the first rule-based 
classification methods for predicting the residue interactions of the TCR to the MHC-peptide 
antigen complex based on interactions found in actual structures of the TCR-MHC-peptide 
                                                 
5
 The work reported in this section was performed in collaboration with Francisco Domingues (MPI for 
Informatics, Germany). It has been published in Molecular Immunology and appears with the journal‟s 
permission (Roomp and Domingues 2011). My own contribution to the publication comprises the crystal 
structure selection, structural alignments, extraction of non-covalent interactions, development and testing of the 
prediction methods resulting in 4 of the 4 published tables (Tables 6.1, 6.2, 6.3 and 6.4) and 5 of the 5 published 
figures (Figures 6.1, 6.2, 6.3, 6.4 and 6.5). 
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complexes. Additionally (3), we have performed a comprehensive evaluation of TCRs known 
to interact with HLA-A*0201 in cell assay studies, as this type of data is more commonly 
available than crystal structure data. We were interested in identifying possible biases in the 
different datasets, i.e., in determining if the available crystal structures are broadly 
representative of the known TCR types. 
6.2  Materials and Methods 
6.2.1 Crystal structure selection 
One serious obstacle to the study of TCR-MHC-peptide interactions is the small 
number of solved crystal structures available. In 2005, 24 such structures for both human and 
mouse were recorded (Rudolph et al. 2006) and mid-2010 just 31 structures were available. It 
should be noted that this statistic does not contain structures that were superseded by 
redetermination at higher resolution. However, MHC and TCR complexes with other 
molecules, such as superantigens or antibodies, were included.  
The relatively low number of available structures, when compared to the many TCR 
V and J genes which exist in both human and mouse, is due to the many technical challenges 
faced when generating such complexes (Rudolph et al. 2006). Additionally, the type of 
structures represented are thought to be a biased sample because some types of TCR are 
difficult to crystallize (Marrack et al. 2008). The TCRα chains appear to show more 
variability in terms of the structures available than the TCRβ chains. 
We initially selected the complexes for this study based on the following criteria: each 
complex had to consist of the MHC molecule HLA-A*0201, a 9 or 10mer peptide and a T 
cell receptor. Subsequently, the sequences of the CDR1, CDR2, and CDR3 in both TCR 
subunits were aligned and only seven structures that differed in the CDR1, CDR2, and CDR3 
sequences were retained (Table 6.1). The PDB entries included in the study were 1OGA 
(Stewart-Jones et al. 2003), 1AO7 (Garboczi et al. 1996), 1BD2 (Ding et al. 1998), 2BNQ 
(Chen et al. 2005), 1LP9 (Buslepp et al. 2003), 3HG1 (Cole et al. 2009) and 3GSN (Gras et 
al. 2009). In PDB entries with two co-crystallized complexes, one complex was chosen for 
the analysis. 
 
PDB ID Resol-
ution
Peptide Affinity 
(nM)
a
TRAV
b
TRAJ
b
TRBV
b
TRBJ
b
1OGA 1.40 GILGFVFTL 17 (SB) 27*01 (100.00%) 42*01 (100.00%) 19*01 (100.00%) 2-7*01 (100.00%)
1AO7 2.60 LLFGYPVYV 3 (SB) 12-2*02 (100.00%) 24*02 (100.00%) 6-5*01 (100.00%) 2-7*01 (100.00%)
1BD2 2.50 LLFGYPVYV 3 (SB) 29/DV5*01 (98.90%) 54*01 (89.50%) 6-5*01 (100.00%) 2-7*01 (100.00%)
2BNQ 1.70 SLLMWITQV 5 (SB) 21*01 (100.00%) 6*01 (100.00%) 6-5*01 (100.00%) 2-2*01 (100.00%)
1LP9 2.00 ALWGFFPVL 8 (SB) 12D-2*01 (100.00%)(mouse) 50*01 (100.00%)(mouse) 13-3*01 (100.00%)(mouse) 2-7*01 (100.00%)(mouse)
2-7*02 (100.00%)(mouse)
3HG1 3.00 ELAGIGILTV 417 (WB) 12-2*01 (98.90%) 27*01 (100.00%) 30*01 (100.00%)
30*02 (100.00%)
2-2*01 (100.00%)
3GSN 2.80 NLVPMVATV 35 (SB) 24*01 (100.00%) 49*01 (100.00%) 6-5*01 (1 0. 0%) 1-2*01 (100.00%)
 
Table 6.1 The PDB crystal structures selected for the study 
a
The binding affinities were predicted using NetMHC: SB is a strong binder, WB is a weak binder. 
b
The TCRα and TCRβ subunits V -domains were classified using the IMGT nomenclature (Kaas et al. 
2004). The percentages indicate the level of similarity between the structures‟ V- and C-domains and 
those of IMGT reference protein sequences.  
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All peptides have been experimentally verified to bind to HLA-A*0201 and a 
comprehensive listing of these experiments can be found in the Immune Epitope Database 
and Analysis Resource (Vita et al. 2010). A variety of assay types have been used in these 
experiments and the results are often qualitative not quantitative. To allow for a better 
comparisons of the peptides in the study, we calculated their binding affinity to HLA-A*0201 
in silico by using NetMHC (Buus et al. 2003; Nielsen et al. 2003; Lundegaard et al. 2008), 
which was found to be among the best predictors for MHC peptide binding (Zhang et al. 
2009). Six of seven peptides were found to be strong binders (binding affinity <35 nM), 
while the single 10mer peptide was a weak binder (417 nM). A number of structures were 
excluded from this analysis: 2VLR (TCR has same amino acid sequence as 1OGA), 2F54 
(TCR is same as 2BNQ, except for a few amino acids in TCRα subunit which are outside of 
the CDRs), 3D39 (TCR same as 1AO7, with slightly different peptide), 3D3V (TCR same as 
1AO7, with slightly different peptide), 3H9S (TCR same as 1AO7, with slightly different 
peptide), 3GJF (has a TCR-like antibody), 3E3Q (is a high affinity mutant), and 2PYE (in 
vitro enhanced mutant). 
To summarize the similarities of the CDRs between the chosen structures: CDR1α, 
1AO7 and 3HG1 have the same sequence; CDR2α, all are different; CDR3α, all are different; 
CDR1β, 3GSN, 1BD2, 2BNQ and 1AO7 have the same sequence; CDR2β, 3GSN, 1BD2, 
2BNQ and 1AO7 have the same sequence; CDR3β, all are different; peptides, 1AO7 and 
1BD2 have the same sequence. 
6.2.2 Structural alignments and the identification of CDRs 
Structural alignments of all seven TCRα and TCRβ subunits were generated with 
MultiProt (Shatsky et al. 2004) using default parameters. These results were confirmed using 
Matt (Menke et al. 2008). Additionally, HLA-A*0201 amino acid positions were confirmed 
to be the same in each of the structures to ensure that all comparisons were valid. 
For CDR1 and CDR2 these regions were identified and numbered to be consistent 
with previous studies (Arden et al. 1995; Marrack et al. 2008). For CDR3 IMGT 
classification was used (Kaas et al. 2004) and the numbering of the amino acids was kept 
consistent with CDR1 and CDR2. 
6.2.3 Interactions analysis 
Hydrogen atoms were placed on the experimental structural models using Reduce 
(Word et al. 1999b) , the non-covalent interactions were identified using Probe (Word et al. 
1999a). Interactions between the TCRα chain and the MHC-peptide complex were extracted, 
as were interactions between the TCRβ chain and the MHC-peptide complex. Hydrogen 
bonds and van der Waals interactions between (1) two amino acid side chain atoms, (2) two 
amino acid backbone atoms or (3) an amino acid side chain atom and a backbone atom were 
treated equally in subsequent analyses.  
Alternative representations of the residue interaction data were produced. We 
generated a table with a detailed listing the contacts and a heat map to highlight the most 
important residue interactions using the statistical computing software R (Team 2003). We 
also generated a 2D residue interaction network representation using Cytoscape (Shannon et 
al. 2003) showing all interactions between TCRα/TCRβ and MHC-peptide. Furthermore, we 
represented the interactions between residues that occurred in the majority of structures in a 
3D molecular graphics visualization using VMD (Humphrey et al. 1996). 
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6.2.4 Predicting interactions between TCR and MHC-peptide 
We have developed two new rule-based classification algorithms to predict 
interactions between the T cell receptor and the MHC-peptide antigen. The methods are 
heuristic and consist of hierarchical sets of rules. Each amino acid position in TCR‟s CDR 
loops is examined for an interaction (contact) with either the MHC or peptide and a 
prediction is made based as to whether an interaction has been observed at that position or 
not. Hydrogen bonds and van der Waals interactions were weighted equally for the purposes 
of the method. The accuracy of the two methods was assessed by generating areas under the 
curve (AUC), see ROC analysis (Fawcett 2004). AUC is a widely used non-parametric 
performance measure. In particular, the performance analysis tested the ability of the methods 
to accurately separate positions which have no interactions from positions which have 
interactions. The values AUC ≥ 0.90 indicate excellent and 0.90 > AUC ≥ 0.80 good 
prediction performance, with a random predictor having an AUC of 0.5 (Swets 1988). We 
used leave-one-out cross validation to assess the accuracy of the predictions. The algorithms 
and accuracy evaluation were implemented in R. 
These two methods calculate a score in the range of 0 to 1 at each amino acid position 
i in the TCR‟s CDR1, CDR2, and CDR3 loops based on the rules described in Figures 6.1 
and 6.2. A score of 0 indicates no interaction to the MHC-peptide is predicted at that position, 
while a score of 1 predicts an interaction. In the cross validation procedure a test structure is 
selected from the seven structures in the study and compared to the other six structures 
(called training structures). 
The methods were developed in an intuitive manner, based on examining the existing 
structural data. The methods were kept as simple as possible, parameter optimization was not 
performed, and overfitting was avoided. In fact the only adjustment made to the original 
methods, which were constructed prior to actually testing the methods‟ performance, was to 
include a threshold for the percentage of contacts in a position, which is described below. The 
decision to include the threshold was based on the recognition that in many CDR amino acid 
positions, where the majority of structures show an interaction, diverse amino acids are 
found. These diverse amino acids have highly differing side chain polarities and charges (acid 
- base properties) and showed themselves to be impossible to group based on such physical 
and chemical properties. In the future, when more HLA-MHC-peptide complexes become 
available i.e. the datasets which can be studied become sufficiently large, statistical learning 
methods could well be applied to this problem.  
 Overall the first method (Method I) can be described as follows: 
 If a gap exists in the test TCR at position i, the amino acid is skipped 
 If the overall fraction of training structures with contacts at this position is 
more than 50%, a score of 1 is given 
 If the overall fraction of training structures with contacts at this position is less 
than or equal to 50%, and if the test TCR has an amino acid at the position of 
interest (i.e. no gap), then the score is calculated as follows: 
o If the test TCR‟s amino acid type (Ti) exists in the training structures 
and at least one such training structure‟s amino acid has a contact, 
variable A is 1. Otherwise A is 0. 
o A is multiplied by variable B. B is the proportion of the amino acids of 
type Ti in the training structures that have contacts. 
o A penalty is given when only a small number of training structures 
with the amino acid Ti type have contacts: penalty score C of 0.25 is 
given, where fewer than 25% of amino acids Ti have contact. 
Otherwise C is 0. 
o Score = Max (0, A*B – C).  
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Figure 6.1 First rule-based classification algorithm (Method I) for predicting contacts between the 
TCR and the MHC-peptide antigen using crystal structures 
The second approach (Method II) is a simplification of the first approach, in which 
the type of amino acid is disregarded (Figure 6.2): 
 If a gap exists in the test TCR, the position i in the amino acid sequence is 
skipped 
 If the overall number of training structures with contacts at position i is more 
than 50%, a score of 1 is given 
 If the overall number of training structures with contacts at position i is less 
than or equal to 50%, and if the test TCR has no gap in i then the score was 
calculated in the following manner: 
o Variable A is 1 if some training structures have contacts, else A is 0. 
o A is multiplied by variable B. B is the proportion of amino acids of any 
type that have contacts.  
o There is a penalty when only a very small number of structures have 
contacts: penalty score C of 0.25 is given, where fewer than 25% of 
amino acids have a contact. Otherwise C is 0. 
o Score = Max(0, A*B – C). 
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Figure 6.2 Second rule-based classification algorithm (Method II) for predicting contacts between the 
TCR and the MHC-peptide antigen using crystal structures 
6.2.5 Experimentally verified TCRs 
Due to the small number of solved crystal structures of a TCR binding to HLA-
A*0201 we were interested in determining if the available crystal structures were broadly 
representative of TCRs identified by other experiments to bind to HLA-A*0201; we searched 
for sequence data on TCRs which were verified in the laboratory to bind to HLA-A*0201 
with high avidity. The T cell clone SK22, specific for the FMNL1-derived peptide PP2, was 
identified as being such a TCR (Schuster et al. 2007). A further study by the same group 
(Liang et al. 2010) identified four allo-HLA-A2-restricted T cell clones expressing TCRs 
with specificity for a peptide derived from the tumor associated antigen (HER2/neu) called 
HER2-dervied peptide 369 (HER2369). Additionally, the clone JG-9 was isolated which 
recognizes the endogenously processed Ag pp65 (Schub et al. 2009). A further study 
identified a CTL clone named R6C12 expressing a TCR highly avid for a GP100 derived 
peptide in an HLA-A201-restricted manner (Morgan et al. 2003). Finally, a study identified a 
number of CTL clones which bind to an influenza matrix protein antigen in complex with 
HLA-A2 (Moss et al. 1991). 
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6.3 Results 
6.3.1 Interactions in TCR-MHC-peptide complexes 
Six different types of interactions were distinguished in this analysis: (1) a hydrogen 
bond between two backbone atoms, (2) a hydrogen bond between backbone and side-chain 
atoms, (3) a hydrogen bond between two side-chain atoms, (4) a van der Waals contact 
between two backbone atoms, (5) a van der Waals contact between backbone and side-chain 
atoms, and (6) a van der Waals contact between two side-chain atoms. Different types of 
interactions are usually observed at each CDR position (Table 6.2). In the case of interactions 
occurring between the TCR and the peptide this is not unexpected as the peptide sequence 
varies among the selected structures with the exception of the structures with PDB identifiers 
1AO7 and 1BD2.  
The only pairs of interacting positions which occur in the majority of structures 
(greater than or equal to four of seven structures) and where all interactions were of the same 
type comprised: (1) position 93 in CDR3α interacts with position 5 in the peptide by a van 
der Waals contact between side chain atoms (five of seven structures), (2) position 95 in 
CDR3α interacts with position 5 in the peptide by a backbone to side chain van der Waals 
contact  (five of seven structures; structure 3HG1 also forms additional interactions at this 
position), (3) position 28 in CDR1β interacts with position 8 in the peptide by van der Waals 
contact between side chains (four of seven structures), and (4) position 46 in CDR2β interacts 
with position 65 in the MHC by van der Waals contact between side chain atoms (four of 
seven structures). Interestingly, although these frequently observed interactions were 
consistently of the same type, there was great variability in amino acid types of the TCR and 
peptide at these positions. There are a number of further interactions which occur in four or 
more structures, where the types of interactions are not consistent (Table 6.2).  
In the heatmap analysis (Figure 6.3) the highest number of structures which shared an 
interaction between two residue positions (independent of the interaction type) was five out 
of seven; this occurred at three positions between the CDR3α loop and the peptide. A number 
of interactions were also identified which were shared by four structures and these could be 
found between CDR1α and both the MHC and the peptide, between CDR1β and the peptide, 
between CDR2β and the MHC, between CDR3α and the peptide, and between CDR3β and 
both the MHC and peptide. Only CDR2α did not have an interaction with either the MHC or 
peptide which was shared by a majority of the seven structures analyzed. 
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cnt: 
mc_mc
cnt: 
mc_sc
cnt: 
sc_sc
H-bond: 
mc_mc
H-bond: 
mc_sc
H-bond: 
sc_sc
>=2 cnt
e
CDR1a27 W167 3 1 1 1
CDR1a28 W167 4 2 2
CDR1a30 Pep1 2 2
CDR1a30 Pep2 2 1 1
CDR1a30 Pep4 3 1 1 1
CDR1a30 Pep5 4 1 1 2
CDR1a30 Q155 3 2 1
CDR1a30 T163 3 3
CDR1a31 Pep5 3 2 1
CDR2a50 H151 3 3
CDR2a50 E154 3 2 1
CDR2a50 Q155 3 2 1
CDR2a50 A158 3 1 2
CDR2a51 A158 2 1 1
CDR3a93 Pep5 5 5
CDR3a93 Q155 2 2
CDR3a94 R65 3 1 1 1
CDR3a95 Pep4 5 2 1 1 1
CDR3a95 Pep5 5 4 1
CDR3a95 R65 2 1 1
CDR3a95 K66 3 2 1
CDR3a95a Pep4 4 1 1 2
CDR3a95a Pep5 2 2
CDR3a96 Pep4 3 1 1 1
CDR3a96 R65 2 1 1
CDR3a96 K66 3 2 1
CDR3a96a R65 2 1 1
CDR3a97 Pep4 2 1 1
CDR3a97 Pep5 4 2 1 1
CDR3a97 R65 2 2
CDR3a97 A69 2 1 1
CDR1b28 Pep8 4 4
CDR1b28 Q72 2 1 1
CDR2b46 R65 4 4
CDR2b48 K68 2 1 1
CDR2b48 A69 2 1 1
CDR2b48 Q72 2 1 1
CDR2b49 Q72 4 2 1 1
CDR2b50 Q72 2 1 1
CDR2b52 Q72 3 3
CDR2b52 R75 2 2
CDR2b54 R65 3 2 1
CDR3b97 Pep8 2 2
CDR3b98 Pep5 3 1 2
CDR3b98 Pep6 2 1 1
CDR3b98 Pep7 2 1 1
CDR3b98 K146 2 1 1
CDR3b98 A150 2 1 1
CDR3b98 V152 2 1 1
CDR3b99 Pep6 4 2 1 1
CDR3b99 Pep7 3 2 1
CDR3b99 Pep8 2 2
CDR3b99 T73 2 1 1
CDR3b99a Pep5 2 1 1
CDR3b99a Pep7 4 2 1 1
CDR3b99b Pep5 3 1 2
CDR3b99b Pep7 4 1 2 1
CDR3b99b A150 4 2 1 1
CDR3b99c Pep5 3 2 1
CDR3b99c Q155 4 1 1 1 1
CDR3b100 A149 2 1 1
CDR3b100 A150 4 3 1
CDR3b100 H151 2 2
Type of Contact
d
TCR aa
a HLA or 
Peptide aa
b
Total No of 
Contacts
c
 
Table 6.2 Interaction analysis where two or more structures have interactions between residues at the 
same position 
a
TCRα or TCRβ residues of the CDR1, CDR2 or CDR3. The table is ordered with respect to the 
amino acid position in the TCR. 
b
HLA or peptide residues. 
c
Total number of contacts between the 
TCR and HLA/peptide. 
d
Type of contacts. cnt is a van der Waals bond contact, H-bond is a hydrogen 
bond, mc_mc is a residue interaction between backbone atoms, mc_sc is an interaction between a 
backbone atom and the side-chain atom of another residue, sc_sc is an interaction between the side 
chain atoms in two residues. 
e
Cases where there are multiple interactions between two residues of 
different types. Interactions between the TCR and peptide are highlighted in grey 
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Figure 6.3 Heatmap analysis 
Interactions between CDR1, CDR2 and CDR3 of both TCRα and TCRβ (columns) and HLA-A*0201 
and peptide (rows) are indicated with regard to their frequency. Black lines indicate discontinuous 
regions. No interactions were identified in the majority of positions (gray), up to a maximum of 5 
interactions (dark blue). 
The most common interactions were between the TCR and peptide residue positions 4 
and 5. All nine peptide residues were found to be capable of interacting with the TCR in at 
least one of the structures (Figure 6.4). 
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Figure 6.4 Common interactions between TCR and the MHC and peptide 
(A) A view of the common interactions where the MHC α-helices and peptide go from left to right, 
(B) a view after a 90º rotation around the horizontal axis. TCRα (orange), TCRβ (dark yellow), 
peptide (yellow), MHC (blue), interactions occurring in five of seven structures (thick red cylinders), 
interactions occurring in four of seven structures (thin red cylinders). 
When all interactions between TCRα, TCRβ, the peptide and the MHC are examined 
(Figure 6.5), the broad variety of interactions between the TCR and MHC-peptide becomes 
clear. Most residues in all chains are capable of a broad range of interactions, as would be 
expected considering that the overall interaction between the TCR and the MHC-peptide is a 
relatively weak one and that cross reactivity is common. 
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Figure 6.5 All interactions occurring in the structures with PDB identifiers 1OGA, 1AO7, 1BD2, 
1LP9, 2BNQ, 3HG1 and 3GSN 
All identified interactions (black edges) between TCRα (orange), TCRβ (dark yellow), peptide 
(yellow) and MHC (blue). CDR1, CDR2 and CDR3 are grouped together. Amino acids which did not 
participate in interactions are not shown. All edges have the same width, there is no indication of 
frequency at which each interaction occurs. 
6.3.2 Prediction results 
Using Method I or Method II, models were generated with six complexes and tested 
with a seventh complex not included in the training set (leave-one-out cross validation). Area 
under the curve (AUC, ROC analysis) values were computed for both methods for each case 
(Table 6.3).  
Method II classified more true positives correctly, but also had a somewhat increased 
rate of generating false positives. Method I was able to make good to excellent predictions in 
6 or 7 cases (only one AUC was less than 0.80), while the Method II was able to make good 
to excellent predictions in all cases. No statistically significant difference between the AUCs 
produced by the two methods could be found based on the two sample Wilcoxon test, 
although the second method produced a higher AUC in 6 of 7 cases. 
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PDB ID Method I (AUC)
a
Method II (AUC)
a
1ao7 0.84 0.86
1bd2 0.76 0.83
1lp9 0.82 0.90
1oga 0.85 0.90
2bnq 0.83 0.87
3gsn 0.92 0.94
3hg1 0.89 0.88
Average AUC 0.84 0.88  
Table 6.3 Assessment of prediction accuracies of the rules-based algorithms 
a
AUC = area under the curve (ROC analysis). The average AUC for each method is included at the 
bottom of each column 
6.3.3 TCRs which are known to bind to HLA-A*0201 
In addition to the solved crystal structures selected for this study, we have identified 
studies describing further TCRs which have been shown to experimentally bind to HLA-
A*0201 with high avidity (Table 6.4). Solved crystal structures show a bias towards TRBV6-
5, TCRs binding to influenza matrix peptide show a bias towards TRAV27/TRBV19 and the 
remaining TCRs show a bias towards TRBV12. 
 
PDB ID 
or 
[clone name]
Peptide
Affinity 
(nM)
a TRAV
b
TRAJ
b
TRBV
b
TRBJ
b Reference
1OGA GILGFVFTL 17 (SB) 27*01 42*01 19*01 2-7*01 (Stewart-Jones et al., 2003)
1AO7 LLFGYPVYV 3 (SB) 12-2*02 24*02 6-5*01 2-7*01 (Garboczi et al., 1996)
1BD2 LLFGYPVYV 3 (SB) 29/DV5*01 54*01 6-5*01 2-7*01 (Ding et al, 1998)
2BNQ SLLMWITQV 5 (SB) 21*01 6*01 6-5*01 2-2*01 (Chen et al., 2005)
1LP9 ALWGFFPVL 8 (SB) 12D-2*01 50*01 13-3*01 2-7*01/2-7*02 (Buslepp et al., 2003)
3HG1 ELAGIGILTV 417 (WB) 12-2*01 27*01 30*01/30*02 2-2*01 (Cole et al., 2009)
3GSN NLVPMVATV 35 (SB) 24*01 49*01 6-5*01 1-2*01 (Gras et al., 2009)
[HER2-1] KIFGSLAFL 24 (SB) 19*01 24*02 12-3*01 2-3*01 (Liang et al., 2010)
[HER2-2] KIFGSLAFL 24 (SB) 27*01 20*01 12-3*01 2-7*01 (Liang et al., 2010)
[HER2-3] KIFGSLAFL 24 (SB) 38-1*01 28*01 7-8*01 2-7*01 (Liang et al., 2010)
[HER2-4] KIFGSLAFL 24 (SB) 21*01 20*01 12-3*01 2-1*01 (Liang et al., 2010)
[R6C12] ITDQVPFSV 128 (WB) 41*01 54*01 12-3*01 2-1*01 (Morgan et al., 2003)
[JG-9] NLVPMVATV 35 (SB) 35*02 50*01 12-4*01 1-2*01 (Schub et al., 2009)
[SK22] RLPERMTTL 85 (WB) 38-2/DV8*01 41*01 27*01 2-5*01 (Schuster et al., 2007)
[1a11b] GILGFVFTL 17 (SB) 27*01 n/a 19*01 1-1*01 (Moss et al, 1991)
[1a11a] GILGFVFTL 17 (SB) 27*01 n/a 19*01 1-1*01 (Moss et al, 1991)
[1a8] GILGFVFTL 17 (SB) 27*01 n/a 19*01 2-7*01 (Moss et al, 1991)
[1a6] GILGFVFTL 17 (SB) 6*01 n/a 19*01 2-1*01 (Moss et al, 1991)
[B1a] GILGFVFTL 17 (SB) 27*01 n/a 19*01 2-5*01 (Moss et al, 1991)
[B1b] GILGFVFTL 17 (SB) 13-1*01 n/a 19*01 2-7*01 (Moss et al, 1991)
[B1c] GILGFVFTL 17 (SB) 13-1*01 n/a 19*01 2-2*01 (Moss et al, 1991)
[B1d] GILGFVFTL 17 (SB) 14/DV4*01 n/a 19*01 2-3*01 (Moss et al, 1991)
[B1e] GILGFVFTL 17 (SB) 27*01 n/a 28*01 2-7*01 (Moss et al, 1991)
 
Table 6.4 Variable and joining region family affiliation of HLA-A*0201 restricted TCRs 
a
Binding affinities were predicted using NetMHC: SB is a strong binder, WB is a weak binder. 
b
TCRα 
and TCRβ subunits V- and J-domains were classified using the IMGT nomenclature (Kaas et al., 
2004) 
CHAPTER 6. INSIGHTS INTO T CELL RECEPTOR BINDING 
 
91 
 
  
6.4 Discussion 
We present two rule-based methods for predicting interactions between TCRs‟ CDR1, 
CDR2 and CDR3 loops and the MHC-peptide antigen, which are simple, transparent, and 
effective. Both methods show good prediction accuracy with an average AUC of greater than 
0.80 (0.84 for Method 1, 0.88 for Method 2).  
There were no other algorithms to which we could compare our method directly. The 
only other related approach we could find was by developed by Kosmrlj et al. (Kosmrlj et al. 
2008; Kosmrlj et al. 2009; Kosmrlj et al. 2010). In this previous work the problem was 
studied in a highly simplified from. The TCR and MHC-peptide complex are modeled 
numerically as strings of amino acids which are typically 10 amino acids in length. The 
strings indicate the amino acids at the interface between the TCR and MHC-peptide complex 
and the model assumes that only one site on the TCR interacts with a corresponding site 
which consists solely of the bound peptide. The analysis is restricted to the TCR‟s CDR3 and 
interactions between the TCR and MHC are not explicitly considered. This method therefore 
cannot be used to make predictions concerning the individual non-covalent interactions in the 
interface between the TCR CDR loops and the MHC-peptide antigen. 
The non-covalent interactions at protein-protein interaction sites are comprised of van 
der Waals interactions, hydrogen bonds, and salt bridges (Reichmann et al. 2007; Garcia et al. 
2009). The interaction surfaces of both the TCR and MHC-peptide complex are large: 
approximately thousand square angstroms are buried when an interaction event occurs and 
most of the contacts are mediated by van der Waals interactions (Rudolph et al. 2006). 
Although van der Waals interactions are weak, a large number of interactions over a large 
area add up to substantial binding energies. Both hydrogen bonds and salt bridges, which are 
comparatively rare in TCR and MHC-peptide protein-protein interaction interfaces, add 
specificity because of their dependence on the stereochemistry and geometry of the bond 
(Garcia et al. 2009). 
The most common interactions between the TCR and MHC-peptide complex were 
found between the TCRα CDR3 and amino acid positions 4 and 5 of the peptide (Figure 6.4), 
where 5 of 7 structures were found to have such interactions. But common interactions 
between both TCR subunits and the MHC, as well as TCRβ and the peptide, where 4 of 7 
structures had such interactions, were also found. Also, all peptide residue positions were 
capable of forming contacts with the TCR. 
These results are different from those of a previous detailed study (Rudolph et al. 
2006), where the interaction between the peptide component of the MHC-peptide antigen and 
the TCR was examined. In that study, the number of contacts per peptide residue with the 
TCR were evaluated in a number of structures where the MHC was HLA-A*0201. The most 
common interactions in complexes which contained HLA-A*0201 were observed between 
the TCR and peptide residue positions 5, 7 and 8. Additionally, peptide residue positions 2 
and 9 had no observed contacts with the TCR at all. In contrast, our analysis showed that 
interactions between the TCR and peptide position 4 are also very common (five of seven 
structures). And while Rudolph et al. identified no interactions between TCR and peptide 
residue positions 2 and 9, we identified such interactions. In fact, we show that all nine 
peptide residue positions are capable of interacting with the TCR in at least one of the 
structures. It remains unknown whether the same applies to 10mers which bind to HLA-
A*0201 as there is currently insufficient data to make such an analysis. 
Key positions, also called anchor residues, with which the peptide binds HLA-
A*0201, are located at positions 2 and the C-terminus (position 9) of the peptide and tend to 
be hydrophobic (Falk et al. 1991). Furthermore, secondary anchor residues have been found 
to make an important contribution to the binding between the peptide and HLA-A*0201 and 
occur at positions 1, 3 and 7 (Ruppert et al. 1993). Typically, primary and secondary anchor 
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residues are located within binding pockets of the HLA-A*0201 molecule. Therefore, the 
prominent role of peptide residues 4 and 5 in the interaction with the TCR is consistent with 
the occurrence of primary and secondary anchor residues at other locations within the peptide 
which are devoted to MHC-peptide binding. Put another way, the peptide residues which are 
important for interaction with the MHC are located in MHC binding pockets and therefore 
less available to interact with the TCR. Therefore other non-anchor peptide residues, such as 
residues 4 and 5, should be more available to interact with the TCR, which appears to be the 
case. 
Our analysis of complexes consisting of TCR bound to HLA-A*0201 also produced 
quite different results from those proposed evolutionarily conserved interactions found in a 
previous study (Marrack et al. 2008): (1) Marrack et al.‟s proposed evolutionarily conserved 
contacts between CDR1α amino acids positions 29 and 31 and MHC class I α2 domain‟s 
amino acid in position 158 were only observed in one of seven structures examined in our 
study, (2) the proposed evolutionarily conserved contacts between CDR2α positions 50 and 
51 and MHC class I α2 domain‟s in position 158 were only observed in three and two 
structures of seven structures, respectively, (3) the proposed evolutionarily conserved 
contacts between CDR1β positions 28 and 29 and MHC class I α1/α in position 69 were not 
seen in any structure in our study and (4) the proposed evolutionarily conserved contacts 
between CDR2β positions 46 and 48 and MHC class I α1/α position 69 were observed in zero 
and two of seven structures, respectively, in our study. 
We were interested in determining if the available crystal structures are broadly 
representative of the allorestricted TCRs identified by other experiment types. In functional 
cell assays, CTLs expressing TCRs which are HLA-A-02 restricted were observed to have a 
high expression of the specific TRBV12 chains in CD4 and CD8 populations (Liang et al. 
2010). The four clones generated for the study by Liang et al. all possessed CDR3 regions 
differing both in sequence and length, despite being selected to bind to the HER2369 peptide. 
Random combinations of TCRα and TCRβ chains were also tested and one TCRα chain was 
identified (HER2-2α) which was capable of peptide recognition when paired with any of the 
TRBV12-derived TCRβ chains (which also possessed different CDR3 regions). The authors 
suspect a dominant role of the TCRα chain in the selection of the preimmune TCR repertoire 
and HLA-A*0201 specificity. The CDR3 regions of the TCRβ chains are still thought to play 
an important role in peptide recognition, determining the dimensions of functional avidity, 
CD8 dependency, and tumor reactivity. It is not known how common such dominant TCRα 
chains are and it is not clear whether TCRβ chains are also capable of such behavior (Liang et 
al. 2010). Two further studies (Morgan et al. 2003; Schub et al. 2009) identified TCRs 
composed of TCRβ chains containing TRBV12, where the bound peptides were considerably 
different than the peptide used in the HER2369 studies by Liang et al. Previous work with the 
influenza matrix protein showed that this antigen selects a very restricted TCR repertoire, 
with both TRAV27 and TRBV19 (Vα10.2 and Vβ17 respectively in the old nomenclature) 
being overrepresented (Moss et al. 1991). The immunodominance in TCR chain bias has 
been found to predominantly rely on TCRβ chains containing TRBV19 in HLA-A*0201 
positive adults. Four water molecules which are completely buried in the protein-protein 
interaction interface of structure 1OGA, which is of the same type as those identified by 
Moss et al, are thought to strongly contribute to the overall shape complimentarily (Rudolph 
et al. 2006).  
In contrast, the solved crystal structures are heavily biased in favor of TCRβ chains 
using TRBV6-5 (Vβ13 in the old nomenclature) in humans (Marrack et al. 2008). The TRAV 
regions show less bias. It is currently unknown what the reasons for identified biases are i.e. 
why certain TCR chains are more common in crystallographic studies. It has been speculated 
that specific TCRs containing some regions are easier to crystallize (Marrack et al. 2008). 
Interestingly, no TRBV12-3*01 have been crystallized so far, although they were found to be 
common in cell assay studies. Therefore, while solved crystal structures show a bias towards 
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TRBV6-5, TCRs binding to influenza matrix peptide show a bias towards TRAV27/TRBV19 
and the remaining TCRs show a bias towards TRBV12; a crystal structure of the 
TRAV27/TRBV19 is available, but a TCR containing TRBV12 has not yet been crystallized. 
Our prediction approach was developed using the most diverse set of TCR-MHC 
complexes available, restricted to HLA-A*0201. We found that the TCR-MHC crystal 
structures generally are representative of TCRs which have been described to bind HLA-
A*0201 in cell assays (Table 6.4). However, each dataset tends to show a particular bias, as 
described above. While it is not possible to predict which HLA-A*0201 restricted TCRs may 
be isolated experimentally in the future, we believe we have been able to develop a method 
which is capable of reasonable predictions for likely future candidates. 
Overall, it can be said that TCR amino acids will frequently interact with a large range 
of diverse amino acids both in the peptide and HLA-A*0201. Additionally, all CDR loops are 
capable of interacting with the MHC and the peptide, and all peptide residues are capable of 
interacting with the TCR, although the most frequently found interactions occur at positions 4 
and 5 in the peptide. In contrast to previous generalizations of this binding event, where 
CDR1 and CDR2 loops were described as primarily interacting with the MHC molecule and 
the peptide having a preponderance for contacts with the CDR3 loops, we have observed a 
more complex picture which includes important interactions between the CDR1 and CDR2 
loops and the peptide, as well as the CDR3 loop and the MHC. 
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7 Summary 
In this thesis, we have presented work which helps to provide a better understanding 
of virus-host interactions with a particular focus on the human leukocyte antigen system, 
which has been shown repeatedly to be strongly associated with the ability of a human host to 
mount an effective immune response during viral infection. T cell immune responses are 
dependent on (1) the appropriate and effective processing of peptides from a protein source, 
(2) the stable binding of the peptide to the HLA  molecule and (3) the recognition of this 
complex by the T cell receptor. We have examined aspects of each of these components in 
this thesis. 
We have performed comprehensive analysis of the immune-driven evolution of clade 
B HIV-1 viruses in a large patient cohort treated at a single hospital in Germany and 
examined its implications for antiretroviral therapy. We analyzed associations of HLA-A, 
HLA-B and HLA-DRB1 alleles with the emergence of mutations in the complete protease 
gene and the first 330 amino acids of the reverse transcriptase gene of HIV-1, studying their 
distribution and persistence, and their impact on antiviral drug therapy. The clinical data of 
179 HIV-1-infected patients, the results of HLA genotyping and virus sequences were 
analyzed using a variety of statistical approaches. We describe new HLA-associated 
mutations in both viral protease and RT, several of which are associated with HLA-DRB1. 
The mutations reported are remarkably persistent within our cohort, with a minority of 
patients developing them more slowly. Interestingly, several HLA-associated mutations occur 
at the same positions as drug resistance mutations in patients, where the viral sequence was 
acquired before exposure to these drugs. The influence of HLA on thymidine analogue 
mutation pathways was not observed. We were able to confirm immune-driven selection 
pressure by MHC class I and II alleles through the identification of HLA-associated mutation. 
HLA-B alleles were involved in more associations (68%) than either HLA-A (23%) or HLA-
DRB1 (9%). As several of the HLA-associated mutations lie at positions associated with drug 
resistance, our results indicate possible negative effects of HLA genotypes on the 
development of HIV-1 drug resistance. 
The adaptive immune response against HCV is also significantly shaped by the host‟s 
composition of HLA alleles. Therefore, as with HIV-1, the HLA phenotype is a critical 
determinant of viral evolution during infection. In order to identify novel associations of 
HLA class I alleles with polymorphisms of HCV escape variants, the genes encoding the 
HCV proteins E3, NS3 and NS5B in a cohort of 159 patients with chronic HCV genotype 1 
infection were sequenced. Several HLA class I-restricted escape mutations were identified 
within novel putative CD8 T cell epitopes. As many of these epitopes overlap with already 
published epitopes and/or are predicted to lie within epitopes using NetMHC and 
SYFPEITHI, they appear to indicate that a region of high immunogenicity exists within the 
accordant protein region in the virus. A strictly separate analysis of patients infected with 
either HCV subtype 1a or 1b was able to show for the first time that there are strongly 
differing patterns of such escape mutations, implying that there is divergent adaptation to host 
immune pressure at the HCV subtype level. Furthermore, a number of clinical parameters are 
associated with the HLA class I phenotype; these consisted of liver fibrosis, inflammation 
and sustained viral response after therapy with pegylated interferon alpha-2b and ribavirin.  
We have also developed a DAS server which serves as the first reference and 
annotation server for HIV-1 and HCV targeted at the genome annotation community. It is 
specifically adapted from the default DAS server type to meet the requirements posed by a 
viral genome. 
Experimental screening of large sets of peptides with respect to their MHC binding 
capabilities is still very demanding due to the large number of possible peptide sequences and 
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the extensive polymorphism of the MHC proteins. Therefore, there is significant interest in 
the development of computational methods for predicting the binding capability of peptides 
to MHC molecules, as a first step towards selecting peptides for actual screening. We have 
examined the performance of four diverse MHC Class I prediction methods on comparatively 
large HLA-A and HLA-B allele peptide binding datasets extracted from the Immune Epitope 
Database and Analysis resource. The chosen methods span a representative cross-section of 
available methodology for MHC binding predictions. Until the development of IEDB, such 
an analysis was not possible, as the available peptide sequence datasets were small and 
spread out over many separate efforts. We tested three datasets which differ in the IC50 cutoff 
criteria used to select the binders and non-binders. The best performance was achieved when 
predictions were performed on the dataset consisting only of strong binders (IC50 less than 10 
nM) and clear non-binders (IC50 greater than 10,000 nM). In addition, robustness of the 
predictions was only achieved for alleles that were represented with a sufficiently large 
(greater than 200), balanced set of binders and non-binders. All four methods show good to 
excellent performance on the comprehensive datasets, with the method based on artificial 
neural networks outperforming the other methods. However, all methods show pronounced 
difficulties in correctly categorizing intermediate binders. 
Finally, we have examined conserved interactions between T cell receptors and MHC 
proteins with bound peptide antigens, which are still not well understood. In order to gain a 
better understanding of the interaction modes of human TCR V regions, we have performed a 
structural analysis of the TCRs bound to their MHC-peptide ligands in human, using the 
available structural models determined by X-ray crystallography. We identified important 
differences to previous studies in which such interactions were evaluated. Based on the 
interactions found in the actual experimental structures, we developed the first rule-based 
approach for predicting the ability of TCR residues in the CDR1, CDR2, and CDR3 loops to 
interact with the MHC-peptide antigen complex. Two relatively simple algorithms show good 
performance under cross validation. 
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8 Outlook 
The host‟s genetic profile plays an important role in the ability to fight viral 
infections, other pathogens and cancer, and therefore needs to be taking into account during 
the development of immune therapy in its various forms.  A number of interesting therapeutic 
approaches have been developed over the last few years which are continuing to be 
optimized, involving epitopes bound to HLA molecules and their recognition by T cell 
receptors.  Also, much basic research is being done to help elucidate the immune response 
mechanisms, hopefully then leading to further novel therapeutic approaches. 
For HCV, a HLA-A*0201-restricted T cell receptor has recently been identified 
which has a high affinity for a peptide epitope derived from NS3 protein. The TCR was 
isolated from a patient with chronic HCV infection. The authors were able to transduce both 
CD4 and CD8 T cells which successfully recognized protein-loaded targets. Thus, T cells 
transduced with an HCV-specific TCR may be promising for the treatment of patients with 
chronic HCV (Zhang et al. 2010). 
Epitope mutation presents a significant barrier to the development of immunotherapy 
for HIV-1. A recent approach to dealing with this problem was to develop an HIV-specific 
TCR which was modified to have a broader coverage of epitope variants. A TCR which 
recognized an HLA-A*0201-restricted epitope in the HIV-1 Gag protein was engineered to 
have various combinations of four naturally occurring polymorphisms in the CDR3 loop. 
Higher avidity TCR mutants were shown to have a broad recognition of variant epitopes. 
This more physiologic approach may minimize deleterious TCR reactivities which were 
observed in previous studies which  relied on random mutagenesis (Bennett et al. 2010). 
Work which has identified HLA-A*0201-restricted TCRs that could potentially be 
used in the treatment of HCV and HIV-1 is a relatively recent development. The development 
and use of such methods has a much longer history in the area of cancer treatment and has 
recently been able to demonstrate significant success in patients in specific scenarios. In order 
to better understand the therapeutic approaches and their potential advantages, as well as the 
hurdles encountered with this type of treatment, it is useful to examine how this particular 
type of cancer treatment has developed and continues to develop. 
Adoptive cell therapy (ACT), frequently also called adoptive T-cell immunotherapy 
or cellular immunotherapy, consists of a cancer patient undergoing a preparative regimen, 
consisting of total body irradiation or the administration of cytotoxic drugs, which depletes 
the patient‟s lymphoid compartment. Additionally, a patient‟s own (autologous) lymphocytes 
with anti-tumor activity are cultured from an excised tumor and expanded in vitro. Donor 
(allogeneic) lymphocytes may also be used. These T lymphocytes are then reinfused into the 
cancer patient, often in combination with appropriate growth factors to stimulate their 
survival and expansion in vivo (Rosenberg et al. 2008; Grupp and June 2010).  
This treatment method offers substantial theoretical and practical advantages over 
other immunotherapy methods (e.g. non-specific immunomodulation with interleukin 2 (IL2) 
and active immunization approaches with, for example, cancer vaccines). These advantages 
include the fact that only a small number of anti-tumor cells need to be isolated, as they can 
be selected and expanded ex vivo. They can also be specifically activated to exhibit the 
required anti-tumor effector functions and such high avidity CTLs have superior antitumor 
efficacy in vitro and in vivo. Importantly, this method also allows for the manipulation of the 
host, allowing an optimal environment to be created into which the cells can be transferred 
(Rosenberg et al. 2008).  
ACT has emerged as the most effective treatment for metastatic melanoma; recent 
studies have shown that in patients suffering from this type of cancer between 49% and 72% 
will achieve an objective clinical response (defined as a 30% reduction in the sum of the 
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longest diameters of measurable lesions when comparing post- and pre-treatment 
measurements). A significant proportion of patients will also have a complete response; in 
one of the most recent trials where the patients received maximum immunodepletion, 28% of 
the cohort achieved a complete response. Such complete responses are often durable and are 
seen at all organ sites including the brain (Dudley et al. 2005; Rosenberg and Dudley 2009).  
However, despite the encouraging results in the case of metastatic melanoma, 
applications to other types of common cancer (breast, prostate and ovarian cancers) have 
shown relatively poor results using this methodology, as it can often be difficult to identify 
tumor reactive lymphocytes (Morgan et al. 2006; Berry et al. 2009).  
Further work has been done to improve the adoptive T cell therapy of cancer: 
genetically engineered normal human lymphocytes have been generated which recognize 
cancer antigens and thus mediate cancer regression in vivo. In one ground-breaking study, 
patients were treated with autologous peripheral blood lymphocytes that had been transduced 
with genes encoding a TCR which specifically recognizes the MART1 melanoma antigen 
presented by HLA-A*0201 (Morgan et al. 2006). Thus, the laborious task of isolating and 
expanding specific T cells from individual patients has been bypassed. 
Additional important components in an effective strategy for treating a wide variety of 
cancers are currently being developed. TCRs have been identified which target common 
epithelial cancers, thus giving hope for extending ACT to a wider variety of cancer types;  
(Rosenberg et al. 2008). Work is ongoing with the goal of generating high-affinity TCR 
specific to different major HLAs, so that these can be selected and employed in an “off-the-
shelf” manner (Leisegang et al. 2010). The results of a pilot study by the National Cancer 
Institute has also recently been published. The aim of the study was to prioritize cancer 
antigens, generating a well vetted and priority-ranked list of cancer vaccine target antigens 
using objective criteria defined by different panels of experts. Of the 75 antigens selected, 
none had all the characteristics of an ideal cancer antigen as defined by the study authors. 
However, 46 antigens were immunogenic in clinical trials and 20 are suggestive of clinical 
efficacy in the study‟s therapeutic function category (Cheever et al. 2009). These tumor-
associated antigens may also be suitable targets for genetically engineered TCRs in a variety 
of cancer types, as they represent mutant, overexpressed or abnormally expressed proteins in 
cancer cells, or viral proteins associated with virus-associated malignancies (Leisegang et al. 
2010). 
It is hoped that the knowledge gained from the ACT as well as the development of 
genetically engineered human lymphocytes for cancer, which express a specific TCR, can be 
used in the treatment of viral diseases such as HIV-1 and HCV, where work is currently only 
at the in vitro stage. 
A mouse model has been recently developed which will have an important impact on 
the ability to easily identify high-avidity pathogenic and therapeutic human TCRs. 
Previously, it has been difficult to identify T cells which target self (e.g. tumors) because of 
the innate tolerance mechanisms of the host. The new mouse model was constructed to 
express the human TCR repertoire: the entire human TCRα and TCRβ gene loci were 
inserted into the mouse genome (1.1 and 0.7 Mb respectively). Additionally, the HLA class I 
transgene was also inserted, which increases the generation of CD8 T cells expressing human 
TCRs relative to mouse. This system makes it possible to examine the unskewed TCR 
repertoire against human self antigens. A successful induction of TCRs recognizing Melan-A 
melanoma antigen was preformed and the isolated T cell clones were found to be similar to 
those from patients with autoimmune vitiligo or melanoma (Li et al. 2010). 
A further area of research which involves host genetic HLA profiles and the treatment 
of disease involves peptide-based vaccines. Numerous clinical vaccination trails have been 
carried out or are ongoing using HLA-presented peptides linked to a wide variety of diseases 
with some encouraging results, but a final breakthrough is still lacking. Examples of peptides 
recently evaluated in humans are a vaccine containing a Her2/neu peptide which was tested in 
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a clinical trial of breast cancer patients expressing HLA-A2 or HLA-A3 (Patil et al. 2010), 
clinical trials of multi-epitope peptide vaccines for HIV-1 (Spearman et al. 2009; Graham et 
al. 2010) and immunogenicity and safety studies in humans for  an HCV peptide vaccine 
(Firbas et al. 2010). Theoretical work identifying an ideal vaccine to target Toxoplasma 
gondii in HLA-A*0201 restricted patients is ongoing (Cong et al. 2010).  
Heteroclitic peptides are peptides which have been altered at their anchor residue 
positions and commonly used to enhance peptide vaccines. A recent study compared TCR 
binding to natural and anchor-modified heteroclitic peptides using surface plasmon resonance 
and the analysis peptide-MHC tetramer binding at the cell surface. It was possible, for the 
first time, to distinguish between T cells that have a strong preference for either type of 
antigen. In fact, substantial differences in TCR binding were identified that were, according 
to the authors, unpredictable. Also, the T cells primed by either group of peptide expressed 
different TCRs. Therefore, if a peptide vaccine is generated using heteroclitic peptides, the 
stimulated T cells may exhibit suboptimal recognition of the intended natural target antigen 
in vivo and such vaccines should therefore be carefully evaluated in a clinical setting to 
ensure efficacy (Cole et al. 2010). 
While immune manipulations involving a single modality have shown to be 
successful in individual therapeutic settings, the interactions between tumors, viruses or other 
pathogens and the host‟s immune systems is highly complex. Thus, combination therapies 
may prove to generate superior adaptive immune response and thus efficacy of treatment. 
Without a doubt, the genetic profile of the host plays an important role in the ability to fight 
cancer, viral infections and other pathogens and thus needs to been taken into consideration 
in the development of immune therapy in its various forms. 
  
CHAPTER 8. OUTLOOK 
 
100 
 
  
 
APPENDICES 
 
101 
 
  
Appendices 
Appendix A: HLA Genotyping and HIV-1 Sequencing Methods 
HLA genotyping of patients 
HLA genotyping was performed using the INNO-LiPA line probe assays from 
Innogenetics for HLA-A, HLA-B (MHC Class I loci) and HLA-DRB1 (MHC class II locus) 
according to the manufacturer‟s instructions. These are assays based on the reverse 
hybridization principle (De Vreese et al. 2004). Ambiguous results were further resolved by 
strand specific PCR-SSP (One Lambda, Canoga Park, CA, USA). 
Sequencing of HIV-1 proteins 
For HIV-1 genotyping, a fragment of the pol gene containing the complete protease 
and the first 650-750 nucleotides of the RT were analyzed by direct sequencing of PCR 
products as described in Balduin et al. (Balduin et al. 2005).  
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Appendix B: HIV-1 Population Consensus Sequences 
Protease protein (subtype B) 
>CON_B 
PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTV
LVGPTPVNIIGRNLLTQIGCTLNF 
Reverse transcriptase protein (subtype B) 
>CON_B 
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLV
DFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLP
QGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEP
PFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAE
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKI
ATESIVIWGKTPKFKLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRET
KLGKAGYVTDRGRQKVVSLTDTTNQKTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQL
IKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVL 
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Appendix C: HLA Genotyping, HCV Genotyping and Sequencing Methods 
HLA genotyping of patients 
EDTA blood for HLA genotyping was collected before initiation of antiviral therapy. 
HLA genotyping was performed by strand-specific reverse hybridization with the INNO-
LiPA line probe assays for HLA-A and HLA-B (Innogenetics) according to the 
manufacturer‟s instructions (Ahlenstiel et al. 2007). Ambiguous results were further resolved 
by strand-specific PCR-SSP (One Lambda, Canoga Park, CA). 
HCV RNA detection and quantification, HCV genotyping  
Quantitative reverse transcription polymerase chain reaction (Roche AMPLICOR 
HCV Monitor version 2.0; Roche Diagnostics, Basel, Switzerland) was used to quantify HCV 
RNA levels at baseline and during antiviral therapy. Qualitative HCV RNA detection was 
performed at week 4, 8, 12, 24, and 48 by bDNA assay (Versant 3.0; formerly Bayer 
Diagnostics, Leverkusen, Germany [now provided by Siemens]; detection limit, 615 IU/ml). 
In patients who had HCV RNA levels less than 1,000 IU/ml by bDNA testing, qualitative 
HCV RNA testing was performed with the more sensitive transcription-mediated 
amplification assay (TMA; Versant qualitative HCV RNA; formerly Bayer Diagnostics, 
Leverkusen, Germany; detection limit 5.3 IU/ml; now provided by Siemens). The cut-off of 
1,000 IU/ml instead of 615 IU/ml was chosen to improve the specificity of the bDNA assay. 
SVR was defined as a negative qualitative HCV RNA test 24 weeks after treatment 
completion. Treatment was discontinued in patients with HCV RNA levels greater than 1,000 
IU/ml by bDNA assay after 24 weeks of treatment. HCV genotyping was performed by using 
the INNO-LiPA reverse hybridization assay (INNO-LiPA HCV; Innogenetics, Gent, 
Belgium). All subtypes that remained unclear were subsequently analyzed by comparing their 
sequences of E2, NS3 and NS5B with reference sequences from the Los Alamos HCV 
Sequence Database (Kuiken et al. 2005).  
Sequencing of HCV proteins 
HCV RNA was extracted from 100 μl serum of 159 patients. Complementary DNA to 
HCV RNA was generated by using random hexamer oligonucleotides. HCV proteins were 
amplified by nested PCR. The E2 protein was amplified from amino acid positions 464 to 
576 (112 amino acids), the NS3 protease from amino acid positions 1026 to 1221 (195 amino 
acids) and the NS5B RNA-dependent RNA polymerase from amino acid positions 2670 to 
2987 (317 amino acids). After initial denaturation at 95°C for 2 min, 35 cycles of 95°C for 60 
s, 47°C for 60 s, and 72°C for 60 s were performed for the first and second rounds of PCR in 
a PE9700 thermocycler (Perkin-Elmer Applied Biosystems, Weiterstadt, Germany). For 
amplification, the Expand Long Template PCR System (Roche Diagnostics, Mannheim, 
Germany) and Taq DNA Polymerase (Roche Diagnostics, Mannheim, Germany) were used. 
The amplification product was analyzed on a 2% agarose gel stained with ethidium bromide. 
Primers for nested PCR were: external sense, E2-1s (TGC AAT GAC TCC CTC CAC ACT 
GG), NS3-1s (GGC GTG TGG GGA CAT CAT C), NS5B-1s (TAT GAC ACC CGC TGC 
TTT GAC TC); external antisense, E2-1a (CTT CCG GAA GCA GTC CGT GGG GC), 
NS3-1a (GGT GGA GTA CGT GAT GGG GC), NS5B-1a (AGT GKT TAG CTC CCC GTT 
CA); internal sense, E2-2s (CCA GAG CGC ATG GCC AGC TG), NS5B-2s (GTC ACT 
GAG AAT GAC ATC CG); internal antisense, E2-2a (CAA GGT GTT GTT GCC GAC 
CCC CCC), NS3-2a (CAT ATA CGC TCC AAA GCC CA), NS5B-2a (TAG CTC CCC 
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GTT CAY CGG TTG). For sequencing of E2, NS3, and NS5B genes, 40 μl of the second 
round PCR product were purified with QIAquick PCR Purification Kit (Qiagen GmbH, 
Hilden, Germany). PCR products were labeled (BigDyeTM Terminator Cycle Sequencing 
Ready Reaction Kit, Applied Biosystems, Darmstadt, Germany), purified (DyEx 2.0 Spin 
Kit, Qiagen GmbH, Hilden, Germany), and sequenced (Applied Biosystems 3100 Genetic 
Analyzer, Darmstadt, Germany). 
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Appendix D: HCV Population Consensus Sequences 
Source: HCV Sequence Database in Los Alamos (Kuiken et al. 2008). 
E2 protein 
>CON_1A_E2 (Genotype 1a) 
DFDQGWGPISYANGSGPDHRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFV
LNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGVG 
 
>CON_1B_E2 (Genotype 1b) 
KFAQGWGPITYAEPNSSDQRPYCWHYAPRPCGIVPASQVCGPVYCFTPSPVVVGTTDRFGVPTYSWGENETDVLL
LNNTRPPQGNWFGCTWMNSTGFTKTCGGPPCNIGGVG 
NS3 protein 
Note: first 5 amino acids ("GWRLL") in the consensus sequences were added for the 
analysis, because the patient sequences have them. This added sequence belongs to the 3' end 
of NS2. 
 
>CON_1A_NS3 (Genotype 1a) 
GWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGP
VIQMYTNVDQDLVGWPAPQGARSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLC
PAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQ 
 
>CON_1B_NS3 (Genotype 1b) 
GWRLLAPITAYSQQTRGLLGCIITSLTGRDKNQVEGEVQVVSTATQSFLATCVNGVCWTVYHGAGSKTLAGPKGP
ITQMYTNVDQDLVGWQAPPGARSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPVSYLKGSSGGPLLC
PSGHAVGIFRAAVCTRGVAKAVDFVPVESMETTMRSPVFTDNSSPPAVPQ 
NS5B protein 
>CON_1A_NS5B (Genotype 1a) 
RVAIKSLTERLYVGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVIC
ESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWET
ARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQRLHGLSAFSL
HSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLSRGGRAAICGKYLFNWAVRTKLKLTPIAAAGQLDLSG
WFTAGYSGGDIYHSVSH 
 
>CON_1B_NS5B (Genotype 1b) 
RQAIRSLTERLYIGGPLTNSKGQNCGYRRCRASGVLTTSCGNTLTCYLKASAACRAAKLQDCTMLVNGDDLVVIC
ESAGTQEDAASLRVFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWET
ARHTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSL
HSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFNWAVRTKLKLTPIPAASQLDLSG
WFVAGYSGGDIYHSLSR 
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Appendix E: HCV Alignments against Reference Sequences 
The HCV viral strain H77 (GenBank accession numbers M67463 (nucleotide) and 
AAA45534.1 (protein)) was used as a reference strain in this study, as in the HCV Sequence 
Database at Los Alamos (Kuiken et al. 2008). The position of the E2, NS3, and NS5B 
population consensus sequence locations relative to the sequence of the H77 protein are 
indicated.  
E2 protein alignment 
CON_1A_E2       ------------------------------------------------------------ 
AAA45534.1      YFSMVGNWAKVLVVLLLFAGVDAETHVTGGNAGRTTAGLVGLLTPGAKQNIQLINTNGSW 420 
CON_1B_E2       ------------------------------------------------------------ 
                                                                             
 
CON_1A_E2       -------------------------------------------DFDQGWGPISYANGSGP 17 
AAA45534.1      HINSTALNCNESLNTGWLAGLFYQHKFNSSGCPERLASCRRLTDFAQGWGPISYANGSGL 480 
CON_1B_E2       -------------------------------------------KFAQGWGPITYAEPNSS 17 
                                                           .* ******:**: ..  
 
CON_1A_E2       DHRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFVLN 77 
AAA45534.1      DERPYCWHYPPRPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGANDTDVFVLN 540 
CON_1B_E2       DQRPYCWHYAPRPCGIVPASQVCGPVYCFTPSPVVVGTTDRFGVPTYSWGENETDVLLLN 77 
                *.*******.*:*******..******************** *.****** *:***::** 
 
CON_1A_E2       NTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGVG------------------------- 112 
AAA45534.1      NTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGVGNNTLLCPTDCFRKYPEATYSRCGSG 600 
CON_1B_E2       NTRPPQGNWFGCTWMNSTGFTKTCGGPPCNIGGVG------------------------- 112 
                ***** ****************.**.*** *****                          
NS3 protein alignment 
Note: first 5 amino acids ("GWRLL") in the consensus sequences were added for the 
analysis, because the patient sequences have them. This added sequence belongs to the 3' end 
of NS2. 
 
 
CON_1A_NS3      ------------------------------------------------------------ 
AAA45534.1      HNGLRDLAVAVEPVVFSRMETKLITWGADTAACGDIINGLPVSARRGQEILLGPADGMVS 1020 
CON_1B_NS3      ------------------------------------------------------------ 
                                                                             
 
CON_1A_NS3      -GWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWT 59 
AAA45534.1      KGWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTATQTFLATCINGVCWT 1080 
CON_1B_NS3      -GWRLLAPITAYSQQTRGLLGCIITSLTGRDKNQVEGEVQVVSTATQSFLATCVNGVCWT 59 
                 ***********:***************************:****:*:*****:****** 
 
CON_1A_NS3      VYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGARSLTPCTCGSSDLYLVTRHADVI 119 
AAA45534.1      VYHGAGTRTIASPKGPVIQTYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVI 1140 
CON_1B_NS3      VYHGAGSKTLAGPKGPITQMYTNVDQDLVGWQAPPGARSLTPCTCGSSDLYLVTRHADVI 119 
                ******::*:*.****: * *********** ** *:*********************** 
 
CON_1A_NS3      PVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVEN 179 
AAA45534.1      PVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPTGHAVGLFRAAVCTRGVAKAVDFIPVEN 1200 
CON_1B_NS3      PVRRRGDSRGSLLSPRPVSYLKGSSGGPLLCPSGHAVGIFRAAVCTRGVAKAVDFVPVES 179 
                *****************:**************:*****:****************:***. 
 
CON_1A_NS3      LETTMRSPVFTDNSSPPAVPQ--------------------------------------- 200 
AAA45534.1      LETTMRSPVFTDNSSPPAVPQSFQVAHLHAPTGSGKSTKVPAAYAAKGYKVLVLNPSVAA 1260 
CON_1B_NS3      METTMRSPVFTDNSSPPAVPQ--------------------------------------- 200 
                :********************                                        
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NS5B protein alignment 
CON_1A_NS5B      -----------------------------RVAIKSLTERLYVGGPLTNSRGENCGYRRCR 31 
AAA45534.1       TRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCGYRRCR 2700 
CON_1B_NS5B      -----------------------------RQAIRSLTERLYIGGPLTNSKGQNCGYRRCR 31 
                                              * **:*******:*******:*:******** 
 
CON_1A_NS5B      ASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFT 91 
AAA45534.1       ASRVLTTSCGNTLTRYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFT 2760 
CON_1B_NS5B      ASGVLTTSCGNTLTCYLKASAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAASLRVFT 91 
                 ** *********** *:** ****** ******** ************.********.** 
 
CON_1A_NS5B      EAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETA 151 
AAA45534.1       EAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETA 2820 
CON_1B_NS5B      EAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETA 151 
                 ***********************************.:*********************** 
 
CON_1A_NS5B      RHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLP 211 
AAA45534.1       RHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALNCEIYGACYSIEPLDLP 2880 
CON_1B_NS5B      RHTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLP 211 
                 **************:****************:*:*::***:**:*:************** 
 
CON_1A_NS5B      PIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLSRGGRAAI 271 
AAA45534.1       PIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRAWSVRARLLARGGKAAI 2940 
CON_1B_NS5B      QIIERLHGLSAFSLHSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAAT 271 
                  **:**********************:***********.***** ****:**::**:**  
 
CON_1A_NS5B      CGKYLFNWAVRTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSH-------------- 317 
AAA45534.1       CGKYLFNWAVRTKLKLTPITAAGRLDLSGWFTAGYSGGDIYHSVSHARPRWFWFCLLLLA 3000 
CON_1B_NS5B      CGKYLFNWAVRTKLKLTPIPAASQLDLSGWFVAGYSGGDIYHSLSR-------------- 317 
                 *******************.**.:*******.***********:*:               
 
CON_1A_NS5B      ----------- 
AAA45534.1       AGVGIYLLPNR 3011 
CON_1B_NS5B      ----------- 
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